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ABSTRACT
Staphylococcus aureus is a pathogenic organism which has an
impressive armoury of extracellular toxic factors. In recent years,
S. aureus has developed resistance to some of the new 4-quinolone
antibacterials. Since this resistance is a result of a chromosomal
mutation, and not plasmid mediated, it was proposed that the resistant
bacteria might be less pathogenic. This thesis has studied this postulate.
Ciprofloxacin sensitive and resistant strains of S. aureus were compared
to establish any difference in their respective production of virulence
factors both in vitro and in vivo. Since S. aureus produces a large
number of virulence factors, four were studied in detail; coagulase,
protein A , a and 8 haemolysin.
The in vitro production of the four factors by ciprofloxacin sensitive
and resistant strains was investigated in the presence and absence of 1/4
and 1/2 minimum inhibitory concentration (MIC) levels of six
antibiotics: ciprofloxacin, enoxacin, methicillin, gentamicin,
chloramphenicol and tetracycline. The production of soluble and bound
coagulase was measured by a chromogenic substrate assay. The
production of cell bound and extracellular protein A, a and 8
haemolysin was measured by ELISAs. In the absence of the antibiotics,
the production of the four virulence factors was similar in the resistant
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and sensitive strains. The acquisition of ciprofloxacin resistance did not
affect the production of the factors. Conversely, the presence of 1/4
and 1/2 MIC levels of gentamicin, chloramphenicol and tetracycline
reduced the production of both bound and soluble coagulase, and
protein A, in both sensitive and resistant bacteria. In the presence of 1/2
MIC levels of ciprofloxacin, enoxacin, chloramphenicol and tetracycline
the production of a and 8 haemolysin was reduced and in some cases
completely inhibited. The presence of 1/4 MIC levels of the antibiotics
had a reduced effect on the inhibition of the toxins. The presence of
gentamicin at 1/2 or 1/4 MIC levels had little effect on haemolysin
production. The presence of 1/4 and 1/2 MIC levels of methicillin both
increased the production of the toxins, but the increase was less
significant in the presence of 1/4 MIC levels.
In order to correlate these in vitro results with pathogenicity, an
S. aureus abscess model in mice was used, since this allowed easy
comparisons of strains under in vivo conditions. Paired strains of
ciprofloxacin sensitive and resistant bacteria were injected
subcutaneously into mice and the resulting lesions examined. The
ciprofloxacin phenotype did not affect lesion production or degree of
tissue damage. The effect of 1/2 and 1/4 MIC levels of ciprofloxacin on
the development of the abscesses was also investigated, and it was
shown that they reduced the size of the abscesses if treatment was started
one hour after the subcutaneous injection of S. aureus. The number of
ii
viable organisms recovered from mice treated with sub MIC levels of
ciprofloxacin was less than the number recovered from control mice.
Ciprofloxacin resistant bacteria were recovered from abscesses of mice
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1 Introduction
In general terms, the type of association between two different organisms
can be listed as parasitic, where one benefits and one doesn't, or
symbiotic, where both benefit. There is an intermediate category, where
only one organism derives benefit without doing damage to the other
organism and this is termed commensalism.
The association between man and microorganisms could be classified as
symbiotic - bacteria in the gut providing vitamins, or as commensal -
bacteria on the skin. Only a small number of microorganisms associated
with man give rise to pathological changes or cause disease. This is not a
surprising revelation since successful parasitic microbes need to
maintain themselves in nature and avoid extinction, i.e. live on or in
the host, multiply and then spread to a new host. The parasitic microbe
will try to get as much as it can from the host without causing too much
damage, but some degree of tissue damage may be necessary. Different
microbes have attained different balances in this respect.
The hosts have developed a highly efficient recognition system for
invaders, and inflammatory and immune responses to restrain their
growth and spread, and eliminate them from the body. The
microorganisms, for their part, have evolved and developed ways of
bypassing the host defences. The ability to adapt and evolve, and exploit
1
weak points in the host defences, is a trait shared by most successful
microorganisms.
This thesis is going to examine one particular microorganism
Staphylococcus aureus which has been described as a successful
pathogen (Mudd 1970). Its pathogenic determinants will be described, as
will their importance in causing various diseases and how they can be
"attenuated" by antimicrobials. First it is necessary to look at the various
host defences and the general principles of microbial pathogenicity.
1.1 Host Defences
It is convenient to divide host defence mechanisms against infection
into those that operate externally and those that function internally.
1.1.1 External Defences
The skin presents a mechanical barrier to penetration of microorganisms
and infection of the skin usually takes place only when the continuity of
the skin has been mechanically broken.
The skin possesses an indigenous microflora (Price 1938), which is
mostly non pathogenic (Williams 1973). It usually has an acid pH (Noble
1968) and long chain fatty acids, which are bactericidal, occur in sebaceous
gland secretions (Pillsbury and Rebell 1952; Aly et al 1972).
2
The conjunctiva and the alimentary, respiratory and urogenital tracts
offer pathways for infection by microorganisms. The cornea is covered by
lacrimal fluid (tears) which contains lysozyme (Fleming 1922), an
enzyme that has an antibacterial function (Zinder et al 1956). The
respiratory tract, particularly the upper respiratory tract is exposed to a
wide variety of particulate material, including microorganisms. The
majority of the particles are trapped by the secretions that cover the
mucous membranes (McNabb and Tomasi 1981) and once trapped, the
particles are transported by means of a mucous stream to the base of the
tongue, where they are periodically swallowed (Richardson 1987). The
epithelial surfaces of the gastrointestinal tract are covered by a layer of
mucus. It contains components such as lysozyme which attacks
susceptible bacteria (Creeth et al 1979) and lactoferrin which may deprive
bacteria of iron, an essential growth requirement (Emery 1980). In the
urinary tract mechanical elimination is the most important factor
(Mooney et al 1976; O'Grady et al 1988).
1.1.2 Internal Defences
The internal defence mechanisms can be divided broadly into non
specific immunity and specific immunity. Non specific immunity can be
described as those processes which, without being directed against any
specific microbe, help to prevent infection. Specific immunity involves
some degree of special recognition and sometimes the immunity may
not extend beyond a particular bacterium.
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Non Specific Immunity
Non specific factors are soluble materials present in the tissues and body
fluids such as blood lymph, tears, saliva and mucus. Lysozyme, found in
many body fluids, splits cell wall peptide (Muschel 1963) and beta-lysins,
whose amounts increase during infection lyse Gram positive bacteria
(Myrvik and Leake 1960). Transferrin and lactoferrin present in serum,
milk and other secretions, prevent the growth of many pathogens by
denying them essential iron (Weinberg 1971).
If bacteria penetrate into or through epithelial surfaces, they act as
foreign bodies and therefore stimulate an inflammatory response. The
most important event is the accumulation of large numbers of
phagocytic cells at the inflammatory site. Although these cells also
function to remove microbial and host tissue debris and to dispose of
inflammation-producing factors, they are particularly important in
engulfing and destroying pathogenic bacteria (Ryan and Majno 1977). An
early inflammatory response has been shown to be a major protective
factor against Staphylococcus aureus infection (Easmon and Glynn
1975a).
Specific immunity
Specific immunity involves phagocytosis and antibodies. Phagocytosis is
the ingestion of invading bacteria into the cytoplasm of cells (Hirsch
1974). Phagocytosis is greatly improved by the presence of antibodies
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which the body has produced as a result of such contact. The process
whereby substances improve phagocytosis is called opsonisation (Wright
and Douglas 1903). Protein A , a cell wall component of S. aureus
interfers with opsonization and phagocytosis (Peterson et al 1977).
Antibodies are proteins produced as a result of the introduction of
substances which the body recognises as foreign (antigens). They are
supported by the complement system. Complement, a normal
constituent of human blood plasma (Muller-Eberhard 1969), can be
subdivided into two pathways; the classical pathway activated by IgG and
IgM-type complexes (Muller -Eberhard 1969) and the alternative pathway
activated by aggregates of IgA and naturally occurring polysaccharides
and lipopolysaccharides (Muller-Eberhard 1971). They act to produce a
cascade of enzyme reactions culminating in the activation of a molecular
complex which will attack and dissolve the phospholipid wall of bacteria
and tissue cells (Kolb et al 1972; Poddack and Tschopp 1982).
1.2 Microbial Pathogenicity
Microbial pathogenicity has been defined as "the biochemical
mechanisms whereby microorganisms cause disease" (Smith 1968). Not
all pathogens have the same capacity to cause infection and disease.
Microbial pathogenesis is usually complex and multifactorial. Pathogens
have several biochemical mechanisms which may act individually or
together to produce disease. Removal of any one of these components
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may or may not render the organism avirulent. To be pathogenic a
microorganism must be able to: (1) Break through the skin barrier (by
trauma or insect bite) or infect the mucous surfaces, (2) Enter the host
-penetration of the mucous surfaces, (3) Multiply, (4) Resist or interfere
with host defence mechanisms, and (5) Cause damage to the tissue of the
host (Smith 1984).
1.2.1 Break through skin / Infect mucous surface
Large or small breaks in the skin resulting from wounds are obvious
routes for infection. Bites are also important sites for the entry of
microorganisms.
The majority of infections start on the mucous surface. When a
pathogen enters the alimentary, respiratory or urogenital tract, the first
requirement for infection is to make contact with the epithelial surface
through the overlaying mucus layer (Freter 1980). After contact is made
the pathogen must adhere to the surface, to prevent removal by moving
lumen contents or mucociliary action.
Factors produced by Haemophilus influenzae seem to result in the
immediate slowing of ciliary beating. This would have the effect of
delaying mucociliary clearance and giving the bacterium time to
multiply and bind with the receptors on epithelial cells (Wilson et al
1986).
6
Attachment is mediated by cell-surface structures termed "adhesins"
(Duguid 1959). Some strains of Escherichia coli which cause diarrhoea
produce surface antigens and colonisation factor antigens, which are
responsible for the adherence of the bacteria to the surface of the
intestine (Beachey 1981). Other bacterial surface components contributing
to their adherence to mucous membranes include carbohydrates,
glycoproteins, glycolipids, K antigens, M proteins and pili (Lancefield
1962; Smith 1977; Arbuthnott and Smyth 1979).
Fibronectin is a large multifactorial, extracellular matrix and plasma
glycoprotein which promotes adherence functions in mammalian cells.
This molecule also adheres in large quantities to mucosal surfaces.
S. aureus and Streptococcus pyogenes adhere to fibronectin on
epithelial cell surfaces (Beachey and Courtney 1987; Proctor 1987).
Although these two organisms adhere to the same molecule under
similar conditions, they use different mechanisms (Mosher and Proctor
1980; Courtney et al 1983).
To maintain infection on mucous surfaces pathogens must be able to
resist the host defence mechanisms located there, such as acid /alkaline
pH, bactericidal materials and extruded phagocyctes. They must be able to
compete with their neighbours for space on the host surface and possibly
for nutrients (Savage 1972). Bacteria overcome these mucosal defences by
devices similar to those used later within the tissues.
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1.2.2 Entry to the host
Upon attachment, one of these three disease producing processes occur:-
(1) The parasite may multiply upon the surface of the epithelial cell
without penetrating into the cell or deeper tissue. Disease in this
instance is caused by the elaboration by the parasite of a soluble toxin
substance that is absorbed through the mucous membrane, producing
local or distant tissue damage e.g. in the disease diphtheria - the
causative agent Corynebacterium diphtheriae attaches to the epithelium
of the pharynx, where it elaborates a potent toxin that is absorbed and
transported to other tissues. All symptoms of the disease can be
attributed to activities of this toxin (Pappenheimer 1965; Bowman and
Bonventre 1970).
(2) The parasitic bacteria may attach to epithelial cells, then penetrate
into these cells where they multiply and produce disease by destroying
the epithelial cell layer. An example of this is Shigella flexneri, which
produces dysentery without penetrating into submucosal tissues. The
mechanism by which bacteria of this type penetrate into epithelial cells
is not well understood but they seem to enter by a process resembling
phagocytosis. The infection is usually confined to the superficial layers of
the intestinal mucosa, and the organisms spread to the other surface
epithelial cells and cause much tissue damage, excessive fluid secretion
and inflammation (Formal et al 1983; Hale and Formal 1987).
(3) Certain pathogenic bacteria, after attachment to epithelial cells may
enter these cells and pass through them into submucosal tissues, often
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without significant damage to the mucosal cells. The factors and forces
involved in this phagocytosis and transport of the parasite through
epithelial cells are not known (Takeuchi and Sprinz 1967). Invasion of
the gastrointestinal tract is an essential step required for Salmonella
typhimurium pathogenesis (Giannella et al 1973). Most Salmonella
species proceed through the surface intestinal epithelial cells into deeper
tissue and often enter reticuloendothelial cells. They are ingested by
macrophages, within which they multiply readily.
1.2.3 Bacterial Multiplication
In order to produce disease, a pathogenic bacterium, once it has escaped
the external defence mechanisms and gained access to sub-epithelial
tissue, must multiply, since the number of pathogenic bacteria that infect
the host is too small to produce disease immediately.
Only in a few cases and early in infection has the multiplication rate in
vivo been measured (Smith 1983). This rate was much slower than that
seen in laboratory cultures, suggesting that limiting nutritional and
physiological conditions may exist in vivo before tissue breakdown
occurs. The nutrients or other environmental factors that limit growth
at the beginning of infection are largely unknown except for the
influence of iron supply. Most bacteria need iron to grow
(Weinberg 1966) and in vivo the amount of free iron is restricted by
iron-complexing host proteins, transferrin and lactoferrin. Virulent
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strains secrete siderophores into the surrounding environment and so
obtain sufficient iron (Griffiths 1983).
1.2.4 Resist or interfere with host defences
At the beginning of any infection, the non specific defence mechanisms
act to prevent or reduce it. If infection occurs this is strengthened by
specific immune response which usually eliminates the infection.
Therefore, to make progress against the host defences, a pathogenic
bacterium must be able to inhibit or interfere with the humoral factors,
the phagocytes, complement and the immune response.
Interference with humoral factors
The major humoral bactericidins are the later components of the
complement cascade for Gram negative bacteria and lysozyme, beta
lysins and basic peptides for Gram positive bacteria (Smith 1976; Penn
1983). Resistance to humoral bactericidins has been shown by virulent
strains Bacillus anthracis (Keppie et al 1963), S. aureus (Cybulska and
Jeljaszewicz 1966) and some Enterobacteriaceae (Braun et al 1960).
Interference with the action of phagocytes
The four stages of the phagocytic defence system are: (1) mobilisation by
inflammation (2) chemotaxis towards bacteria (3) attachment and
engulfment (4) killing by oxygen dependent systems.
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Mobilisation may be prevented by an active process e.g. virulent
staphylococci produce an anti inflammatory cell wall peptidoglycan
(DOCR; deoxycholate residue) (Easmon et al 1973). They also produce
leukocidins which dispatch phagocytes which are attracted to sources of
inflammation (Rogers and Tomsett 1952).
Chemotaxis was prevented in vitro by fractions from tubercle bacilli
(Dubos and Hirsch 1965) and a cell wall product of staphylococci which
was different from the anti inflammatory mucopeptide (Weksler and
Hill 1969; Glynn 1972).
Resistance to attachment and ingestion by phagocytes of virulent strains
was one of the first areas of bacterial pathogenicity to receive attention.
In most cases inhibition of ingestion has not been distinguished from
inhibition of attachment. Bacterial surface components (aggressins) can
interfere with ingestion of invading microorganisms by phagocytic cells
(Glynn 1972; Smith 1977). There are two general types of aggressins:
surface and capsular products which do not appear to harm phagocytes,
and toxic materials that do direct damage. These antiphagocytic factors
include the polysaccharides of meningococci and pneumococci (Dubos
and Hirsch 1965), the M protein and hyaluronic acid of streptococci (Fox
1974), protein A and coagulase of staphylococci (Peterson et al 1977b).
These capsules are weakly immunogenic and mask more immunogenic
underlying bacterial surface structures and would directly activate
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complement. Toxic aggressins probably harm phagocytes in the same
way as they affect ordinary cells; for example interference with
membrane function by a toxin of S. aureus (Bhakdi et al 1989).
Interference with the action of complement
Mobilisation of phagocytes and their chemotaxis towards bacteria are
promoted by earlier components of the complement cascade which also
opsonise the bacteria for attachment and ingestion by phagocytes (Wilton
1981; Penn 1983). Preventing activation of complement or destroying its
components can interfere with both humoral and cellular defences.
Some surface or capsular materials of bacteria have been strongly
implicated in masking cell-wall components which would otherwise
activate complement directly or after reaction with natural antibody.
Capsular polysaccharides of Streptococcus pneumoniae are often poor
activators of the alternative and classical pathways in the absence of
specific antibody (Giebink et al 1978). Some bacteria destroy components
of complement thereby preventing its action. S. aureus produces and
sheds a decomplementation antigen (Bhakdi and Muhly 1985) which
consumes early but not terminal pathway components from serum in
conjunction with antibody. Many Gram positive bacteria are innately
resistant to lysis by complement, which might be explained by the cell
wall acting as a barrier hindering access of complement to the
cytoplasmic membrane (Braude 1981).
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Proteus and Klebsiella spp inactivate complement. Their urease splits
urea in the kidney and thereby releases ammonia, which can inactivate
complement (Braude 1981). The elastase of Pseudomonas aeruginosa
destroys part of the complement cascade (Schultz and Miller 1974;
Densen and Mandell 1980).
Interference with the immune response
Bacteria can interfere with the immune response either by directly
suppressing it or by subverting its action. Many bacteria, particularly
those causing chronic infections, suppress the action of B and T cells by
various mechanisms (Falconi and Campa 1981).
Bacteria can also subvert the immune response by one of three ways.
First, the determinants can be poor antigens, i.e. they stimulate the
immune response inadequately or nor at all. Thus, the determinants
will not be completely neutralised by the immune response and
infection will persist (Malakian and Schwab 1967; Finger et al 1971).
Second, bacteria can undergo antigenic change or shift; when the host
has responded immunologically to their surface antigens, new bacterial
types emerge with different surface antigens and the immune response
is rendered ineffective. This shift seems to occur in some bacterial
disease and during persistence of potentially pathogenic commensals on
mucous surfaces. The surface antigens of Borrelia recurrentis seem to
change during relapsing fever (Smith 1984). Finally, the bacteria may
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hide away in cells such as epithelial cells or impaired mononuclear
phagocytes; within these cells the bacteria are protected against the host
defence mechanisms. Examples of bacteria that hide in cells are
Salmonella spp (Roantree 1967), Shigella flexneri (Yee and Buffenmyer
1970) and Mycobacterium tuberculosis (D'Arcy Hart and Armstrong
1974).
1.2.5 Damage to the host
Pathogenic bacteria damage the host tissues in two ways: production of
toxins and stimulation of harmful immunological reactions.
Production of toxins
Most pathogenic bacteria form toxins, which are responsible for the
harmful, sometimes lethal effects of disease. Most toxins are extracellular
and they can inhibit protein synthesis, produce fluid loss from the gut,
interfere with nerve action, lyse cells and cause vascular effects. Toxin
elaboration may also inhibit the immune response of the host or
perhaps in the case of enterotoxins, flush away competing bacterial
neighbours (Cantey 1985). The most important cell-bound toxins are
endotoxins in the cell walls of Gram negative bacteria, these are
lipopolysaccharides whose toxicity appears to lie in their lipid portion
(Stephen and Pietrowski 1981).
Toxins are often just one of several virulence factors produced by
14
pathogens, and although toxins may represent the principal determinant
of virulence, and the cause of disease, they may not be the principal
determinant of infectivity.
Damage by immunopathological mechanisms
Bacteria can produce severe, even fatal effects on the host by stimulating
an immune response to otherwise non-toxic bacterial components, and
then interacting with this response in a subsequent infection or late in a
chronic infection in a manner which damages tissue immunopathology.
There are four types of immunopathological reaction: immediate
hypersensitivity, Arthus type responses, cytotoxic reactions and delayed
hypersensitivity (Parish 1972). Immediate hypersensitivity is where IgE
antibody is present on mast cells and releases histamines, thereby
producing vascular and respiratory effects seen in hay fever or asthma.
Arthus type reactions occur when antigen-antibody complexes are
deposited on tissue, which then gets attacked by phagocytes and causes
tissue damage. This seems to happen in kidney damage following
infections with Proteus mirabilis and streptococci (Parish 1972). Delayed
hypersensitivity reactions occur where cell mediated immunity
stimulated by previous interaction with the bacteria, mobilise
mononuclear phagocytes to the site of additional or persistent infection
and cause tissue damage (Rich 1951; Easmon and Glynn 1975b).
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1.3 Staphylococcus aureus
As already mentioned, a successful parasite must gain access to its host,
must survive and multiply, then leave the host and spread to a new
host. S. aureus is a pathogenic bacterium par excellence which has
become adapted to the fulfilment of these requirements. They are among
the most important bacteria causing disease in humans. They are normal
inhabitants of the human upper respiratory tract, skin, intestinal tract
and vagina and are particularly prone to produce infection when a
foreign body has lowered host resistance. These microorganisms also are
noteworthy for the production of large numbers of exotoxins and other
substances, some of which undoubtedly play an important role in their
capacity to cause disease (Arvidson 1983).
The name Staphylococcus is derived from the Greek word Staphule,
meaning cluster of grapes (Ogston 1882). These cells are able to divide on
more than one plane, and so as a result the cells form irregular masses
resembling bunches of grapes (Baird-Parker 1972).
1.3.1 Pathogenesis
Staphylococci may produce disease in almost every organ and tissue of
the body. The skin is particularly prone to infection and it is thought that
staphylococcal skin infections are probably the most common of all
infectious diseases. S. aureus infections may spread by extension to
contiguous tissues or by way of lymphatics and then blood. The disease
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process is initially localised wherever S. aureus lesions occur. There is
an acute inflammatory response and an accumulation of enormous
numbers of segregated neutrophils. Lesions tend to be walled off, owing
to the subsequent deposition of fibrin, central necrosis appears and an
abscess is formed. Thus staphylococcal infections are characterised by
abscess formation. Dissemination may occur from an initial abscess.
It is not only S. aureus which is pathogenic, since coagulase negative
staphylococci have become formidable nosocomial pathogens (Horan et
al 1986). There is evidence that coagulase negative staphylococci produce
a number of virulence factors that resemble those of S. aureus
(Gemmell and Roberts 1974). They have the ability to adhere irreversibly
to and grow on polymer surfaces and to produce an extracellular slime
substance (Christensen et al 1985).
1.3.2 Virulence factors
Probably no other bacterium produces as many extracellular toxins,
haemolysins, enzymes and cellular components, all of which at one time
or another have been thought to be responsible for the virulence of
S. aureus.
It is not possible to state that any one of a combination of these factors
accounts for the virulence of S. aureus. Probably many of them play
some role in the pathogenesis of staphylococcal disease, since
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pathogenicity is a multifactorial process (Smith 1984). As previously
mentioned, five requirements have to be fulfilled in order for disease to
occur. These requirements can be broadly placed into two groups - entry
and infection, and multiply and resist host defences. The pathogenicity
factors of S. aureus can be placed in these two groups as well.
Table 1. Virulence factors of Staphylococcus aureus
Toxins Exoenzymes Cell Bound Factors
a Coagulase Clumping Factor
p Staphylokinase Protein A








Entry and infection of mucosal surface
S. aureus is particularly well endowed to colonise the outer or inner
surface of its host, or to survive in sites of injury or infection. Resistance
to desiccation and to skin fatty acids might be important in the early
stages of infection. Methicillin-resistant S.aureus isolated from a burns
unit, where spread was through the air, environment or staff contacts
were significantly more resistant to desiccation than were strains
common on a neonatal unit where hand-borne transmission is
predominant (Farrington et al 1992). All staphylococci possess lipase and
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esterase, which are able to breakdown the fats and waxes of the skin
(Stewart 1965). S. aureus is also able to transport and oxidise amino acids,
and metabolise carbohydrates (Ivler 1965).
Capsulation was found to provide increased protection from bactericidal
lipids (Mortensen and Kapral 1992). However the effect was limited with
only a 3-4 fold greater resistance in the capsulated strains than in the
non-capsulate strains (Mortensen and Kapral 1992). Also, a strain which
was very resistant to the bactericidal lipids was not capsulate, so other
mechanisms besides capsule formation must be involved in sensitivity
to lipids.
Pathogenic staphylococci are in practice distinguished from
non-pathogenic strains by the secretion of coagulase (Cruiskshank 1937;
Christie et al 1946). Coagulase is a protein which has the capacity to cause
the clotting reaction of plasma (Zajdel et al 1976), by forming a
stoichiometric, non-covalent complex with prothrombin (Hemker et al
1975). The formation of staphylothrombin does not involve proteolytic
cleavage of the blood protein. It converts fibrinogen into insoluble fibrin
in a manner similar to the action of physiologically formed thrombin
(Hemker et al 1975; Zajdel et al 1976). The fibrin network may help form
a wall round the staphylococcal infection site or, it may impede the final
access of phagocytic cells, as well as depositing host fibrin on the bacterial
cell wall, which therefore presents a less foreign surface to phagocytic
19
cells (Suter 1956; Jeljaszewicz et al 1983).
A second factor usually present at the surface of virulent staphylococci is
bound coagulase (or clumping factor) (Duthie 1954; Engels and Kamps
1981). It is an antigenic protein which adsorbs fibrinogen with resulting
aggregation of the staphylococcal cells. It is related antigenically to the
extracellular Staphylocoagulase and is linked hydrophobically to the cell
membrane (Engels and Kamps 1981). It has been suggested that it is an
intermediate in the secretion process (Engels and Kamps 1981). It binds
fibrinogen in the absence of prothrombin, which is the basis for the
clumping reaction of staphylococci (Boden and Flock 1989). Clumped
staphylococci are held together by fibrin fibres originating from the cell
surface (Umeda et al 1980).
It has long been inferred that coagulase is a virulence factor and
coagulase negative strains are less virulent than coagulase positive S.
aureus (Kinsman and Arbuthnott 1980). This was supported by
observations that coagulase-deficient mutants of S. aureus are less
virulent for mice (Hasegawa and San Clemente 1978; Josson et al 1985).
However, in these cases the mutants were isolated following chemical
mutagenesis, so the loss of virulence may be due to mutation(s) which
affect other factors, or the ability of the organisms to grow in vivo could
have been compromised. A recent study reported the isolation of a
single-site, coagulase deficient mutant by allele-replacement, which
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would only affect the expression of coagulase. The coagulase negative
mutant was no less virulent than otherwise isogenic coagulase positive
strains both in terms of skin lesions and mastitis infections of mice
(Phonimdaeng et al 1990).
The majority of coagulase positive staphylococci produce Staphylokinase
which is fibrinolytic. Staphylokinase activates plasminogen to plasmin
and is indirectly responsible for the fibrinolytic activity of S. aureus
(Lewis and Ferguson 1951). They also produce hyaluronidase (spreading
factor), an enzyme capable of hydrolysing the mucoid ground substance
of the connective tissue (Linker et al 1956). The term 'spreading factor'
originates from Duran-Reynals who found that extracts from S. aureus
culture fluid enhanced the intracutaneous spreading of vaccinia virus,
toxins and dyes (1933). It is not thought to be of clinical importance but it
might have a role in the initial stages of infection (Elek 1959).
Fibronectin, which is a high molecular weight glycoprotein found in
blood and other body fluids, has been shown to bind S. aureus (Kuusela
1978; Verbrugh et al 1981). The binding of fibronectin to S. aureus is
mediated via the 27 kilodalton fragment of the amino terminus (Mosher
and Proctor 1980). Fibronectin has been shown to increase adherence of
bacteria to neutrophils (Verbrugh et al 1981; Proctor et al 1982b). Several
groups have tried to isolate and purify the native cell wall associated
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fibronectin protein of S. aureus, and there now seems to be full
agreement that the fibronectin binding protein is 210 kilodalton as
determined by SDS-PAGE (Froman et al 1987). The presence of
fibronectin at sites of tissue damage may allow S. aureus to adhere. This
is supported by the observation that a quantitative relationship exists
between the number of fibronectin binding sites and the tendency of
S. aureus to invade (Proctor et al 1982a). Besides serving as a substrate for
bacterial attachment and colonisation, fibronectin has also been
suggested as a factor in host defence. Fibronectin opsonizes S. aureus for
neutrophils (Proctor et al 1979), which might be important for
neutrophil activity in early S. aureus infection. Duckworth and Jordens
(1990) found that methicillin resistant S. aureus (MRSA) adhere less well
to HEp2 cells and fibronectin than methicillin-sensitive S. aureus.
Multiplication and resistance to host defences
S. aureus produces a large number of extracellular and cell bound toxic
factors - at least 30 have been identified (Bernheimer and Schwartz 1961).
Some of these will be considered individually.
Alpha toxin
Since the early studies of Burnet (1930) to a recent study by Bhakdi and
Tranum-Jensen (1991), a toxin has been the most intensely studied
staphylococcal toxin. Its main significance in pathogenicity is that of
producing tissue damage after establishment of a focus of infection. It is
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dermonecrotic, haemolytic to erythrocytes (Bernheimer 1965) and lethal
to animals in sufficient dosage (Jeljaszewicz et al 1969). It produces spasm
and paralysis of both smooth and skeletal muscle (Thai and Egner 1961)
and can destroy or damage a wide variety of tissue culture cells, as well as
leukocytes (Szmigielski et al 1967), platelets (Bernheimer and Schwartz
1965) and lysosomes (Bernheimer and Schwartz 1964).
The primary mechanism of membrane damage is the formation of pores
(Fussle et al 1981). After binding to target membranes, toxin molecules
oligomerize to form noncovalently associated, stable hexameric protein
complexes. This process is associated with an exposure of lipid-binding
domains, that enable the hexamer to insert spontaneously into the
membrane. The hollow interior of the hexamer generates a hydrophilic
channel across the lipid bilayer (Bloomquist and Thelestam 1988; Forti
and Menestrina 1989). Toxin binds to target cells via two distinct types of
interaction. At low concentrations, the toxin binds exclusively to a
specific site, and at high concentrations, the toxin binds to membranes
via a non specific absorptive interaction (Hildebrand et al 1991). The
pores (1-2 nm diameter) permit free passage of ions and low-molecular
weight molecules such as nucleotides, so cell death can be expected to
ensue. Permeabilized erythrocytes undergo irreversible osmotic swelling,
and haemoglobin is finally liberated as the membrane ruptures. Death of
a particular cell type can have some primary biological consequences as a
direct result of loss of the respective cell function. For example,
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monocytes and macrophages are effectively killed by a toxin, and this
conceivably cripples the phagocytic defence system in tissues (McGee et al
1983; Bhakdi et al 1989). It seems probable that such a powerful enzyme,
producing injurious changes in the membrane permeability of a wide
variety of cells, must have survival value to the parasitic staphylococcus
in the tissues of its host. This is especially true in the light of S. aureus'
ability to metabolise breakdown products of cells (Arvidson 1983).
Mutants of S. aureus deficient in a toxin production are less virulent
than parental strains (Van der Vijer et al 1975; Jonsson et al 1985). These
mutants were chemically induced and other characteristics might have
been altered which also affect the virulence. Another major difficulty in
these experiments, is that the production of several potentially
important virulence factors in addition to a toxin are under regulation
by a common control element (Yoshikawa et al 1974; Bjorklind and
Arvidson 1980; Coleman 1981). The use of genetically engineered,
isogenic bacterial strains differing solely in the expression of the a toxin
gene gives proof for a pathogenic role of the toxin. In a study with
isogenic strains a toxin was shown to be the major causative factor in the
development of staphylococcal lesions in animal infections (Patel et al
1987). In another study employing site directed mutagenesis, an a toxin
producing strain was more virulent than the toxin deficient isogenic
strain in a mouse peritonitis model (O'Reilly et al 1986).
24
Beta toxin
This toxin is produced mainly by strains of S. aureus of animal origin,
although human strains may produce it as well (Sperber 1977). It appears
to be much less toxic than a toxin. It is a phospholipase C specific for
sphingomyelin in the cell membrane (Wadstrom and Molby 1971; Molby
1976). The property which first focused on p toxin was the classic hot-cold
haemolytic phenomenon (Bigger et al 1927). Little or no lysis occurs
when p toxin is incubated at 37°C in the presence of Mg2+ with sheep
erythrocytes. But if the reaction mixture is chilled for a period below
10°C, dramatic rapid lysis takes place. The sensitivity of erythrocytes of
different species to p toxin is directly related to the relative amount of
sphingomyelin in the membrane phospholipids. The most sensitive
species are sheep, goat and ox, since their membrane phospholipids
consist of about 50% sphingomyelin (Wiseman and Caird 1967). It has
been shown that p haemolysin inhibits the Fc region of immunoglobulin
from binding to monocytes, lymphocytes and polymorphonuclear
leucocytes (PMNs), as well as being a negative chemotactic substance
(Wilkinson 1977).
Gamma haemolysin
The production of a y haemolysin from strains of staphylococci was
demonstrated by Smith and Price (1938). It consists of two distinct
cationic proteins (Taylor and Bernheimer 1974), which act synergistically.
A recent report (Clyne et al 1992) suggests that the yi component is a
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protease or protease-like molecule that acts specifically on the 72
component to give enhanced haemolysis. The toxin exhibits a specificity
for rabbit, human and sheep erythrocytes (Fackrell and Wiseman 1976).
In this respect it resembles a toxin however it differs from it
antigenically (Mollby 1983).
Delta toxin
8 toxin differs in many respects from the other three haemolysins
excreted by staphylococci in its characteristics, properties and
mechanisms of action, which is detergent like. It can damage a variety
of cell types as a result of this activity (Rahal 1972; Wadstrom and Molby
1972). The toxin is lytic for erythrocytes and other mammalian cells,
intracellular organelles and bacterial protoplasts and spheroplasts
(Kreger and Bernheimer 1971). It has been shown to interact with many
types of phospholipid monolayers as well as cod and sheep erythrocyte
lipid films (Bhakoo et al 1982) suggesting an amphiphilic structure. The
toxin forms an unusually stable monolayer and induces membrane
permeability changes of large unilamelar vesicles composed of
structurally defined lipids (Bhakoo et al 1985). It causes lesions in
membranes strikingly similar to those caused by melittin and the
detergent Triton X-100 (Thelestam and Mollby 1975). 8 toxin is thought to
be a surfactant because it is inhibited by phospholipids (Kreger 1970) and
dilute normal serum (Jackson and Little 1958), has a low specific
haemolytic activity and lyses a wide range of cell types (Kreger et al 1971).
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It affects erythrocytes of all animal species without the significant
differences in susceptibility so characteristic of a and (3 toxin (Kayser and
Raynaud 1965).
Panton-Valentine leucocidin
Another exotoxin which probably serves to protect S. aureus against the
defending leucocytes of the host is Panton-Valentine leucocidin
(Woodin 1960; Woodin 1970). The leucotoxic action of this non
haemolytic leucocidin requires the synergistic action of two proteins, the
F and S components (Woodin 1970). When exposed to a mixture of F
and S components, susceptible leucocytes exhibit an increased
permeability to cations but larger molecules such as phosphates,
nucleotides and reducing sugars are retained within the cell (Woodin
1972). This causes efflux of potassium and magnesium ions from the
cells and impairs the function of the sodium-potassium pump, which is
accompanied by influx of sodium and calcium ions into the leucocytes,
with osmotic swelling of cells (Woodin 1965). It has been suggested that
leucocidin enhances staphylococcal invasiveness by allowing the
organism to resist phagocytosis (Rogers and Tomsett 1952).
Protein A
Protein A is a widely distributed cell wall protein of many strains of
S. aureus which is covalently bound to the peptidoglycan of the cell wall
(Sjoquist et al 1972; Sjodahl 1977). Its main feature of interest is its high
27
affinity for the Fc region of many classes of IgG from a wide range of
mammalian species (Goding 1978). Five repeated domains which bind
the immunoglobulin molecules protrude from the cell surface (Lofdahl
et al 1983). These complexes can activate both the classical and
alternative pathways of complement (Dossett et al 1969). The presence of
protein A on the surface of the staphylococcus has also been shown to
impair its phagocytosis by human polymorphonuclear leucocytes in
vitro (Peterson et al 1977a). It impairs opsonophagocytosis of bacterial
cells and can induce hypersensitivity and histamine release from
basophils (Fosgren et al 1983). Evidence for a role for protein A in
pathogenesis is not definitive, although the level of its expression has
been shown to correlate with resistance to opsonophagocytosis in vitro
(Peterson et al 1977a). Protein A deficient mutants were less virulent
than wild type strains in a peritonitis and skin abscess model (Patel et al
1987). A mutant which expresses high levels of protein A was found to
be virulent for mouse mammary gland. Protein A was found to be
virulent for mouse mastitis when it is expressed at a sufficiently high
level (Foster et al 1990).
Disease caused by S. aureus may be the result of tissue invasion by a
variety of extracellular products. Of these, three toxins are known which
have closely related clinical features. Enterotoxins produce food
poisoning, exfoliative toxins cause staphylococcal scalded skin syndrome
and toxic shock syndrome toxin may cause toxic shock syndrome.
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Enterotoxins
The enterotoxins of S. aureus form a group of five serologically distinct
extracellular proteins, designated A, B, C, D and E (SEA - SEE) (Bergdoll
et al 1973). SEC is further broken down into three subtypes (SECj, SEC2
and SEC3) that have minor differences in serological reactions. They are
recognised as the causative agents of staphylococcal food poisoning (Dack
et al 1930). Ingestion of preformed toxin in contaminated food leads to
the rapid development (2-6 h) of the symptoms of vomiting and
diarrhoea that characterise staphylococcal food poisoning. The toxin is
absorbed and reaches the central nervous system via the systemic
circulation (Sugiyama and Hayama 1965). It is the action of the toxin on
the vomiting centre of the central nervous system that results in often
violent gastrointestinal tract manifestations of disease. Besides being
emetic toxins, they have potent immunological activities such as
stimulation of T-cell proliferation and induction of interleukin-1 and
tumour necrosis factor (Parsonet et al 1985; Fast et al 1989). The
enterotoxins are often called neurotoxins because of their effect on the
nervous system (Freer and Arbuthnott 1986).
Exfoliative Toxin
It is produced by certain strains of S. aureus and is controlled by a
plasmid. It causes exfoliation of the skin of infected children, a clinical
condition known as "scalded skin syndrome" (Melish et al 1972; Piemont
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et al 1984). The disease is characterised by a region of erythema which
usually begins around the mouth and in 1-2 days, extends over the
whole body. The most striking feature of the disease, is that the
epidermis although apparently healthy, can be displaced and wrinkled
like the skin of a ripe peach by the slightest pressure. Soon large areas of
the epidermis become lifted by a layer of serous fluid and peel at the
slightest touch (Melish and Glasgow 1970). The mechanism by which
exfoliation achieves intra-epidermal splitting is not known, but all
available evidence suggests that it is an extracellular, not cytotoxic
process (Elias et al 1977). Two serotypes of the toxin, ET A and ET B have
been recognised (Kondo et al 1975); ET A is encoded chromosomally
while ET B is plasmid encoded (O'Toole and Foster 1986). Certain strains
produce only a single form of ET, while others produce both toxins
(Kondo et al 1975).
Toxic Shock Syndrome
The syndrome is characterised by fever, rash, hypotension and eventual
desquamation of the skin of the palms of the hands and the soles of the
feet (Todd et al 1978). It was thought that the persons most at risk were
young menstruating women who used tampons (Davis et al 1980;
Shands et al 1980). It is now known that toxic shock may occur in persons
of any age, race or sex, provided there is an associated staphylococcal
infection. There is broad agreement that the multisystem effects
observed in toxic shock syndrome patients are induced by toxic shock
30
syndrome toxin-l(TSST-l)(Bergdoll et al 1981; Schlievert et al 1981).
The multisystem effects that typify TSS point to an indirect action of
TSST-1, followed by the release of mediator substances such as
interleukins and tumour necrosis factor (Parsonnet et al 1985; de
Azavedo et al 1988). Occasionally clinical strains lack the ability to
produce TSST-1; this gives rise to speculation that toxic factors other
than TSST-1 e.g. enterotoxin B (Crass and Bergdoll 1986) may be able to
induce physiological and pathological changes similar to TSST-1.
Role of staphylococcal virulence factors in disease
Staphylococcal disease in man encompasses a spectrum of clinical
manifestations (eg. toxin-mediated syndromes, contiguous infections,
bacteraemia, asymptomatic colonisation) depending on the properties of
the strain of S. aureus, the site of infection and the degree to which host
defences are compromised. The role of S. aureus virulence factors in
tissue damage and infection has not been studied in much detail. Since
several toxins are elaborated in staphylococcal lesions, interactions
between the toxins might occur and need to be taken in to account,
before the overall contribution to the virulence factors can be
determined.
S. aureus isolates from septicaemia showed a higher incidence of
enterotoxins A,B and C production (Humphreys et al 1989), indicating
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that the enterotoxins have a role to play in S. aureus infections other
than food poisoning. Christensson and Hedstrom (1986) found an
inverse relationship between a toxin production and TSST-1 production.
1.3.3 Antibiotic resistance in S. aureus
Staphylococci are widely distributed in nature and are among the
commonest human parasites. One of the most threatening problems is
the great ability of staphylococci to become resistant to most antibacterials
introduced to combat the organism. Penicillin was introduced in the
early 1940's, and at that time, less than 1% of S. aureus strains isolated
showed resistance. By the late 1940's penicillin resistance in S. aureus
had increased, such that by 1946, 60% of hospital strains in the UK were
penicillin resistant (Barber and Rozwadowska-Dowzenko 1948).
Streptomycin and tetracycline were introduced towards the end of the
1940's. Streptomycin resistance rapidly appeared (Demerec 1948) but
tetracycline was often successfully used to treat infections caused by
penicillin-resistant staphylococci.
During the 1950's, there was an increase in the incidence of multiple
antibiotic resistant strains and virulent penicillinase-producing strains.
A new virulent phage type 80/81, which could spread extensively in
hospitals and was penicillin resistant was observed in Australia
(Rountree and Freeman 1955). Many strains had a broad range of
resistances to four or more antibiotics (Bulger and Sherris 1968).
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Methicillin and cloxacillin were introduced early in the 1960's, and there
was a general decline in the prevalence of multiple resistant S. aureus
strains during the mid and late 1960's (Bulger and Sherris 1968).
Staphylococcal resistance to methicillin and cloxacillin did not emerge
immediately, as seen after the introduction of other antibiotics.
However, in Europe, methicillin resistance problems were increasingly
reported and the strains were also resistant to tetracycline, erythromycin
and kanamycin (Benner and Kayser 1968; Rosendal 1971). Britain also
experienced an increase in methicillin resistance, reaching 5% in 1969
(Parker and Hewitt 1970). Multiple antibiotic resistant S. aureus were still
common at the end of the 1960's although they were gradually declining.
Cloxacillin could be used to treat infections caused by these organisms
and vancomycin and gentamicin were used to treat MRSA infections
(Pittman et al 1965; Benner and Marthland 1967).
The declining incidence of multiple antibiotic resistance observed in the
1960's continued during the 1970's, not only in Britain (Phillips 1979) but
in other countries as well (Plorde and Sherris 1974; Rosendal et al 1977).
Gentamicin had been used for almost a decade and resistance had been
rare. Then in 1976 gentamicin resistant strains emerged (Blint 1976;
Speller et al 1976).
An upsurge of methicillin - resistant S. aureus was noted in the 1980's
causing clinical problems since they were resistant to many antibiotics
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(Marples et al 1986). Some strains of S. aureus showed resistance to as
many as 20 antimicrobial agents, including antiseptics and heavy metal
ions (Lyon and Skurray 1987). Novel MRSA strains emerged which
could be distinguished from other MRSA by their antibiotic resistance
profile, location of resistance genes and their phage type (Cookson and
Phillips 1988, 1990). During the early 1980's a new group of quinolone
antibacterials were being developed which were found to be active
against S. aureus and were useful in the treatment of infections caused
by MRSA (Neu 1987; Smith et al 1987). This new group of quinolone
derivatives were termed the 4-quinolones.
1.4 Quinolone Antibacterials
1.4.1 History
The quinolone antibacterial agents are similar to trimethoprim and the
sulphonamides, in the sense that they are chemically synthesised
compounds and were not naturally isolated from moulds or fungi. The
antibacterial activity of nalidixic acid, the progenitor of the 4-quinolones,
was fortuitously discovered during chloroquine synthesis (Lesher et al
1962). Nalidixic acid has low activity against Gram negative bacteria
along with poor pharmacology plus reports of clinical failures and
development of resistance (Ronald et al 1966), it soon fell out of favour.
Development of more potent and wider spectrum derivatives has
continued with the introduction of the new fluoroquinolones such as
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ofloxacin, norfloxacin and ciprofloxacin. In contrast to nalidixic acid
originally used for urinary tract infections, the newer agents had a
broader spectrum of activity. Whereas oxolinic acid, norfloxacin and
ciprofloxacin are true quinolones in the chemical sense, other
derivatives are not; for example nalidixic acid and enoxacin are strictly
naphthyridines. For the sake of simplicity the collective term
4-quinolone was proposed as a generic name for all these bacterial agents,
despite the fact that this does not necessarily conform to strict chemical
terminology (Smith 1984).
1.4.2 Mode of action
Bacteria are confronted with a major problem, because each contains a
chromosome that is composed of double stranded DNA 1300 jim long
and yet the average bacterium is only 2 nm long and 1 |im wide. Worcel
(1974) studied how the chromosome is packed in Escherichia coli and
found that it is subdivided into about 65 regions which he termed
domains. Each domain, on average about 20 |im long, is attached to an
RNA core and the size of each domain is reduced by being wound up
tightly through the introduction of supercoiling. Such supercoiling
occurs in E. coli and most other bacteria against the normal direction of
the helical state of DNA in its linear form (Wang 1974) and is termed
negative supercoiling. Each domain is supercoiled in an event during
which the chromosome is transiently nicked. The enzyme that nicks
double-stranded chromosomal DNA, is termed DNA gyrase (Gellert et al
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1976). DNA gyrase is composed of four subunits, two A and two B
(Higgins et al 1978) and there seems to be one tetramer per domain. It is
believed that the A subunit first introduces a nick into each strand of the
double stranded DNA (Gellert et al 1977). The nicks are staggered by four
base pairs (Morrison and Cozzarelli 1979). The DNA is then thought to
be supercoiled by the B subunits which utilise a molecule of ATP for
each twist removed. Finally, the resultant negative supercoils are locked
into each domain by the A subunits, which are thought to seal the nicks
that they first introduced (Gellert et al 1977). It was proposed (Crumplin
and Smith 1976; Gellert et al 1977) that the 4-quinolones prevent the A
subunits of DNA gyrase from finally sealing the staggered nicks they first
introduced into chromosomal DNA. However, it is known that
mutations that affect the B subunit of DNA gyrase change bacterial
sensitivity to the 4-quinolone antibacterials (Inoue et al 1978; Smith 1984)
and so the 4-quinolones would seem to affect not only the A subunits of
DNA gyrase but also the B subunits.
1.4.3 Resistance
The 4-quinolones have not yet been affected by plasmid mediated
resistance, which is exceptional among antibacterial agents. As a result of
this, the frequency of clinical resistance to the 4-quinolones is much less
than that seen with other major groups of antibiotics and
chemotherapeutic agents (Burman 1977).
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At present plasmid-mediated resistance to the modern 4-quinolones has
not been identified in clinical isolates. There have been reports of
plasmid-mediated nalidixic acid resistance in Shigella dysenteriae
strains isolated in Kashmir (Panhotra et al 1985) and Bangladesh
(Munshi et al 1987). However, these reports were inconclusive and it
was suggested that the plasmid carried mutator genes that increased the
frequency of chromosomal mutations to nalidixic acid (Crumplin 1987).
As plasmid-mediated quinolone resistance has yet to be identified in a
clinical strain, chromosomal mutations are the only mechanism by
which bacteria are able to develop resistance to the 4-quinolones during
therapy. Chromosomally mediated resistance to the 4-quinolones can
occur by one of two mechanisms - either an alteration in the target
enzyme, DNA gyrase, or a mutation that reduces drug accumulation.
In most species investigated so far, high level resistance to all
4-quinolones appears to be conferred by mutations in the gyr A gene
which codes for the A subunit of DNA gyrase. Gyr A mutations confer
high level cross resistance to all 4-quinolones, but do not seem to be
associated with resistance to other, unrelated antibacterial agents. Such
mutations have been identified in E. coli ( Hooper et al 1986; Nakamura
et al 1989), Pseudomonas aeruginosa (Robillard and Scarpa 1988),
Haemophilus influenzae (Setlow et al 1985) and Serratia marcescens
(Fujimaki et al 1989). Mutations in the B subunit of DNA gyrase coded by
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the gyr B gene have shown to cause 4-quinolone resistance in
Ps. aeruginosa and E. coli (Nakamura et al 1989; Yoshida et al 1990b).
Most of the investigations on the effect of 4-quinolones on DNA gyrase
activity have been carried out on Gram negative bacteria with few
investigations on Gram positive organisms. It has been suggested that
mutations in gyr A gene of S. aureus are responsible for ciprofloxacin
resistance (Sreedharan et al 1990).
The second mechanism of 4-quinolone resistance - reduced drug
accumulation, causes low level resistance to quinolones and structurally
unrelated drugs such as beta-lactam agents, tetracycline and
chloramphenicol. Mutations in E. coli which confer resistance to the
4-quinolones by an impermeability mechanism are associated with outer
membrane porin F (omp FXHirai et al 1986; Hooper et al 1989). An
energy-requiring saturable quinolone efflux system at the inner
membrane of E. coli has been described (Cohen et al 1988). The efflux
system was identified with the use of everted (inside out) inner
membrane vesicles, that accumulated norfloxacin when lactate was
added to allow generation of a proton motive force. Since the
membranes were everted the observed drug accumulation reflected drug
efflux in an intact cell. A mutation in the so-called nor A gene has been
linked to quinolone resistance in S. aureus. The gene seems to code for a
protein which is involved in some essential physiological activity in
the cell. As a point mutation of the nor A gene caused quinolone
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resistance by preventing cell accumulation of quinolone antibacterials, it
was suggested that the function of the nor A gene product is to transport
hydrophilic quinolone molecules across the cell membrane (Ohshita et
al 1990; Yoshida et al 1990a).
1.4.4 Relationship between resistance and virulence
Many virulence factors are known to be encoded by plasmids eg. toxins,
adhesion factors etc. In a study of enterotoxigenic E. coli, 72% were
resistant to one or more antibiotics and 44% were resistant to four or
more antibiotics (Echeverria et al 1987). In transfer experiments, none of
the recipients acquired toxigenicity without antibiotic resistance. Genes
coding antibiotic resistance and enterotoxins production could be
transferred together (Echeverria et al 1978). Enteropathogenic E. coli
adhere to HeLa cells in two different ways - localised adherence (LA) and
diffuse adherence (DA). Naturally occurring plasmids encoding for both
LA and antibiotic resistance have been recognised in E. coli (Laporta et al
1986). Curing by acridine orange showed that both features were lost
simultaneously. Lacey and Chopra (1975) suggested that acquisition of
resistance plasmids by S. aureus is associated with a decrease in
virulence.
The situation is different in bacteria possessing chromosomal mutations
conferring antibiotic resistance. Chromosomal mutations occur at a
frequency of 10"6 to 10 "8 per cell as a result of spontaneous mutations in
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chromosomal genes encoding the target site, or affecting access to the
target site. In practice, such mutations are found less frequently in
natural bacterial populations which may be attributed to the fact that
mutations reduce the fitness of bacteria to survive, i.e. that they lack
pathogenicity (Smith 1983; Saunders 1984).
The effect of chromosomal mutations conferring antibiotic resistance on
bacterial virulence has been demonstrated. An example is the alteration
in outer membrane porins of Gram negative bacteria which are
responsible for movement into bacteria of nutrients, ions and certain
antibiotics. A complex control mechanism regulates the quantitative
production of porins and affects their sensitivity to various antibiotics
such as the quinolones, chloramphenicol, tetracycline and beta-lactams.
Mutations which affect the transcriptional regulator of this mechanism,
Omp R, resulted in strains with markedly reduced virulence (Dorman et
al 1989). Cyclic AMP and the cAMP receptor protein are essential for
transcription of genes and operons involved in catabolite transport and
breakdown. The cAMP levels in cells influence synthesis of fimbriae and
flagella and manufacture of some OMPs. Deficiency in cAMP can be
associated with (5-lactam resistance. Mutations in Salmonella
typhimurium causing a loss of cAMP production lead to avirulent
strains (Curtis and Kelly 1987). In another study, gentamicin resistant
strains of Ps. aeruginosa showed a significant decrease in virulence. They
had slower growth rates, and two of the mutant strains had uncapped
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lipopolysaccharide (Bryan et al 1985). The possession of fully capped
lipopolysaccharide (smooth LPS) is a well known virulence factor in
Gram negative bacteria (Stephen and Pietrowski 1981). These examples
of chromosomal mutations show that genetic changes which are known
to be related to antibiotic resistance (eg alteration in OMPs) are associated
with decrease virulence.
Exposure of S. aureus to increasing concentrations of gentamicin
resulted in bacteria that grew as small nonhaemolytic colonies and did
not produce coagulase, deoxyribonuclease and mannitol (Musher et al
1977). Penicillin resistant S. aureus strains showed reduced pathogenicity
in mice and reduced production of coagulase and protein A (Rake et al
1944; Blair et al 1946). A similar situation was observed in methicillin
resistant staphylococci i.e. a reduction in virulence in some of the
resistant variants (Barber 1961; Knox and Smith 1961). Some
methicillin-resistant S. aureus had reduced production of protein A and
clumping factor (Lacey et al 1986). Epidemic MRSA produced low levels
of protein A and high levels of coagulase, whereas sporadic strains
produced high levels of protein A and a wide variety of coagulase
reactions (Roberts and Gaston 1987). Another study showed that MRSA
produced significantly more coagulase than MSSA and that enterotoxin
A was produced by MRSA and not by MSSA (Jordens et al 1989). MRSA
were more likely to be a haemolysin producers than MSSA (Coia et al
1992). Rifampicin-resistant mutants of S. aureus exhibited altered
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production of virulence factors and were less virulent for mice (Ai-Ani
etal 1991).
4-quinolone resistant Ps. aeruginosa were obtained from parental strains
by serial transfer through subinhibitory concentrations of quinolones.
The resistant mutants exhibited reduced virulence for mice and also had
increased sensitivity to aminoglycosides (Ravizzola et al 1987). Mutants
of E. coli which were resistant to 4-quinolones failed to haemagglutinate
as a result of a lack of surface pili (Crumplin 1990). It was suggested that
these 4-quinolone resistant E. coli may be less capable to colonise the
urinary tract and initiate an acute infection (Crumplin 1990). In some
strains of S. aureus resistant to ofloxacin, there was a loss of production
of coagulase (Smith 1990). In this study however, only a small number of
mutants were tested for coagulase production and they were tested by the
slide coagulase test, which is known to detect only bound coagulase
production (Smith, personal communication). Gemmell and
Felmingham (1990) observed that low level quinolone resistance in S.
aureus and Ps. aeruginosa resulted in a depression of respiratory burst
in PMN and that high level quinolone resistance resulted in a
potentiation of respiratory burst.
Despite these few examples, such changes in pathogenicity associated
with the development of antibiotic resistance has hardly been studied. If
4-quinolone - resistant bacteria are less pathogenic as proposed (Smith
42
1983), then this might represent an important counterbalance to the
development of resistance. Studies which examine the pathogenicity of
4-quinolone-resistant mutants would help to assess both the likelihood
of such organisms initiating an infection, or sustaining an established
infection if the resistance-conferring mutations occur during the course
of therapy (Crumplin 1990).
1.5 Investigating the role of microbial products in pathogenicity
1.5.1 Studying Pathogenicity
The role of a microbial product in the pathogenicity of an organism can
be studied when the infecting organism secretes only that product, as is
the case with Clostridium botulinum (Pappenheimer 1965). However,
the situation is more complex when the infecting organism secretes
more than one product, as with the staphylococci. In these cases, various
approaches have been taken to elucidate the role of each of the microbial
products. A direct approach has been to isolate and purify each product
and to investigate its effect in vitro and in vivo. Another method has
been to compare virulent and avirulent strains or, strains deficient or
enhanced in the production of particular toxins. They are compared both
in vitro, based on their biochemical characteristics and in vivo, based on
the infection they produce in laboratory animals (Shibl 1983).
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Isolation and purification of determinants
Two methods have been used for identifying virulence determinants,
chemical purification and genetic manipulation. The second now takes
precedence. The chemical approach was first used for the classical
bacterial toxins. Culture filtrates were fractionated employing toxicity as
an assay until purity was achieved. Neutralisation of toxicity by specific
antibody sealed the proof of causation. Once identified the determinant
is investigated in vivo and in vitro (Roth 1988). Genetic manipulation
can be used to identify virulence determinants and pinpoint their active
sites. Cell components of pathogens that previously were not readily
available e.g. those of Treponema pallidum, can be produced in
sufficient quantity for a representative demonstration of biological
activity and influence on virulence (van Emden et al 1983).
Comparison of virulent and avirulent strains
The multifactorial nature of pathogenicity can be analysed more
effectively by comparing strains of high and low virulence than by
observations on a single strain. The presence or absence of a particular
virulence determinant has been a matter of chance. Now, genetics is
widely used for producing strains of differing virulence. Classic methods
of genetic analysis including spontaneous or induced mutation and the
standard techniques of gene transfer have been used successfully to study
virulence factors. It is possible to compare two homogenic
microorganisms which differ from each other in only a single
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determinant of pathogenicity (Patel et al 1987; Phonimdaeng et al 1990).
Strains showing high and low virulence should be compared in vitro as
well as in vivo (Smith 1989).
1.5.2 Effect of antibiotics on expression of virulence determinants
The use of antibiotics that have the ability to inhibit production of
virulence factors without interfering with bacterial growth is one
approach to the study of the role of microbial products. The activity of
antibiotics is usually expressed in terms of concentrations that either
inhibit or kill microorganisms in vitro, or that prevent or treat
experimental infection in laboratory animals i.e. the minimum
inhibitory concentration (MIC). There has been interest in the effects of
sub inhibitory concentrations of antibiotics on bacterial cells. These
include changes in cell morphology, ultrastructure, rate of
multiplication and secretion of microbial products (Lorian 1980).
However, the MIC specifies the minimum inhibitory concentration
which keeps the bacterial inoculum below the threshold of visibility at
the time of inspection in the particular environment of the test
(Greenwood 1976b). Therefore it varies with the size of the bacterial
inoculum, incubation period and the medium used. Examining the
behaviour of strains in the presence of sub-MIC levels of antibiotics over
short periods of time will not fulfill the conditions used to determine
the MIC. This limitation should be noted. Also, when sub-MICs are used
in in vivo models, inaccuracies may occur and should be considered.
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Effects on growth rate
Abraham (1949) recognised three effects of sub-MIC antibiotic
concentrations; a prolongation of the lag phase, reduction in the rate of
logarithmic phase and diminution in the size of the bacterial population
reached in the stationary phase. For a given antibiotic one or all of these
effects could be observed. Subsequent reports confirmed that sub-MIC
antibiotic concentrations significantly inhibited growth (Greenwood
1976a; Shah et al 1976).
Effects on adherence
As previously mentioned, adhesion of microorganisms is an essential
event in pathogenicity. Sub-MIC levels of antibiotics may alter the ability
of various bacteria to adhere to host cells. Sub-MIC levels of penicillin
reduced the ability of resting-phase Streptococcus pyogenes to adhere to
human oral epithelial cells and yet adherence of dividing
Strep, pyogenes remained unchanged (Alkan and Beachey 1978).
Sub-MIC levels of clindamycin increased the adherence of dividing
Strep, pyogenes, which is due to an alteration in the conformation of the
surface of streptococci, so that previously buried structures become
exposed. In S. aureus sub-MIC levels of antibiotics effect adherence to
buccal epithelial cells. Lincomycin and clindamycin decreased the
adherence of this organism, whereas enhancement in adherence was
shown in the presence of penicillin (Shibl 1985). Sub-MIC levels of
penicillin, streptomycin, gentamicin, chloramphenicol and tetracycline
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markedly suppressed the adherence of Escherichia coli to human buccal
epithelium. This loss in adhesion appears to be a result of the inhibition
of the formation of surface adhesins rather than to the loss of adhesion
once it has formed (Beachey et al 1980). The effect of sub-MICs of
antibiotics on the interaction of S. aureus with fibronectin has been
shown (Proctor et al 1983). Sub-MICs of lincomycin, erythromycin and
chloramphenicol decrease fibronectin binding to S. aureus, whereas
beta-lactam antibiotics and vancomycin enhanced their interaction.
Effects on the production of toxins and enzymes
Toxin biosynthesis can be either inhibited or stimulated when the
producer organisms are grown in the presence of sub-MIC levels of
antibiotics. The production of protease by Ps. aeruginosa is inhibited by
tetracycline (Shibl and Al-Sowaygh 1980). Streptomycin inhibited the
production of haemolysin by E. coli (Shibl and Gemmell 1983). A variety
of toxins and enzymes produced by S. aureus can be inhibited by sub-MIC
levels of various antibiotics. Coagulase, a and 8 haemolysin and DNase
can be inhibited by lincomycin, clindamycin and fusidic acid (Gemmell
and Shibl 1976). Lincomycin stimulates the production of enterotoxin
both in E. coli and Vibrio cholera (Levner et al 1977). In S. aureus
penicillinase is stimulated by erythromycin and clindomycin (Michel et
al 1980). Penicillin and vancomycin stimulated the production of
haemolysin by Strep, pneumoniae (Lorian et al 1973).
47
1.5.3 Necessity to study pathogenicity in vivo
Most of the difficulties in the attempts to identify virulence
determinants have stemmed from two facts. First, as previously
mentioned, pathogenicity is multifactorial and loss of any single factor
can result in either partial or almost complete loss of virulence (Smith
1958). Second, virulence is only really detectable in vivo and is markedly
influenced by changes in growth conditions because of the selection of
phenotypes (Meynell 1961). The genetic information which determines
virulence may be expressed only under conditions of the test for
virulence, namely during growth in vivo. When microbes are removed
from infected animals and grown in vitro, the change of environment
will induce phenotypes different from those found in vivo; i.e. they may
lack some virulence determinants. Also, suspected determinants of
pathogenicity, indicated by experiments employing in vitro grown
organisms, may not be produced in vivo (Smith 1964).
Staphylococcus aureus grown in vivo differ in their overall amino acid
composition from cells grown in vitro (Watson and Prideaux 1979).
There is evidence that fresh clinical isolates of S. aureus (Karakawa and
Kane 1975) and S. aureus grown under in vivo cultural conditions
(Watson and Prideaux 1979) possess a different antigenic composition
compared with the same strain propagated in the laboratory. Freshly
isolated human strains of S. aureus were more resistant to phagocytosis
by polymorphonuclear leucocytes, a property attributed to the production
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by the organism of an acidic polysaccharide surface antigen under in
vivo cultural conditions (Karakawa and Kane 1975).
Animal models
The importance of the use of animal models in the understanding of the
pathogenesis of disease states is well established (Dalhoff 1985). Animal
studies can be divided into four general categories : basic screening
models, ex vivo models, monoparametric models and discriminative
models (Zak 1980).
Basic screening models include systemic infection, thigh-lesion test,
meningitis or pneumonia in mice. Infection is usually induced with an
inoculum that ensures death (or thigh swelling) in all the animals. They
are most frequently used in the early evaluation of new antibiotics (Zak
et al 1985). This model only gives a rough estimate of whether an
antibiotic is likely to be effective in vivo, since there are several inherent
limitations e.g. infections are initiated with a large inoculum and are
sensitive to the size of the infective inoculum (Nishino and Zak 1985).
Ex vivo models use a foreign body usually implanted subcutaneously,
which is subsequently infected with bacteria. These chambers can be
constructed so that only a limited number of parameters such as
antibiotic selection, nutrient supply and host immune response can be
evaluated during a given investigation (Zak and O'Reilly 1991). Their
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major drawback is that they represent a relatively artificial setting of
infection (Peterson 1986).
Monoparametric models do not estimate survival as in screening
models, but rely on different end points such as serial bacterial
concentrations in blood or tissues or alterations in bacterial morphology
during the course of therapy (Carbon 1990).
Discriminative models attempt to simulate human infections in order to
provide insight into both the pathogenesis and treatment of clinically
relevant infections. Many criteria for an ideal model have been described
(Harter and Petersdorf 1960). The model should be simple and
reproducible and should closely reflect the human disease e.g.
meningitis, endocarditis, abscesses (intradominal, subcutaneous).
Aims of the thesis
This thesis is going to study the postulate that ciprofloxacin-resistant
mutants of S. aureus lack pathogenicity. Ciprofloxacin sensitive and
resistant strains will be compared to establish any differences in their
respective production of virulence factors both in vitro and in vivo.
Since S. aureus produces a large number of virulence factors, it was not
possible to study all of them in the time available. A small number were
chosen to be studied in detail. The ciprofloxacin-resistant strains were
obtained from clinical sources but the type of staphylococcal infection
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from which the strains were isolated was not known. Therefore, it did
not seem appropriate to investigate the production of TSST-1,
epidermolytic toxin or the enterotoxins, since they are mainly specific to
disease producing strains. Four factors were chosen which are produced
by the majority of S. aureus strains; coagulase, protein A, a and 8
haemolysins. The production of the factors will be monitored in the
absence and presence of sub-MIC levels of certain antibiotics. Then, in
order to correlate the in vitro results with pathogenicity, the
ciprofloxacin-resistant mutants will be investigated in vivo. The in vivo
model was chosen for its reproducibility and ease. A model was needed
which could indicate the differences in the pathogenicity of the strains
investigated. Lethal dose 50 (LD50) calculations were the archetypal
measure of bacterial virulence but they are no longer considered
ethically acceptable. A subcutaneous abscess model in mice was
considered a good alternative and would extend the study of the
pathogenicity of the strains beyond the four factors mentioned in the in
vitro section of the project.
2 Materials and Methods
2.1 Bacterial Strains
Bacterial strains used during the project are listed in table 2. Paired
isolates of ciprofloxacin-sensitive and -resistant strains were obtained
from the PHLS, Colindale and Royal Infirmary of Edinburgh i.e. where
resistance to ciprofloxacin developed during therapy. However, since
only two such pairs were acquired as a result of difficulty in obtaining the
pre-therapy ciprofloxacin sensitive isolates, mainly clinical ciprofloxacin
-resistant strains were used. The ciprofloxacin-resistant strains (MIC
ciprofloxacin > 4 mg/L) were obtained from the PHLS, Colindale and
Royal Infirmary of Edinburgh. Ciprofloxacin-sensitive laboratory strains
and high virulence factor producing strains were acquired as mentioned
in Table 2. Ciprofloxacin-resistant mutants of the high virulence factor
producing strains were made as described in section 2.4.5.
All isolates were stored at -70°C in broth containing 10% glycerol and
were subcultured on to blood agar and incubated overnight immediately
before use.
Bacteriophage typing was kindly performed at the Central Public Health
Laboratory, Colindale, London.
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Table 2. Bacterial Strains
Strain Characteristics Origin
E 3T Standard sensitive J T Smith, London
Oxford Standard sensitive R Paton, Edinburgh
12009 Coagulase producer C Gemmell, Glasgow
Cowan 1 Protein A producer C Gemmell, Glasgow
Wood 46 Alpha haemolysin producer C Gemmell, Glasgow
E5662 Delta haemolysin producer C Gemmell, Glasgow
cip 63 Ciprofloxacin resistant strain R Paton, Edinburgh
cip 86 Ciprofloxacin resistant strain R Paton, Edinburgh
cip 92 Ciprofloxacin resistant strain R Paton, Edinburgh
cip 103 Ciprofloxacin resistant strain R Paton, Edinburgh
cip 132 Ciprofloxacin resistant strain R Paton, Edinburgh
591-89 Ciprofloxacin resistant strain PHLS, Colindale, London
4953-88 Ciprofloxacin resistant strain PHLS, Colindale, London
411-87 Ciprofloxacin resistant strain PHLS, Colindale, London
8984-88 Ciprofloxacin resistant strain PHLS, Colindale, London
5538-88 Ciprofloxacin resistant strain PHLS, Colindale, London
417-87 Ciprofloxacin resistant strain PHLS, Colindale, London
2219 Ciprofloxacin sensitive strain PHLS, Colindale, London
2221 Cipro resistant mutant of 2219 PHLS, Colindale, London
2222 Cipro resistant mutant of 2219 PHLS, Colindale, London
6989 Ciprofloxacin sensitive strain Edinburgh (RIE)
3225 Cipro resistant mutant of 6989 Edinburgh (RIE)
12009-3 Cipro resistant 12009 This study
Cowan-3 Cipro resistant Cowan 1 This study
Wood 46-3 Cipro resistantWood 46 This study
E5662-3 Cipro resistant E5662 This study
All the strains listed are Staphylococcus aureus except strains E5662 and




The complex media used were Nutrient Broth No.2 (CM67), Diagnostic
Sensitivity Test Agar (CM261), Columbia Agar base (CM331B), Brain
Heart Infusion Broth (CM225), Tryptone Soya Broth (CM129) (Oxoid,
Basingstoke, Hants).
2.2.2 Minimal Media
Single strength minimal salts medium (DM) was prepared as described
by Davis and Mingioli (1950). For the preparation of diluents, single
strength DM base was distributed in 9.9 ml and 4.5 ml aliquots which
were autoclaved at 121°C for 15 minutes.
2.2.3 Preparation of plates
All laboratory media were made up according to the manufacturer's
instructions and were autoclaved at 121°C for 15 minutes. The plates
were poured while the agar was still molten, each containing
approximately 20 ml. With antimicrobial drug sensitivity plates, the agar
was allowed to cool to 50°C before the appropriate antimicrobial drugs
were added and the plates poured. After setting, the plates were dried,




The antibacterial agents used are listed in table 3. All were supplied
sterile and prepared aseptically as listed.
Table 3. Antibacterial Agents
Antibacterial
agent












Chloramphenicol Boehringer Mannheim Alcohol
2.3.2 Buffers
Sodium phosphate buffers and sodium carbonate /bicarbonate buffers




Sterile dilutions were made with 1 in 10 and 1 in 100 dilution steps in
single strength DM i.e. 0.5 ml of culture and 4.5 ml diluent or 0.1 ml
culture and 9.9 ml of diluent respectively. Suspensions were mixed on a
Rotamixer (Hook and Tucker Ltd) and 0.1 ml amounts spread with a
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sterile glass spreader onto nutrient agar plates. The plates were
incubated, inverted at 37° C for 18 hours, after which time the plates
from dilutions yeilding 10-100 colonies were selected for counting. The
number of colonies on the plate were counted and the viable count was
calculated using the following equation:
colony forming units (cfu)/ml = N x 10a x 0.1,
where N is the number of colonies on the plate from 10*a dilution and
10a is the dilution factor. All dilutions were plated out in duplicate and a
average of the counts from the two plates was calculated.
2.4.2 Minimum Inhibitory Concentration (MIC) Determinations on
Solid Media
Oxoid No.2 Nutrient broth (4.5 ml amounts) was seeded with an
inoculum from a fresh nutrient agar plate and grown overnight at 37°C.
A 1 in 104 dilution was prepared by serial dilutions in DM base and 2 jxl
of this suspension was spotted onto media containing varying
concentrations of the drug with a multipoint inoculator (Denley). Plates
were incubated for 18 hours. Concentrations were increased by a factor of
2 and the MIC was taken as the first concentration permitting no visible
growth. A control plate lacking any drug was used in each case.
2.4.3 MIC Determination in Broth
Dilutions of each drug were made in 1 ml amounts of broth prior to
inoculation with 1 x 10 5 colony forming units (cfu)/strain and incubated
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for 18 hours at 37°C to determine their MIC. Concentrations were
increased by a factor of 2 and the MIC was defined as the lowest
concentration that inhibited visible growth.
2.4.4 Protein Estimations
Protein estimations were performed by the method of Waddell (1956).
All samples to be tested were suitably diluted (1:100 or 1:1000) in 50 mM
sodium phosphate buffer pH 7.4 and the absorbance measured at 215 and
225 nm. The protein concentration could then be calculated with
reference to a standard curve which had previously been prepared. This
method has been shown (Hesslewood 1973) to be as precise and more
sensitive than the protein estimation of Lowry et al (1951).
2.4.5 Mutational resistance to ciprofloxacin
Ciprofloxacin resistant mutants were selected by culturing the strains on
increasing concentrations of ciprofloxacin. The bacteria were grown
overnight in nutrient broth and then they were centrifuged at 4,500 rpm
for 15 minutes. The cell pellet was resuspended in fresh nutrient broth,
before being serially diluted to produce 10"2 and 10"4 dilutions. One
hundred microlitre amounts of the neat culture and the two dilutions
were spread with a sterile glass spreader on nutrient agar containing
ciprofloxacin at 1 , 2 or 4 times the MIC against sensitive parental strains.
The plates were incubated overnight at 37°C. Any colonies which grew
on the ciprofloxacin containing plates were subcultured onto nutrient
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agar plates containing the same amount of ciprofloxacin. The process
was repeated, except that the ciprofloxacin resistant mutant was grown
overnight and then plated out on higher concentrations of ciprofloxacin.
2.4.6 Growth Rate Determinations
Growth of strains was monitored over a defined period. Overnight
cultures of organisms were subcultured in 50 mis of fresh prewarmed
broth and incubated at 37°C with shaking. At hourly intervals, samples
were removed for viable counts to be taken. In some cases, the optical
density (590 nm) was monitored as well. In experiments where the
production of toxins or enzymes was being related to bacterial growth,
samples were taken at hourly intervals, the optical density at 590 nm
read and then the sample was prepared for the assay of the toxin or
enzyme in question.
2.4.7 Anaerobic growth of strains
Overnight cultures of organisms were subcultured into nutrient broth,
which had been maintained overnight in an anaerobic cabinet. Strains
were then incubated anaerobically overnight. The presence or absence of
growth was investigated the next day by viable counts as described in
section 2.4.1.
2.4.8 Purification of Staphylocoagulase
Staphylocoagulase was purified by a modification of the method of
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Igarashi et al (1979), by affinity chromatography on bovine-prothrombin
Sepharose 4B. CNBr-activated Sepharose 4B (Sigma) was coupled with
bovine prothrombin (Sigma) in accordance with the manufacturer's
instructions, before being poured into an Econo-Column (Bio-Rad)(0.375
cm2 x 20 cm). The filtered sterile culture supernatant of strain 12009 - a
high coagulase producer, was applied to the column. The column was
washed with 50 mM sodium phosphate buffer pH 7.4 containing 1M
NaCl and 0.0001% thiomersal (Sigma) (equilibration buffer) until the
absorbance at 280 nm returned to zero. The absorbed staphylocoagulase
was eluted with 1M NaSCN and 2 ml fractions were collected. These
fractions were dialysed overnight against equilibration buffer. The
dialysed samples were assayed for coagulase activity employing the
standard tube test (Sperber and Tatini 1975). Two hundred microlitre
amounts of sample were mixed with 0.2 ml of 1:10 diluted rabbit plasma
(Oxoid). The mixture was incubated for one hour at 37°C and examined
for the formation of a plasma clot. Then the purified coagulase was
concentrated in Amicon Centriprep 10 and Centricon 10 concentrators.
Concentrators were used in accordance with manufacturer's
instructions. The concentrated sample was stored at -20°C until use.
2.4.9 Quantitative assay for Staphylocoagulase
Staphylocoagulase activity was measured by a modification of the
chromogenic substrate assay of Engels et al (1981). In the assay,
staphylocoagulase activates prothrombin (Blood Products Laboratory,
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Elstree London) to staphylothrombin. The thrombin-like activity of this
complex cleaves a synthetic tripeptide, Chromozym T H (Boehringer
Mannheim) liberating a yellow product, p-nitroaniline and the optical
density is measured at 405 run. The assay was modified and improved to
distinguish bound, soluble and combined coagulase production and the
modifications will be discussed in detail in section 3.
2.4.10 Measurement of Protein A
Cell bound and extracellular protein A were detected by a modification of
the capture ELISA (enzyme linked immunosorbent assay) described by
Warnes et al (1986). Extracellular protein A was measured from the
supernatant of a broth culture and the pellet was processed to yield
cell-free lysates. Cell-free lysates were prepared as described by Warnes et
al (1986), except that after lysostaphin (Sigma) treatment, the lysates were
sonicated twice for 30 seconds at amplitude 10 on an MSE Soniprep,
while kept on ice. The lysates were centrifuged at 11 K rpm for 45
minutes before the pellets were discarded and the supernatants used as
the cell free lysates. The capture ELISA utilised human IgG (Sigma)
bound to the plates (Nunc Immuno module polysorp F8, Gibco Life
Technologies Ltd). Protein A was detected by incubation with rabbit
anti-protein A serum (Sigma) and then with goat (anti-rabbit IgG)
IgG-alkaline phosphatase conjugate (Sigma). The bound conjugate was
incubated with p-nitrophenylphosphate (Sigma) for 30 minutes at room
temperature, and the optical density determined at 405 nm in a Titertek
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Multiskan plate reader (Flow Laboratories Ltd). All isolates were tested in
duplicate on at least two separate occasions.
The amount of protein A produced by the isolates was related to total cell
protein. The protein concentration of the cell-free lysates was estimated
by the method of Waddell (1956) described in section 2.4.4. This gave an
estimate of the total cell protein. Each protein A ELISA contained
standard protein A (Sigma) concentrations, so that the amount of
protein A in the samples could be calculated from a standard curve.
Then the protein A in the samples was calculated in relation to total cell
protein. Extracellular protein A was measured in the supernatant of the
culture and cell bound protein A was measured from the processed cell
pellet i.e. cell free lysates.
2.4.11 IgG Column for elimination of Protein A
a and 8 haemolysins were measured by two separate ELISAs.
Unfortunately, major interferences occurred as a result of IgG-binding
protein A which is also present in the culture supernatant to be tested.
This problem was resolved by passing the supernatants through a CL-4B
Sepharose-IgG column, which adsorbed any protein A present (Berdal et
al 1981). The adsorption column was prepared as described by Berdal et al
(1981) and also according to the manufacturer's instructions. Filtered
supernatants were prepared as described by Berdal et al (1981), except that
the strains were grown in Tryptone Soya broth supplemented with 0.3%
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yeast extract which is reported to enhance haemolysin production
(Goode and Baldwin 1973). The supernatants were then passed through
the adsorption column. Once supernatants had been passed through the
column, they were tested for the presence of protein A by the protein A
ELISA described in section 2.4.10. All the samples should have been free
of protein A and any that were not, were passed through the column a
second time. The column was eluted after 10 samples had been passed
through it in order to remove all the bound protein A. This was
achieved by flushing through 0.1M Glycine and then 0.05M Borate buffer
for 30 minutes (Berdal et al 1981).
2.4.12 Measurement of a haemolysin
a haemolysin was detected and quantified by an indirect ELISA.
Microtitre plates (Nunc Immuno module polysorp F8, Gibco BRL Life
Technologies) were filled with 100 jxl of either sample or pure a
haemolysin (Gibco) serially diluted in coating buffer (50 mM sodium
carbonate/sodium bicarbonate buffer pH 9.6 and 0.02% sodium azide).
The plates were left overnight at room temperature. The wells were
decanted and washed four times with phosphate buffered saline
containing 0.1% Tween 20 (PBS-T). They were then filled with 100 nl of
1:100 dilution of a haemolysin antisera (gift from Mr D Pickard,
Wellcome Research Laboratories, Beckenham, Kent) and incubated at
room temperature for 90 minutes. The wells were decanted and washed
as before, and then filled with 100 |il of 1:4000 dilution of goat (anti-rabbit
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IgG) IgG-alkaline phosphatase conjugate (Sigma) and incubated for 90
minutes at room temperature. The wells were decanted and washed, and
then filled with 1 mg/ml p-nitrophenyl phosphate (Sigma) which was
dissolved in substrate buffer (50mM carbonate buffer pH 9.6) and
incubated for 120 minutes at room temperature. The optical density at
405 nm was read on a Titertek Multiskan plate reader (Flow Laboratories
Ltd). All isolates were tested in duplicate on at least two separate
occasions.
a haemolysin production was related to viable cells and to total cell
protein. Each ELISA plate had standard a haemolysin concentrations, so
that the amount of a haemolysin in the samples could be calculated.
Viable counts were performed on the cultures by serial dilution with 1 in
10 and 1 in 100 dilution steps in DM. 0.1 ml amounts were spread on
nutrient agar plates with a sterile glass spreader. Plates were incubated,
inverted at 37°C for 18 hours. Total cell protein concentration was
calculated as described in section 2.4.10. Once this, and the viable counts
had been calculated, the a haemolysin concentration in the samples
could be related to them.
2.4.13 Purification of 5 haemolysin
8 haemolysin was purified by the method of Heatley (1971, 1976) from
S. epidermidis strain E5662 - a strain known to produce large amounts of
8 haemolysin. The final precipitate was freeze dried before being stored at
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-20° C until use. Haemolytic activity of the purified toxin was measured
by the method of Heatley (1971). Human blood was obtained from the
Blood Transfusion Service, Edinburgh. One haemolytic unit was taken
as the amount of toxin yielding 50% haemolysis in the standard assay.
2.4.14 Measurement of 8 haemolysin
The measurement of 8 haemolysin was based on a method described by
Scheifele et al (1987) employing an indirect ELISA. Samples and purified
8 haemolysin were serially diluted in coating buffer (50 mM sodium
carbonate/sodium bicarbonate buffer pH 9.6 and 0.02% sodium azide)
and 100 jil of the samples were added to the wells of a microtitre plate
(Nunc Immuno Module polysorp F8, Gibco BRL Life Technologies).
Plates were incubated overnight at room temperature. Plates were
washed with phosphate buffered saline containing 0.1% Tween 20
(PBS-T) four times. 8 haemolysin antiserum (gift from Mr D Pickard,
Wellcome Research Laboratories, Beckenham, Kent) was added (1:200
dilution) and incubated for 90 minutes at room temperature. The wells
were washed as before and then filled with 100 nl of 1:4000 dilution of
goat (anti-rabbit IgG) IgG-alkaline phosphatase conjugate (Sigma) and
incubated for 90 minutes at room temperature. Finally the substrate,
p-nitrophenylphosphate conjugate (Sigma) dissolved in coating buffer,
was added to the wells and incubated for 120 minutes at room
temperature. Optical density (405 nm) was read by a Titertek Multiskan
plate reader (Flow Laboratories Ltd). All isolates were tested in duplicate
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on at least two separate occasions. 8 haemolysin production was related
to viable cells and to total cell protein as described in section 2.4.12 for a
haemolysin production.
2.4.15 In vivo pathogenicity of the strains
The in vivo pathogenicity of the strains was established employing a
subcutaneous abscess model in mice (Bunce et al 1992). The bacterial
culture was grown to an optical density (590 nm) of 0.2 which is
equivalent to 108 cfu/ml, as determined from a standard curve which
had been prepared previously. Five hundred microlitres of this was
mixed with 190 nl Cytodex-1 microcarriers (Sigma), which had been
prepared according to the manufacturer's instructions. Brain Heart
Infusion broth (310 nl) was added to the inoculum mixture before it was
mixed thoroughly. Two hundred microlitre amounts of this mixture
were drawn up into a 1 ml syringe (Beckton/Dickinson) with a 25 gauge
needle. A separate syringe was prepared for each mouse. The inoculum
was injected subcutaneously into C3H mice (male, 8 weeks old). The fur
had been shaved off the rear flank where the bacterial inoculum was to
be injected, to enable easy viewing of the abscesses. The bevel of the
needle faced upwards when the needle was inserted, to ensure spherical
abscess formation and also consistency of injections. The initial bacterial
inoculum was measured to ensure that lx 107 cfu/ml was injected. This
was achieved by viable counts as described in section 2.4.1. Each mouse
was identified by a notch on the ear, with each of the 4 mice in a cage
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having a different marking. The syringes were coded so that the
injections were randomised and 'blind'. The development of the
abscesses was monitored over a period of 10 days, with the size and
severity of the abscesses being noted. The code was not consulted until
the end of the experiment to ensure unbiased monitoring of the
abscesses. Ten mice were used for each test strain. The volumes of the
abscesses were calculated using the equation for a spherical ellipsoid (71/6
x 1 x w2), taking 1 as the longest measurement and w as the shortest.
The method was reproducible, in the sense that abscesses produced by a
particular strain in each of 10 mice, were of similar size and the standard
error for the mean of the daily volumes was small.
2.4.16 Estimation of viable bacteria in abscesses
Abscesses were removed from dead mice so that an estimate of viable
bacteria could be calculated. The area surrounding the abscess was wet
with alcohol. The skin on three sides of the abscess area was cut and
peeled back. The abscess was then cut out and placed in PBS. The abscess
was broken up and the mixture was serially diluted with 1 in 10 and 1 in
100 dilution steps in DM. Suspensions were mixed and then 0.1 ml
amounts were spread with a sterile glass spreader onto nutrient agar
plates. Plates were incubated, inverted at 37°C for 18 hours.
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2.4.17 Estimation of ciprofloxacin levels in serum and abscesses of mice
The level of ciprofloxacin in the serum and abscesses of mice was
estimated as follows. Known amounts of ciprofloxacin (Bayer UK) were
injected subcutaneously and intravenously into mice. Thirty minutes
later blood samples were taken ocularly and the serum separated from
the blood cells and stored in ice. Three hours later the mice were
sacrificed and the abscesses were excised. The blood samples and the
abscesses were analysed by HPLC for levels of ciprofloxacin (Les White,
Southmead Hospital). The amount of ciprofloxacin injected
subcutaneously or intravenously could be related to levels in the blood
or in the abscess.
2.4.18 Treatment of mice with ciprofloxacin
Mice were given subcutaneous injections of ciprofloxacin diluted in PBS
every two hours on the opposite side from the injection of the bacterial
inoculum.
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3 Results - Pathogenicity and Ciprofloxacin
Resistance
The first section of the study investigated the postulate that ciprofloxacin
resistant mutants of S. aureus lack pathogenicity. Ciprofloxacin sensitive
and resistant strains were compared for their production of virulence
factors both in vitro and in vivo. The production of four virulence
factors was studied in detail - the four factors being coagulase, protein A,
a haemolysin and 8 haemolysin.
3.1 Bacterial Strains
The strains used during the study were selected mainly because of their
resistance to ciprofloxacin. Since only two sets of paired isolates of
ciprofloxacin sensitive and resistant strains could be obtained, most of
the ciprofloxacin resistant strains were compared to sensitive laboratory
strains. Four strains were acquired which were known to produce high
levels of the four virulence factors which were going to be studied in
detail. These strains were used to establish the assay procedures and
conditions. The minimum inhibitory concentrations (MICs) of the
strains were determined for several antibiotics on both solid media and
in broth. A narrow spectrum of concentrations was tested since accurate
MICs were needed later in the project (Table 4).
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Table 4. Minimum Inhibitory Concentrations of six antibiotics for the
Bacterial strains used
Minimum Inhibitory concentrations (mg/L)
Strain Cip Enox Meth Gent Chlor Tetra
E3T 0.187 0.75 1 0.187 3 0.5
Oxford 0.187 0.5 1 0.25 3 0.125
12009 0.75 1.5 1 0.187 2 0.187
Cowan 1 0.187 0.75 1 0.187 1.5 0.187
Wood 46 0.187 0.75 1 0.375 2 0.187
E5662 0.187 0.75 3 0.375 1.5 0.187
cip 63 16 48 2 0.5 2 96
cip 86 64 64 1.5 0.5 6 0.5
cip 92 4 6 1 0.5 3 0.375
cip 103 48 48 1.5 0.5 4 0.375
cip 132 32 48 2 0.5 3 0.375
411-87 48 48 2 0.5 3 0.375
417-87 12 24 16 48 4 64
591-89 24 48 12 96 3 8
4953-88 24 32 24 96 24 64
5538-88 24 48 48 0.5 4 96
8984-88 128 128 1.5 0.5 4 0.375
2219 0.375 1 96 0.5 4 128
2221 6 8 96 0.5 4 128
7777 24 32 96 0.5 4 128
6989 0.375 1.5 1 0.375 4 0.5
3225 3 24 1 0.375 4 0.5
12009-3 32 64 1 0.187 2 0.187
Cowan-3 32 64 1 0.187 1.5 0.187
Wood46-3 32 64 1 0.375 2 0.187
E5662-3 32 64 3 0.375 1.5 0.187
Cip - ciprofloxacin, Enox - enoxacin, Meth - methicillin, Gent -
gentamicin, Chlor - chloramphenicol, Tetra - tetracycline
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The ciprofloxacin resistant strains were bacteriophage typed, since this is
a normal way of distinguishing staphylococcal strains (Table 5). Strains
2219, 2221, 2222 and 5538-88 were indistinguishable MRSA, strains 591-89
and 417-88 were different MRSA. Strains 6989 and 3225, which were a
pair of ciprofloxacin sensitive and resistant isolates, were
indistinguishable by phage typing suggesting that they were the same
strain which had developed resistance to ciprofloxacin during therapy.
Strains 2219, 2221 and 2222 had been isolated from a patient over a period
of 10 days during ciprofloxacin therapy, were also indistinguishable by
phage typing which suggests that they were the same strain which had
developed resistance.
3.2 Growth Rate Determinations
Growth rate is important in pathogenicity. A fast growing pathogen can
overwhelm the initial, non specific defences and cause disease before the
more powerful immune defences can operate fully (Smith 1990).
Avirulence can arise from inability of bacteria to grow and divide (Smith
1968). For this reason, the growth rates of some ciprofloxacin sensitive
and resistant strains of S. aureus were compared.
3.2.1 Growth rates of ciprofloxacin sensitive and resistant strains
The growth rates of some ciprofloxacin resistant clinical isolates were
compared with those of ciprofloxacin sensitive laboratory strains, since at
the beginning of the project, paired strains of ciprofloxacin resistant and
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Table 5. Bacteriophage Typing
Strain Phage typing pattern
E3T 77 (42E, 84)
cip 63 29,52,52A, 42E
cip 86 (53, 83A, 84,85)
cip 92 NT (95)
cip 103 NT
cip 132 (53, 83A)
411-87 29,52, 52A, 80, 95







7777 84 ( 85)
6989 3A
3225 3A
Figures in parentheses Routine Testing Dose (RTD) x 100
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sensitive strains were unavailable. Overnight nutrient broth cultures
were subcultured into fresh prewarmed broth and the viable count
monitored every hour for six hours.
Figures 1 and 2 show the growth curves of the strains grown statically
and with aeration. No detectable differences could be seen between the
growth rates of the ciprofloxacin sensitive and resistant strains in
logarithmic phase.
3.2.2 Growth rates of paired ciprofloxacin sensitive and resistant strains
Some strain series were obtained - a triplet 2219, 2221, 2222 and a pair
6989, 3225. The growth rates of these strains were compared as described
above. Figures 3-6 show the growth curves of these strains. Again, no
detectable differences could be seen between the strains.
3.2.3 Growth rates in mixed cultures
No detectable differences in the growth of the strains could be seen in
logarithmic phase but differences might occur in stationary phase,
especially if a ciprofloxacin resistant strain is grown in the presence of a
ciprofloxacin sensitive strain. Would the resistant strain persist in a
mixed culture in the absence of ciprofloxacin? Overnight cultures of a
sensitive and a resistant strain were subcultured into fresh nutrient
broth. Approximately equal titres of each strain were added to make the
mixed culture. The cultures were incubated statically and growth
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Figure 4. Growth curves of paired ciprofloxacin sensitive and resistant
























Figure 6. Growth curves of triplet of ciprofloxacin sensitive and resistant









monitored over a period of 30 hours by viable counts at regular intervals
on nutrient agar containing or lacking 4 mg/L ciprofloxacin. The
ciprofloxacin containing plates detected the number of ciprofloxacin
resistant bacteria in the mixed culture. In all cases, the ciprofloxacin
resistant strains persisted in the mixture; the level of persistence
remaining steady over the 30 hours (Figures 7-10).
3.2.4 Anaerobic growth of ciprofloxacin sensitive and resistant S. aureus
The ability of bacteria to grow aerobically and anaerobically considerably
improves their survival potential and flexibility. It has been shown that
alteration in DNA gyrase can cause facultative anaerobes to become strict
aerobes (Yoshizawa and Yamamato 1989). Therefore some ciprofloxacin
sensitive and resistant strains were grown in an anaerobic cabinet to see
if they could still grow anaerobically. Overnight cultures were
subcultured into nutrient broth which had been pre-incubated in an
anaerobic cabinet overnight. These cultures were incubated anaerobically
overnight after which time viable counts were performed. All strains
retained the ability to grow anaerobically (Table 6). The strains had also
been grown aerobically for comparison.
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Figure 7. Growth curves of a ciprofloxacin sensitive strain (E3T), a
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Figure 8. Level of persistence of the ciprofloxacin resistant strain (cip 103)

























Figure 9. Growth curves of a ciprofloxacin sensitive strain (6989), a











Figure 10. Level of persistence of the ciprofloxacin resistant strain (3225)
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3.3 Production of Coagulase
3.3.1 Chromogenic assay for Staphylocoagulase
Staphylocoagulase is an extracellular protein which has the ability to
stimulate the clotting reaction of plasma, by forming an active molecular
complex with prothrombin. The two methods which are accepted for the
detection of coagulase, the slide test and the tube test, are prone to false
positive and negative reactions. Also, there is difficultly in standardising
and quantifying these assays. Therefore another method for detecting
coagulase production was devised by Engels et al (1981), which is more
reliable than the clotting assays. It is a direct assay of Staphylothrombin
based on the limited proteolysis of a synthetic chromogenic substrate.
The thrombin-like activity of Staphylothrombin cleaves the synthetic
tripeptide Chromozym T H, liberating p-nitroanaline, which is yellow.
The previously described method was used to measure soluble
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coagulase production only by assaying the supernatant fluid of an
overnight culture. Therefore the assay was revised so that it could
distinguish soluble and bound coagulase.
3.3.2 Purification of Staphylocoagulase
Staphylocoagulase was purified according to section 2.4.8. The tube
coagulase test was used to detect the presence of coagulase during the
purification procedure. Coagulase was present in the culture filtrate
going into the bovine prothrombin Sepharose 4B column (minimum
clotting dose 1: 32), but was not present in the liquid coming off the
column, suggesting that it had bound to the column. The first few
fractions after elution with 1M NaSCN were tested for the presence of
coagulase and the clotting reaction showed that there was no coagulase
present. However, it was thought that coagulase was present in the
elutant, but that the clotting assay was not working because of the
presence of 1M NaSCN, which was interfering with the reaction. The
elutants were dialysed overnight in phosphate buffer and the tube
coagulase reaction was repeated. This time a clot developed, indicating
the presence of coagulase. The purified coagulase had a minimum
dotting dose of 1: 2500.
The protein concentration of the purified coagulase was determined as
5.2 mg/ml. A small amount of the coagulase was run on a
homogeneous 20% gel by SDS- PAGE using a Phast System (Pharmacia
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LKB). However, the protein did not show up on the gel, even with silver
staining. So it was assumed that the sample was 100 % pure in all
subsequent calculations as no contaminating protein could be identified.
3.3.3 Modification of Chromogenic Substrate assay
The purified coagulase was used to develop the chromogenic substrate
assay. First the amount of prothrombin needed in the assay was
established, since it had been acquired from a different source than the
original method of Engels et al (1981). Different amounts of prothrombin
were used with 2 jj.1 coagulase or 30 jxl of an overnight culture of strain
12009, which is known to produce high levels of coagulase, and 123 til
reaction buffer. The absorbance at 405 nm was noted after two hours.
Figure 11 shows that the relationship between prothrombin
concentration and absorbance is linear up to a certain level of
prothrombin and then it is in excess. When pure coagulase was used
with the different amounts of prothrombin any amount of prothrombin
over 6 til was in excess. Figure 11 shows that over 8 til of prothrombin
was in excess when strain 12009 was used as the coagulase source. Since
strain 12009 is a high producer of coagulase, any amount greater than 8 til
of prothrombin should be in excess for most strains and should not be a
limiting factor in the reaction. Therefore, in all subsequent assays 9 |il
prothrombin was used.
The purified coagulase was used to construct a standard curve of
81
Figure 11. Optimisation of prothrombin amounts for chromogenic
substrate assay using purified coagulase and strain 12009 as the
coagulase sources
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coagulase concentrations against time (Figures 12 and 13). Figure 13
would be used in subsequent assays to estimate the amount of coagulase
in the reaction mixtures.
Since the original assay measured soluble coagulase production only, the
assay was revised so that it measured bound as well as soluble coagulase.
An overnight culture of strain 12009, which is known to produce high
levels of coagulase, was centrifuged and the supernatant removed. The
cell pellet was washed and resuspended in DM. Then this resuspended
cell pellet was assayed to estimate the bound coagulase production. The
original culture could be used to measure the combined coagulase
production. However, an inhibitor would be needed in this assay
mixture, since there might be bacterial growth during the two hour
incubation period. The inhibitor used was carbonyl cyanide
m-chlorophenyl hydrazone (CCCP), which is an inhibitor of cell growth.
Ten mis of culture were grown in the presence of different
concentrations of inhibitor. Viable counts were taken at the beginning
(T= 0) and after two hours (T = 2). The recommended concentration of
CCCP was 50 jtM but this was found to kill the cells rather than inhibit
their growth. Other concentrations were used and the one which was
finally used was 5 uM since this inhibited growth without killing the
cells (Table 7).
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Figure 12. Time course of the hydrolysis of Chromozym TH with
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Table 7. Growth (cfu/ml) of strain 12009 in the presence of an inhibitor
(CCCP)
Time (hours) Concentration of CCCP
50pM 25|xM 5|iM
0 3.8 x 10 8 3.6 x 10 8 3.9 x 10 8
2 3.2x108 3.3 x 10 8 4.0 x 10 8
Coagulase is produced mainly in early exponential phase and it had
been noticed in the course of the previous experiments, that if the
overnight culture was subcultured into fresh broth, a much higher
coagulase reading was obtained. It was therefore decided that the
production of coagulase over a period of time would be monitored so
that the optimum time for the production of coagulase during the assay
could be determined (Figure 14). Since coagulase was mainly produced in
the first 2-3 hours, the assay would measure the level of coagulase after
two hours growth.
The final reaction mixture and conditions were as follows : 30 ixl sample,
15 )xl 50 nM carbonyl cyanide m-chlorophenyl hydrazone, 9 p.1
prothrombin, 100 nl reaction buffer (Engels et al 1981)(which included 5
mM EDTA as recommended by Wegrzynowicz et al (1980), to eliminate
false positive reactions). The strains were grown in Brain Heart Infusion
broth (BHI) supplemented with 0.2 % bovine serum albumin (Altenbern
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Figure 14. Production of coagulase by strain 12009
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1966). Overnight cultures were subcultured into fresh BHI and grown for
two hours in an orbital shaker. After two hours, 1 ml of each culture
was centrifuged at low speed (5,800 rpm) in a microfuge for 1 minute.
The supernatant was removed into an eppendorf tube. The cell pellet
was washed and resuspended in 1 ml DM. The whole culture was
labelled sample A, the supernatant was labelled sample B and sample C
was the resuspended cell pellet. Since sample B did not need the
inhibitor because it did not contain cells, the inhibitor was omitted from
the reaction mixture for sample B. Each sample was added to two wells
of a microtiter plate. To one of the two wells the reaction mixture,
described previously, was added. Prothrombin was omitted from the
reaction mixture of the remaining well to provide a bacterial background
count. The assay mixtures were incubated for two hours and the optical
density was measured at 405 nm by a Titertek Multiskan plate reader.
This automatically accounts for the blank medium reactions. Subtraction
of the OD 405 value corresponding to the bacterial background count from
the test value gave a measure of the change in absorbance as a result of
coagulase. This was then related to the standard curve of coagulase
concentrations (Figure 13) to get the concentration of coagulase in the
test sample.
3.3.4 Production of coagulase by ciprofloxacin sensitive and resistant
strains
The modified coagulase assay was used to compare the amount of
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coagulase produced by ciprofloxacin sensitive and resistant strains. Strain
12009 was a strain known to produce high levels of coagulase. The other
sensitive strains were standard laboratory strains. Varying amounts of
bound and soluble coagulase were produced by the ciprofloxacin
sensitive and resistant strains (Table 8). The paired strains produced
similar amounts. The ciprofloxacin resistant mutant of strain 12009
(12009-3) produced similar amounts of coagulase to strain 12009. Strain
E5662, a S. epidermidis strain which does not produce any coagulase,
was used as a negative control. It is interesting to note that the combined
coagulase amount did not equal the sum of the soluble and the bound
coagulase amounts, indeed it was always less. Since this is a general
trend and not restricted to individual strains, it must be as a result of the
assay procedure. Maybe when the cells are being centrifuged and
resuspended, coagulase is released from an intracellular pool giving
higher readings for samples B and C. However, as the differences were
often small, it may just come from biological variation.
3.4 Production of Protein A
Protein A is a cell wall component which is covalently bound to the
peptidoglycan of the cell wall. It binds to the Fc portion of
immunoglobulins thus preventing phagocytosis of the bacteria. Since
most strains secrete about 15-30% of all their protein A (Forsgen 1970), it
is necessary to measure both cell bound and extracellular protein A
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Table 8. Coagulase production in ciprofloxacin sensitive and resistant
strains of Staphylococcus aureus (ng coagulase per 109 cells)
Strain Combined Soluble Bound
12009 (S) 22.50 17.70 5.20
12009-3 (R) 23.70 18.50 6.10
E3T (S) 7.80 6.45 1.65
Oxford (S) 4.80 3.45 1.55
Cowan 1 (S) 9.00 7.50 2.00
Wood 46 (S) 3.00 2.50 1.00
E5662 (S) UD UD UD
cip 63 (R) 11.85 10.10 2.15
cip 86 (R) 5.70 4.80 1.40
cip 92 (R) 3.60 2.60 1.20
cip 103 (R) 6.40 5.70 1.80
cip 132 (R) 7.80 6.45 2.40
411-87 (R) 13.00 10.00 4.90
417-87 (R) 12.00 9.00 4.00
591-89 (R) 3.00 2.00 1.30
4953-88 (R) 7.00 5.85 1.65
5538-88 (R) 7.95 7.05 1.80
8984-88 (R) 6.45 5.10 1.35
2219 (S) 14.00 11.50 3.00
2221 (R) 14.50 11.00 3.90
2222(R) 13.00 9.00 4.50
6989 (S) 8.00 6.00 2.00
3225 (R) 10.00 7.00 3.50
UD - undetectable R - resistant to cipro S - sensitive to cipro
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when measuring protein A production. Exploiting protein A's ability to
bind to immunoglobulins allows protein A production to be measured
by an enzyme linked immunosorbent assay.
3.4.1 Production of Cell Bound and Extracellular Protein A
Bound and extracellular protein A production of strain Cowan 1 was
followed over a period of 6 hours, as well as bacterial growth. Figures 15
and 16 show that it is produced mainly in exponential phase and so
production of protein A was measured after 3 hours growth, when it
would be most actively produced.
3.4.2 Production of Protein A by ciprofloxacin sensitive and resistant
strains
The production of cell bound and extracellular protein A by ciprofloxacin
resistant and sensitive strains was compared (Table 9). All strains
produced extracellular protein A but at differing levels. Some strains
produced 15-30% extracellular protein A and others produced mainly
extracellular protein A. This is in keeping with Winbald and Ericson
(1973) who observed that methicillin resistant strains produce mainly
extracellular protein A. Most of the strains in Table 9 which produced
mainly extracellular protein A were methicillin resistant. Strain Wood
46, which is reported not to produce protein A, did produce low levels of
cell bound protein A. Again, strain E5662 was used as a negative control
since S. epidermidis do not produce protein A. Ciprofloxacin resistance
90
Figure 15. Production of extracellular protein A by strain Cowan 1
Figure 16. Production of cell bound protein A by strain Cowan 1
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Table 9. Protein A production in ciprofloxacin sensitive and resistant
strains of Staphylococcus aureus (ng Protein A per mg cell
protein)
Strain Cell Bound Extracellular
Cowan 1 (S) 79.00 12.00
Cowan 1 - 3 (R) 69.00 10.00
E3T (S) 2.60 0.87
Oxford (S) 0.38 0.09
12009 (S) 3.04 1.05
Wood 46 (S) 0.25 UD
E5662 (S) UD UD
cip 63 (R) 60.00 21.00
cip 86 (R) 6.25 3.70
cip 92 (R) UD UD
cip 103 (R) UD UD
cip 132 (R) 3.40 2.30
411-87 (R) 9.60 1.27
417-87 (R) 0.19 0.06
591-89 (R) 15.00 5.00
4953-88 (R) 8.50 60.00
5538-88 (R) 0.39 40.00
8984-88 (R) 60.00 15.00
2219 (S) 20.00 6.70
2221 (R) 19.00 4.70
2222 (R) 21.00 6.50
6989 (S) 4.80 1.20
3225 (R) 9.80 2.40
UD - undetectable R - resistant to cipro S - sensitive to cipro
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did not seem to affect the production of protein A. The sensitive and
resistant strains produced similar amounts of protein A. The resistant
mutant of Cowan 1 (Cowan 1-3) produced similar amounts of protein A
to Cowan 1.
3.5 Production of a haemolysin
a haemolysin is thought to be among one of the most significant
extracellular proteins produced by S. aureus. It is often detected by its
haemolytic activity towards erythrocytes but it can also be detected by an
ELISA. One disadvantage with this a haemolysin ELISA is the
interference of IgG-binding protein A when it is present in the
supernatant along with the a haemolysin and other extracellular
products. However, this problem was resolved by passing culture fluids
through a small adsorption column, which removed all the protein A.
All the samples were run on a protein A ELISA to check that all traces of
protein A had been removed.
3.5.1 Development of a haemolysin ELISA
An ELISA was developed to detect a haemolysin based on an ELISA for
the detection of S. aureus delta-like toxins described by Scheifele et al
(1987). Microtiter plates were coated with two different concentrations of
purified a haemolysin which were serially diluted and left at room
temperature overnight. The next day the plates were washed with PBS-T
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and filled with two different dilutions of a haemolysin antisera. The
plates were incubated at room temperature for 90 minutes before being
washed again with PBS-T. Enzyme conjugated antibody was added at a
concentration recommended by the manufacturer (1:4000) and the plates
were incubated at room temperature for 90 minutes. Finally the substrate
was added, again at a concentration recommended by the manufacturer
(1 mg/ml). The plates were incubated at room temperature for 120
minutes before the absorbance at 405 nm was read on a Titretek
Multiskan plate reader. The assay was repeated but with incubation steps
at 37°C instead of room temperature.
The optimal conditions for the ELISA were found to be 1:100 dilution of
antisera with 250U/ml of a haemolysin as the highest dilution in the
serial dilution steps at room temperature. Even though the higher
amount of a haemolysin gave higher readings, these readings were at
the top end of the absorbance scale at 405 nm (Table 10). Therefore it was
decided that the lower concentration of a haemolysin was sufficient for
the ELISA. This dilution of antisera (1:100) was used for a 'test' ELISA
employing the supernatant of Wood 46 culture as the a haemolysin
source. The absorbances after two hours were high and showed good
correlation to dilutions of the supernatant. Therefore in all subsequent
ELISAs, antisera was used at 1:100 dilution, enzyme conjugated antibody
was used at 1:4000 dilution and the substrate used at 1 mg/ml. The ELISA
was performed at room temperature. Pure a haemolysin (Gibco) was
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used at a starting concentration of 250 U/ml and was serially diluted to
give a range of concentrations.
Table 10. Optimal conditions for a haemolysin ELISA (OD 405 nm)
Anti Room Temperature 37°C
sera a haemolysin a haemolysin
dilutions 50 ul 10 ul 50 ul 10 ul
1:100 1.529 0.616 0.647 0.413
1:200 0.389 0.231 0.300 0.212
3.5.2 Production of a haemolysin
The production of a haemolysin by strain Wood 46 was followed over a
period of 8 hours. It was produced mainly in late exponential phase and
early stationary phase (Figure 17). It was produced after a short lag period
of 2 hours, which is a similar finding to Duncan and Cho (1971) who
reported a lag period of 3 hours before a haemolysin production
commenced. From these results, it was decided that the strains would be
grown for five hours before being harvested and measured for a
haemolysin production.
3.5.3 Production of a haemolysin by ciprofloxacin sensitive and resistant
strains
Production of a haemolysin was measured in ciprofloxacin sensitive and
resistant strains. The amount of a haemolysin produced was related to
viable cells (Table 11). There seem to be no detectable differences
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Table 11. a haemolysin production in ciprofloxacin resistant and
sensitive strains of Staphylococcus aureus (HU/109 cells)
Strain a-haemolysin
Wood 46 (S) 2100





cip 63 (R) 59
cip 86 (R) 210
cip 92 (R) 630
cip 103 (R) 40












UD - Undetectable (R) - resistant to cipro (S) - sensitive to cipro
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between the sensitive strains and the resistant strains. The ciprofloxacin
resistant mutant of Wood 46 (Wood 46 -3) produced similar amounts of
a haemolysin to Wood 46.
3.6 Production of 5 haemolysin
8 haemolysin is another haemolysin which is often detected by its
haemolytic activity towards human erythrocytes but can be detected by
an ELISA. Again this ELISA is affected by the interference of protein A
and this problem is resolved in a similar way as a haemolysin.
3.6.1 Purification of 5 haemolysin
8 haemolysin was purified according to section 2.4.13. The final
precipitates were dried under vacuum overnight. The haemolytic
activity of the precipitates was calculated, to check that they did contain 8
haemolysin.
The haemolytic activity of the purified toxin in the precipitates was
calculated by the method described in the Section 2.4. 13. The absorption
spectrum of haemoglobin was measured, to find the maximum
wavelength which was known to be in the 540 nm range. It was found to
be 545 nm and so this wavelength was used in all subsequent
calculations. 100% haemolysis of the red blood cells was achieved with
purified water in the assay mix. Then, varying amounts of the purified
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toxin were added to the assay mix, and the OD 545 nm measured. The
amount of toxin yielding 50% haemolysis (equivalent to OD 545 nm 0.240)
(Figure 18) was taken to represent 1 haemolytic unit. The haemolytic
activity of the sample was estimated to be 588 U/ml, since 1.7 ^1 pure
haemolysin caused 50% haemolysis (Figure 19).
The first step in the purification procedure, which involved heating the
supernatant to 60°C, should have destroyed any a haemolysin present.
However, the purified 8 haemolysin was run on an a haemolysin ELISA
to check that it did not contain any a haemolysin, which it did not.
3.6.2 Production of 8 haemolysin
The production of 8 haemolysin by strain E5662 was followed over a
period of 8 hours. It was produced mainly in late exponential phase and
early stationary phase (Figure 20). From these results, it was decided that
the strains would be grown for six hours before being harvested and
measured of 8 haemolysin production.
3.6.3 Production of 8 haemolysin by ciprofloxacin sensitive and resistant
strains
8 haemolysin production was investigated in ciprofloxacin sensitive and
resistant strains of S. aureus. The amount of 8 haemolysin produced was
related to viable cells (Table 12). There seemed to be no detectable
differences between the sensitive and resistant strains. Strain E5662-3,
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Figure 20. 8 haemolysin production by strain E5662
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Table 12. 8 haemolysin production in ciprofloxacin resistant and
sensitive strains of Staphylococcus aureus (HU/109 cells)
Strain 5-haemolysin
E5662 (S) 149.0





Wood 46 (S) 14.0
cip 63 (R) 100.0
cip 86 (R) 70.0
cip 96 (R) 105.0
cip 103 (R) 1.6












UD - undetectable (R) - resistant to cipro (S) - sensitive to Cipro
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which is a ciprofloxacin resistant mutant of E5662, produced similar
amounts of 8 haemolysin to the ciprofloxacin sensitive parental strain.
The triplet of strains (2219, 2221 and 2222) did not seem to produce any
detectable levels of 8 haemolysin.
3.7 Pathogenicity of strains in vivo
The pathogenicity of S. aureus strains in vivo was investigated by
subcutaneous injection of bacteria into mice. The development of the
abscesses was noted over 10 days and any morphological details noted.
Mice were also injected with just the cytodex microcarriers - as controls,
to check that the inoculum without the test strain was sterile and that
the injection procedure was aseptic. Mice injected with just cytodex
developed small raised areas which did not develop into abscesses. Their
size remained static over the 10 day period. Mice injected with the
bacterial inoculum developed abscesses which fluctuated in size and
exhibited tissue damage. In some cases a white area covering the skin
was seen which developed into necrosis. As the abscesses developed,
scabs were also formed.
3.7.1 In vivo growth of ciprofloxacin sensitive and resistant strains
When ciprofloxacin sensitive and resistant strains were injected into
mice, no differences were observed in the abscesses which developed
(Figures 21 and 22 ). The abscesses looked similar, developed at a similar
rate and the degree of tissue damage looked similar.
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Figure 21. Development of abscesses by paired isolates of ciprofloxacin














































3.7.2 In vivo growth of high virulence factor producing strains
The 4 high factor producing strains were also put into mice. The strain
which produces high levels of coagulase produced large abscesses with
areas of necrosis. The other 3 strains produced rather small abscesses in
comparison with no necrosis and little tissue damage (Figure 23). Two
strains were chosen, one which was found to produce high levels of
most of the factors studied (strain 8984-88) and one which produced low
levels of the factors studied (Oxford Staph). These strains were injected
into mice to see if there were any differences in their pathogenicity.
Strain 8984-88 produced fairly large abscesses when compared to Oxford
Staph (Figure 24). No sign of any necrosis was seen with either strain.
Oxford Staph is used extensively in laboratories and has probably been
passaged numerous times, which might account for its reduced
virulence.
3.8 Summary
This section investigated the effect of ciprofloxacin resistance on the
pathogenicity of some S. aureus strains. Ciprofloxacin sensitive and
resistant strains were grown statically and with aeration to see if there
were any differences in their growth rates. There appeared to be no
differences either when grown statically or with aeration. When a
ciprofloxacin sensitive strain and a resistant strain were grown in a
mixed culture, the ciprofloxacin resistant strains persisted in the
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Figure 24. Development of abscesses by a high (8984-88) and a low
















mixture. The resistant strains were still able to grow anaerobically,
despite reports that resistance sometimes leads to aerobic growth only.
Therefore the resistant strains seemed to grow under similar conditions
to the sensitive strains.
The ciprofloxacin sensitive and resistant strains were then investigated
for the production of four virulence factors - coagulase, protein A, a
haemolysin and 8 haemolysin. The resistant strains produced similar
amounts of these four factors to the sensitive strains. Again there
seemed to be no differences between the strains.
Finally, to confirm the findings of the in vitro work, some ciprofloxacin
sensitive and resistant strains were injected into mice. The behaviour of
the strains in vivo would confirm or deny if there were any differences
between the strains. Again, the resistant strains produced similar sized
abscesses to the sensitive strains, so supporting the in vitro
determinations that there were no differences in the pathogenicity of the
resistant strains.
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4 Results - Pathogenicity and Sub MIC
levels of antibiotics
One of the many ways of investigating pathogenicity is to look at the
effect of antibiotics on virulence factor production. Concentrations of
antibiotics are used which do not affect cell growth - sub-minimum
inhibitory concentrations (sub - MIC). This approach will be employed in
the next section. Six antibiotics were investigated for their effect on toxin
production two quinolones - ciprofloxacin and enoxacin, three protein
synthesis inhibitors - gentamicin, chloramphenicol and tetracycline and
a cell wall synthesis inhibitor - methicillin. By using antibiotics with
different modes of action, a wide variety of effects on virulence factor
production should be observed.
4.1 Production of coagulase in the presence of sub-MIC levels of
antibiotics
The production of coagulase was monitored in the presence of 1/4 and
1/2 MIC levels of six antibiotics - ciprofloxacin, enoxacin, gentamicin,
chloramphenicol, tetracycline and methicillin. The strains were grown
overnight as described in section 3.3.3 and then they were subcultured
into medium containing the antibiotics. Strains were also grown in
broth lacking the antibiotics, so that the production of coagulase under
normal conditions could be monitored. The strains were grown for two
hours before harvesting and measured for the production of coagulase.
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The amount of coagulase produced in the presence of the antibiotics was
compared to the amount produced when no antibiotic was present.
Viable counts and the total cell protein were also measured for each of
the strains, so that coagulase production could be related to these. Since
coagulase is predominately an extracellular enzyme, the figures for
coagulase production related to viable counts will be discussed here.
Strains grown in the presence of 1/4 and 1/2 MIC levels of the two
quinolones, ciprofloxacin and enoxacin, produced similar amounts,
within 15%, of coagulase to that produced in the absence of antibiotics
(Tables 13, 14 and appendix Tables I and n). These antibiotics did not
seem to affect the production of bound or soluble coagulase. The
presence of 1/2 or 1/4 MIC levels of methicillin also had little or no effect
on coagulase production (Table 15 and appendix table IE). The presence
of gentamicin, chloramphenicol and tetracycline reduced the production
of coagulase to varying degrees (Tables 16 - 21). The effect of 1/2 MIC
levels of these three antibiotics was greater than the effect of 1/4 MIC
levels. When coagulase production was related to viable bacteria, 1/2
MIC levels of the three antibiotics reduced its production to about 50%
of that in the absence of the antibiotics (Tables 16, 18 and 20). Some
strains were not affected as much as other strains. When the strains were
grown in the presence of 1/4 MIC levels of these three antibiotics,
coagulase production was reduced but to a lesser extent - only to 80 - 90 %
of that in the absence of the antibiotics (Tables 17, 19 and 21). This
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Table 13. The effect of 1/2 MIC levels of ciprofloxacin on the production
of coagulase
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 22.73 101 6.97 101
E3T 4.69 102 1.39 99
Oxford 6.86 104 3.07 99
Cowan 1 8.82 98 0.95 106
Wood 46 2.30 92 0.86 95
Resistant bacteria
cip 63 15.51 110 5.30 106
cip 86 4.75 99 1.14 104
cip 92 2.76 106 1.05 105
cip 103 5.61 102 1.56 104
cip 132 4.55 101 0.61 102
411-87 10.40 104 3.09 103
417-87 9.22 97 2.38 99
591-89 1.90 95 1.39 99
4953-88 5.20 104 1.12 101
5538-88 6.83 102 1.41 101
8984-88 3.85 110 0.98 109
Triplet
2219 11.86 104 3.18 106
2221 12.10 110 4.24 106
7777 9.11 99 4.09 95
Paired strains
6989 5.89 95 1.46 97
3225 6.77 101 3.43 98
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Table 14. The effect of 1/2 MIC levels of enoxacin on the production of
coagulase
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 23.40 104 6.83 99
E3T 4.69 102 1.44 103
Oxford 6.67 101 3.16 102
Cowan 1 9.36 104 0.95 106
Wood 46 2.45 98 0.94 104
Resistant bacteria
tip 63 14.24 101 4.95 99
tip 86 4.90 102 1.13 103
cip 92 2.76 102 1.04 104
tip 103 5.67 103 1.53 102
tip 132 4.77 106 0.61 102
411-87 10.40 104 3.21 107
417-87 9.69 102 2.50 104
591-89 2.02 101 1.44 103
4953-88 5.10 102 1.17 104
5538-88 7.17 107 1.44 103
8984-88 3.64 104 0.92 102
Triplet
2219 12.08 106 3.15 105
2221 11.20 102 4.16 104
2777 9.29 101 4.43 103
Paired strains
6989 6.32 102 1.52 101
3225 6.83 102 3.54 101
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Table 15. The effect of 1 /2 MIC levels of methicillin on the production of
coagulase
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 24.53 109 7.45 108
E3T 4.92 107 1.53 109
Oxford 6.93 105 3.32 107
Cowan 1 9.36 104 0.94 104
Wood 46 2.73 109 0.91 101
Resistant bacteria
cip 63 13.96 99 5.30 106
cip 86 4.90 102 1.14 104
cip 92 2.68 103 1.02 102
cip 103 5.56 101 1.56 104
cip 132 4.64 103 0.61 102
411-87 10.40 104 3.06 102
417-87 9.88 104 2.47 103
591-89 2.08 104 1.43 102
4953-88 5.05 101 1.12 102
5538-88 6.97 104 1.53 109
8984-88 3.78 108 0.96 107
Triplet
2219 12.20 107 3.18 106
2221 11.55 105 4.16 104
7777 9.66 105 4.43 101
Paired strains
6989 6.63 107 1.64 109
3225 6.77 101 3.57 102
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Table 16. The effect of 1 /2 MIC levels of gentamicin on the production of
coagulase
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 11.70 52 3.74 54
E3T 2.71 59 0.66 47
Oxford 2.77 42 1.52 49
Cowan 1 4.59 51 0.50 55
Wood 46 1.40 56 0.51 57
Resistant bacteria
cip 63 8.32 59 3.05 61
cip 86 2.98 62 0.70 64
cip 92 1.43 55 0.61 61
cip 103 3.30 60 0.86 57
cip 132 2.48 55 0.29 49
411-87 4.30 43 1.41 47
417-87 4.85 51 1.18 49
591-89 0.90 45 0.67 48
4953-88 2.35 47 0.48 44
5538-88 3.42 51 0.69 49
8984-88 2.00 57 0.50 55
Triplet
2219 5.93 52 1.62 54
2221 5.39 49 2.16 54
7777 5.43 59 2.24 52
Paired strains
6989 3.16 51 0.80 53
3225 3.28 49 1.82 52
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Table 17. The effect of 1/4 MIC levels of gentamicin on coagulase
production
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 18.90 84 6.00 84
E3T 3.77 82 1.22 87
Oxford 6.01 91 2.79 90
Cowan 1 7.47 83 0.72 80
Wood 46 2.03 81 0.78 87
Resistant bacteria
cip 63 11.14 79 4.15 83
cip 86 4.56 95 0.99 90
cip 92 2.00 77 0.75 75
cip 103 4.51 82 1.28 85
cip 132 4.05 90 0.49 82
411-87 7.90 79 2.46 82
417-87 7.98 84 2.04 85
591-89 1.58 79 1.01 72
4953-88 4.70 94 1.01 92
5538-88 5.96 89 1.26 90
8984-88 2.87 82 0.78 87
Triplet
2219 9.80 86 2.43 81
2221 8.69 79 3.00 75
7777 7.45 81 3.57 83
Paired strains
6989 5.27 85 1.31 87
3225 5.29 79 2.84 81
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Table 18. The effect of 1/2 MIC levels of chloramphenicol on the
production of coagulase
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 11.70 52 3.73 54
E3T 2.44 53 0.71 51
Oxford 3.10 47 1.58 51
Cowan 1 4.68 52 0.49 54
Wood 46 1.23 49 0.42 47
Resistant bacteria
cip 63 13.82 98 5.05 101
cip 86 2.83 59 0.67 61
cip 92 1.22 47 0.51 51
cip 103 2.31 42 0.62 41
cip 132 1.76 39 0.25 41
411-87 4.30 43 1.32 44
417-87 5.89 62 1.51 63
591-89 1.18 59 0.77 55
4953-88 2.55 51 0.52 47
5538-88 3.28 49 0.57 41
8984-88 1.65 47 0.47 52
Triplet
2219 6.27 55 1.83 61
2221 6.27 57 2.04 51
7777 4.97 54 2.37 55
Faired strains
6989 4.28 69 0.89 59
3225 3.15 47 1.79 51
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Table 19. The effect of 1/4 MIC levels of chloramphenicol on the
production of coagulase
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 20.48 91 6.14 89
E3T 3.73 81 1.16 83
Oxford 5.54 84 2.70 87
Cowan 1 8.19 91 0.83 92
Wood 46 2.10 84 0.78 87
Resistant bacteria
cip 63 13.25 94 4.95 99
cip 86 3.94 82 0.92 84
cip 92 2.42 93 0.90 90
cip 103 5.45 99 1.52 101
cip 132 3.69 82 0.50 84
411-87 8.20 82 2.37 79
417-87 7.79 82 1.80 75
591-89 1.48 74 1.19 85
4953-88 4.10 82 0.92 84
5538-88 5.90 88 1.27 91
8984-88 3.15 90 0.73 81
Triplet
2219 9.35 82 2.52 84
2221 9.57 87 3.56 89
7777 7.54 82 3.83 89
Paired strains
6989 5.64 91 1.41 94
3225 6.16 92 3.26 93
116
Table 20. The effect of 1/2 MIC levels of tetracycline on the production of
coagulase
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 10.58 47 2.90 42
E3T 2.35 51 0.69 54
Oxford 3.63 55 1.64 53
Cowan 1 4.41 49 0.49 49
Wood 46 1.15 46 0.38 42
Resistant bacteria
cip 63 14.24 101 4.85 97
cip 86 2.02 42 0.46 42
cip 92 1.53 59 0.47 47
cip 103 3.03 55 0.77 51
cip 132 2.12 47 0.31 51
411-87 5.90 59 1.74 58
417-87 4.37 46 0.98 41
591-89 0.86 43 0.69 49
4953-88 2.55 51 0.61 55
5538-88 6.83 102 1.41 101
8984-88 1.65 47 0.50 55
Triplet
2219 6.50 57 1.62 54
2221 5.61 51 2.12 53
7777 3.77 41 1.85 43
Paired strains
6989 2.60 42 0.74 49
3225 3.42 51 1.61 46
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Table 21. The effect of 1/4 MIC levels of tetracycline on the production of
coagulase
Strain Soluble coagulase Bound coagulase
ng coagulase/ % of amount ng coagulase/ % of amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 18.45 82 5.87 85
E3T 4.23 92 1.36 97
Oxford 5.35 81 2.60 84
Cowan 1 8.46 94 0.87 97
Wood 46 2.03 81 0.80 89
Resistant bacteria
cip 63 12.27 87 4.10 82
cip 86 4.37 91 1.02 93
cip 92 2.13 82 0.87 87
cip 103 4.51 82 1.25 83
cip 132 4.01 89 0.52 87
411-87 7.20 72 2.20 74
417-87 7.51 79 1.94 81
591-89 1.64 82 1.18 84
4953-88 4.35 87 0.98 89
5538-88 5.63 84 1.16 83
8984-88 3.19 91 0.86 95
Triplet
2219 10.49 92 2.70 90
2221 9.24 84 3.16 79
7777 8.74 95 4.26 99
Paired strains
6989 5.08 82 1.26 84
3225 5.76 86 3.12 89
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suggests that these antibiotics, which are protein synthesis inhibitors,
not only affect the production of coagulase but also might affect
some other aspect of its production.
Two of the strains behaved differently in the presence of 1/2 MIC levels
of chloramphenicol and tetracycline (strains cip 63 and 5538-88). They
were not affected by 1/2 MIC levels of tetracycline and cip 63 was not
affected by 1/2 MIC levels of chloramphenicol. Coagulase was produced
in similar amounts in the presence of these antibiotics to that produced
in the absence of these antibiotics. These two strains were highly
resistant to tetracycline and so it could have been related to the resistance
mechanism to tetracycline.
4.2 Production of Protein A in the presence of sub-MIC levels of
antibiotics
Protein A production was monitored in the presence of the same six
antibiotics. The strains were grown overnight and then subcultured into
fresh broth. They were grown for an hour, the antibiotics were then
added and growth continued for a further two hours. Strains were also
grown in the absence of the antibiotics for a comparison. The strains
were harvested and measured for cell bound and extracellular protein A
production and total cell protein. The amount of protein A produced in
the presence of the antibiotics was compared to the amount produced in
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the absence.
The presence of ciprofloxacin, enoxacin and methicillin at 1/2 or 1/4 MIC
levels had little or no effect on the production of either bound or
extracellular protein A (Tables 22 - 27). The amount of protein A
produced in the presence of these antibiotics was similar to the amount
produced in the absence. The effect of 1/2 and 1/4 MIC levels of
gentamicin had a limited effect on protein A production (Table 28 and
29). At 1/2 MIC levels the production of protein A was reduced by
varying amounts. In some strains it was reduced to 40 - 60 % of that
produced in the absence of the antibiotics. In other strains the effect was
not so pronounced and they produced 80 - 90 % of the normal amounts
of protein A. The other two protein synthesis inhibitors reduced the
production of protein A considerably more (Tables 30 - 33). At 1/2 MIC
levels, the production of protein A was greatly reduced, to only a fraction
of that in the absence of the antibiotics. In some cases, the level of cell
bound and especially extracellular protein A was reduced to undetectable
levels. At 1/4 MIC levels these two antibiotics still reduced protein A
production but to a lesser extent. Most strains produced about 80% of the
protein A found in the absence of antibiotics. Other strains were either
affected to a greater extent or not affected at all. The effect of gentamicin,
chloramphenicol and tetracycline on bound versus extracellular protein
A was varied. In most strains the production of extracellular protein A
was reduced more than bound protein A, but in a few strains the
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Table 22. The effect of 1/4 MIC levels of ciprofloxacin on the production
of bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng protein A/ % of Sp A ng proteinA/ % of Sp A
mg total cell produced mg total cell produced
protein absence protein absence
Sensitive bacteria
Cowan 1 59.00 98 7.60 104
E3T 0.75 104 0.37 93
Oxford 0.44 94 0.30 103
12009 1.32 97 0.80 104
Wood 46 0.45 100 UD
Resistant bacteria
cip 63 46.00 105 13.30 112
cip 86 1.73 113 0.73 102
cip 92 UD UD
cip 103 UD UD
cip 132 3.70 105 1.00 91
411-87 29.00 97 15.40 101
417-87 0.18 100 0.05 92
591-89 24.90 99 10.25 95
4953-88 2.57 89 35.60 102
5538-88 3.50 88 44.20 98
8984-88 10.17 102 32.30 92
Triplet
2219 27.00 100 9.40 94
2221 25.00 108 12.50 104
7777 23.00 96 11.00 102
Paired strains
6989 28.00 93 5.98 101
3225 37.00 106 12.10 94
UD - undetectable Sp A - Protein A
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Table 23. The effect of 1/2 MIC levels of ciprofloxacin on the production
of bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng protein A/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell producec
protein absence protein absence
Sensitive bacteria
Cowan 1 75.00 95 11.00 100
E3T 2.45 94 0.88 101
Oxford 0.35 92 0.10 94
12009 3.12 103 1.08 99
Wood 46 0.25 100 UD
Resistant bacteria
cip 63 59.30 99 20.10 95
cip 86 6.00 97 3.65 99
cip 92 UD UD
cip 103 UD UD
cip 132 4.10 121 2.20 96
411-87 9.70 101 1.30 102
417-87 0.19 97 0.06 98
591-89 14.30 97 4.30 95
4953-88 8.47 99 58.00 97
5538-88 0.42 107 37.00 93
8984-88 56.00 93 14.00 93
Triplet
2219 19.00 95 6.30 94
2221 17.00 89 4.80 102
7777 21.00 100 6.80 105
Paired strains
6989 4.90 102 1.10 92
3225 9.70 97 2.25 94
UD - undetectable Sp A - Protein A
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Table 24. The effect of 1/4 MIC levels of enoxacin on the production of
bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng proteinA/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell produced
protein absence protein absence
Sensitive bacteria
Cowan 1 58.50 97 7.50 97
E3T 0.71 99 0.37 93
Oxford 0.47 100 0.30 105
12009 1.33 98 0.72 93
Wood 46 0.45 100 UD
Resistant bacteria
cip 63 42.00 95 10.90 92
cip 86 1.49 97 0.70 99
cip 92 UD UD
cip 103 UD UD
cip 132 3.60 103 1.01 91
411-87 29.00 97 15.60 103
417-87 0.17 94 0.06 98
591-89 24.00 96 10.17 94
4953-88 2.54 88 36.80 105
5538-88 4.10 105 43.60 97
8984-88 34.00 97 9.80 98
Triplet
2219 28.00 104 9.70 97
2221 23.00 100 12.80 107
7777 23.00 96 10.70 99
Paired strains
6989 27.00 90 5.80 98
3225 35.00 100 13.90 107
UD - undetectable SpA - Protein A
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Table 25. The effect of 1/2 MIC levels of enoxadn on the production of
bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng protein A/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell produced
protein absence protein absence
Sensitive bacteria
Cowan 1 74.00 94 10.00 91
E3T 2.80 107 0.79 91
Oxford 0.40 106 0.10 98
12009 2.90 94 1.08 99
Wood 46 0.30 111 UD
Resistant bacteria
cip 63 59.00 99 20.90 99
cip 86 5.90 95 3.64 98
cip 92 UD UD
cip 103 UD UD
cip 132 3.10 91 2.10 90
411-87 10.00 104 1.16 91
417-87 0.19 97 0.06 100
591-89 13.60 93 43.00 95
4953-88 7.70 91 57.00 95
5538-88 0.39 100 39.00 98
8984-88 55.00 92 14.00 93
Triplet
2219 18.00 90 6.75 no
2221 18.00 95 4.70 100
9777 22.00 105 6.90 107
Paired strains
6989 4.80 100 1.12 94
3225 10.10 101 2.40 100
UD - undetectable Sp A - Protein A
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Table 26. The effect of 1 /4 MIC levels of methicillin on the production of
bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng protein A/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell produced
orotein absence protein absence
Sensitive bacteria
Cowan 1 59.00 98 7.30 95
E3T 0.67 94 0.38 94
Oxford 0.46 98 0.28 96
12009 1.33 98 0.75 97
Wood 46 0.46 104 UD
Resistant bacteria
cip 63 43.00 98 11.05 99
cip 86 1.68 no 0.70 99
cip 92 UD UD
cip 103 UD UD
cip 132 3.60 103 1.03 94
411-87 31.00 103 15.30 101
417-87 0.16 88 0.50 89
591-89 25.00 100 9.70 90
4953-88 3.01 104 31.20 89
5538-88 3.40 85 49.80 111
8984-88 35.00 100 9.75 98
Triplet
2219 26.50 98 11.00 110
2221 23.00 100 12.48 104
???? 21.00 88 9.76 90
Paired strains
6989 27.00 90 6.40 108
3225 37.00 106 11.40 88
UD - undetectable Sp A - Protein A
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Table 27. The effect of 1/2 MIC levels ofmethicillin on the production of
bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng protein A/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell produced
protein absence protein absence
Sensitive bacteria
Cowan 1 77.00 97 10.00 91
E3T 2.90 115 0.53 61
Oxford 0.41 109 0.11 105
12009 2.67 88 1.01 99
Wood 46 0.23 92 UD
Resistant bacteria
cip 63 56.50 95 22.50 106
cip 86 5.80 93 3.40 92
cip 92 UD UD
cip 103 UD UD
cip 132 3.80 113 2.30 98
411-87 10.70 111 1.26 100
417-87 0.19 98 0.06 100
519-89 11.25 76 4.20 94
4953-88 10.00 113 61.00 102
5538-88 0.16 41 17.00 43
8984-88 64.00 107 15.00 100
Triplet
2219 19.00 95 6.36 95
2221 18.00 95 4.50 96
7777 20.00 95 7.20 110
Paired strains
6989 4.80 100 1.15 96
3225 9.25 93 2.30 96
UD - undetectable Sp A - Protein A
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Table 28. The effect of 1 /4 MIC levels of gentamicin on the production of
bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng proteinA/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell produced
protein absence protein absence
Sensitive bacteria
Cowan 1 61.00 102 7.20 92
E3T 0.71 98 0.20 50
Oxford 0.36 71 0.32 no
12009 1.30 96 0.62 81
Wood 46 0.35 77 UD
Resistant bacteria
cip 63 41.50 94 11.60 100
cip 86 1.67 109 0.66 94
cip 92 UD UD
cip 103 UD UD
cip 132 3.30 95 1.07 98
411-87 28.00 93 15.10 99
417-87 0.18 100 0.06 105
591-89 24.00 96 10.50 98
4953-88 2.74 95 33.60 104
5538-88 4.15 104 34.20 77
8984-88 35.50 101 10.25 103
Triplet
2219 25.50 93 9.70 97
2221 26.00 no 11.70 98
7777 22.00 92 9.70 90
Paired strains
6989 31.00 103 6.12 104
3225 32.00 91 5.90 46
UD - undetectable Sp A - Protein A
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Table 29. The effect of 1/2 MIC levels of gentamicin on the production of
bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng proteinA/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell produced
protein absence protein absence
Sensitive bacteria
Cowan 1 70.00 89 8.00 73
E3T 1.30 50 0.26 30
Oxford 0.23 60 0.09 85
12009 1.77 58 0.65 62
Wood 46 0.10 40 UD
Resistant bacteria
cip 63 57.70 97 21.40 101
cip 86 7.60 121 3.98 107
cip 92 UD UD
cip 103 UD UD
cip 132 3.10 94 2.40 104
411-87 10.80 113 1.21 95
417-87 0.18 92 UD
591-89 15.50 104 3.20 70
4953-88 6.30 75 58.00 97
5538-88 0.29 74 37.00 93
8984-88 29.00 49 10.00 67
Triplet
2219 17.00 85 4.28 64
2221 17.00 89 2.50 53
7777 18.00 86 4.80 74
Paired strains
6989 4.20 80 1.00 80
3225 8.30 83 2.10 89
UD - undetectable Sp A - Protein A
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Table 30. The effect of 1/4 MIC levels of chloramphenicol on the
production of bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng proteinA/ % of Sp A ng protein A/ % of Sp i
mg total cell produced mg total cell produce
protein absence protein absence
Sensitive bacteria
Cowan 1 50.00 83 7.00 89
E3T 0.73 101 0.14 36
Oxford 0.33 70 0.12 41
12009 1.15 84 0.45 59
Wood 46 0.30 67 UD
Resistant bacteria
cip 63 39.00 88 9.20 78
cip 86 1.52 99 0.58 82
cip 92 UD UD
cip 103 UD UD
cip 132 2.80 80 1.23 112
411-87 27.00 90 13.20 87
417-87 0.18 100 0.06 100
591-89 20.00 80 9.80 91
4953-88 2.92 101 35.90 103
5538-88 3.73 94 40.96 91
8984-88 29.00 83 8.50 85
Triplet
2219 25.50 93 9.60 96
2221 22.00 96 12.70 106
???? 23.00 96 8.50 80
Paired strains
6989 31.00 103 6.06 86
3225 30.00 86 5.30 41
UD - undetectable Sp A - Protein A
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Table 31. The effect of 1/2 MIC levels of chloramphenicol on the
production of bound and extracellular protein A
Strain Bound protein A Extracellular protein A










Cowan 1 50.00 63 6.00 54
E3T 0.97 37 0.19 21
Oxford 0.09 24 UD
12009 2.33 76 0.39 37
Wood 46 UD UD
Resistant bacteria
cip 63 20.00 35 8.60 41
cip 86 5.50 88 2.04 55
cip 92 UD UD
cip 103 UD UD
cip 132 1.95 57 1.60 71
411-87 3.40 35 0.77 61
417-87 0.17 89 UD
591-89 5.80 39 2.30 50
4953-88 5.70 68 51.00 85
5538-88 0.36 92 39.00 98
8984-88 15.00 26 9.00 60
Triplet
2219 15.00 75 3.38 50
2221 14.00 74 2.78 59
7777 18.00 86 5.70 87
Paired strains
6989 1.30 27 0.60 50
3225 1.70 17 0.60 25
UD - undetectable Sp A - Protein A
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Table 33. The effect of 1 /4 MIC levels of tetracycline on the production
of bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng protein A/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell produced
protein absence protein absence
Sensitive bacteria
Cowan 1 51.00 85 7.20 92
E3T 0.74 102 0.15 38
Oxford 0.36 77 0.11 38
12009 1.18 87 0.46 60
Wood 46 0.34 75 UD
Resistant bacteria
cip 63 25.40 58 4.80 41
cip 86 1.25 82 0.70 99
cip 92 UD UD
cip 103 UD UD
cip 132 2.90 83 1.06 97
411-87 28.00 93 13.60 90
417-87 0.18 100 UD
591-89 15.00 60 5.30 49
4953-88 2.49 86 35.20 101
5538-88 4.00 101 38.40 86
8984-88 22.50 64 7.50 74
Triplet
2219 26.00 96 8.00 80
2221 22.00 96 8.96 75
7777 17.00 71 5.65 52
Paired strains
6989 30.00 100 4.50 77
3225 28.00 80 4.30 33
UD - undetectable Sp A - Protein A
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Table 33. The effect of 1 /2 MIC levels of tetracycline on the production
of bound and extracellular protein A
Strain Bound protein A Extracellular protein A
ng proteinA/ % of Sp A ng protein A/ % of Sp A
mg total cell produced mg total cell produced
protein absence protein absence
Sensitive bacteria
Cowan 1 45.00 57 6.00 54
E3T 0.85 30 0.09 10
Oxford 0.11 30 UD
12009 2.04 67 0.54 51
Wood 46 0.07 27 UD
Resistant bacteria
cip 63 15.00 25 2.50 12
cip 86 1.70 27 0.92 25
cip 92 UD UD
cip 103 UD UD
cip 132 1.47 43 2.10 90
411-87 3.70 38 0.86 68
417-87 UD UD
591-89 2.20 14 1.10 24
4953-88 6.20 73 53.00 88
5538-88 0.42 107 39.00 97
8984-88 6.90 15 7.00 47
Triplet
2219 13.00 65 4.10 61
2221 13.00 63 2.60 56
7777 14.00 67 2.80 44
Paired strains
6989 1.30 27 0.20 17
3225 0.40 4 UD
UD - undetectable Sp A - Protein A
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opposite was seen. Extracellular protein A produced in logarithmic
phase, is a secreted form of bound protein A and not a precursor or
breakdown product. It would be expected that if production of protein A
was reduced, bound protein A would be affected first and then
extracellular protein A would be affected. However since extracellular
protein A was affected more, it could have been because the levels of
extracellular protein A are already low and so any reduction would be
more marked. The strains which showed a greater reduction in bound
protein A than extracellular protein A, were the strains which produced
predominately extracellular protein A. Some strains produce
predominately extracellular protein A and these strains are usually
MRSA (Winbald and Ericson 1973). Again, the greater effect on cell
bound protein A could have been because this was already secreted at
low levels and so any reduction would be more marked.
4.3 Production of a haemolysin in the presence of sub-MIC levels
of antibiotics
The effect of sub - MIC levels of antibiotics on the production of a
haemolysin was investigated. The strains were grown overnight and
then subcultured into fresh broth. The strains were then grown for three
hours before the antibiotics were added and growth continued for a
further two hours. The strains were harvested and measured for a
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haemolysin production, the number of the viable cells and total cell
protein. The amount of a haemolysin produced in the presence of the
antibiotics was compared to the amount produced in the absence of
antibiotics. Since a haemolysin is an extracellular enzyme, the level of a
haemolysin produced by the strains when related to viable cells will be
discussed.
All six antibiotics had some effect on a haemolysin production, both at
1/4 and 1/2 MIC levels, when a haemolysin production was related to
viable cells and total cell protein. When a haemolysin production was
related to viable cells, the two quinolones, ciprofloxacin and enoxacin,
reduced and in some cases completely inhibited a haemolysin
production (Tables 34 and 35). At 1/4 MIC levels the effect of these two
antibiotics was less than at 1/2 MIC levels. Even when a haemolysin
production was related to total cell protein ciprofloxacin and enoxacin
still reduced a haemolysin production (appendix Table X). Gentamicin
reduced a haemolysin production at 1/2 MIC levels but did not have
much effect at 1/4 MIC levels, when a haemolysin production was
related to viable cells (Table 36). When a haemolysin production was
related to total cell protein, gentamicin still reduced its production but to
a lesser extent (appendix Table XI). The other two protein synthesis
inhibitors, chloramphenicol and tetracycline, also reduced a haemolysin
production and in some cases completely inhibited it (Table 37 and 38).
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Table 34. The effect of sub - MIC levels of ciprofloxacin on the production
of a haemolysin
Strain 1/4 MIC 1/2 MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
Wood 46 1400 67 734 45
E3T 26 34 UD
Oxford 29 52 27 25
12009 1100 85 UD
Cowan 1 29 60 27 49
Resistant bacteria
cip 63 50 85 34 56
cip 86 138 66 171 50
cip 92 566 90 278 85
cip 103 24 60 9 17
cip 132 60 87 48 50
411-87 8 14 UD
417-87 15 115 15 71
591-89 16 36 UD
4953-88 24 63 7 32
5538-88 8 53 UD






6989 23 92 39 49
3225 14 82 15 30
UD - undetectable
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Table 35. The effect of sub - MIC levels of enoxacin on the production of
a haemolysin
Strain 1/4 MIC 1/2MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
Wood 46 1200 57 UD
E3T 45 58 UD
Oxford 44 78 38 35
12009 540 41 250 26
Cowan 1 46 96 33 61
Resistant bacteria
cip 63 28 47 UD
cip 86 71 34 UD
cip 92 627 99 284 87
cip 103 27 67 11 20
cip 132 53 77 27 29
411-87 15 27 UD
417-87 6 46 UD
591-89 41 93 UD
4953-88 23 61 UD
5538-88 UD UD






6989 12 48 25 31
3225 14 82 21 41
UD - undetectable
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Table 36 . The effect of sub- MIC levels of gentamicin on the production
of a haemolysin
Strain 1/4 MIC 1/2MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
Wood 46 1800 86 1200 75
E3T 70 91 30 86
Oxford 57 101 72 65
12009 1200 92 900 95
Cowan 1 34 71 35 47
Resistant bacteria
cip 63 53 90 51 84
tip 86 191 91 257 74
cip 92 500 79 211 65
cip 103 34 85 38 70
tip 132 56 81 46 49
411-87 44 78 58 53
417-87 15 115 19 88
591-89 38 86 31 55
4953-88 41 108 11 50
5538-88 13 87 7 75






6989 22 88 60 75
3225 16 94 41 78
UD - undetectable
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Table 37. The effect of sub - MIC levels of chloramphenicol on the
production of a haemolysin
Strain 1/4MIC 1/2MIC
HU/109 cells % amount HU /109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
Wood 46 140 7 UD
E3T 57 74 UD
Oxford 51 91 32 29
12009 580 45 350 37
Cowan 1 UD UD
Resistant bacteria
cip 63 34 58 23 27
cip 86 no 52 UD
cip 92 612 98 44 14
cip 103 28 70 UD
cip 132 28 40 28 30
411-87 UD UD
417-87 13 10~0 14 66
591-89 18 41 UD
4953-88 39 102 UD
5538-88 UD UD






6989 12 48 14 17
3225 14 82 37 72
UD - undetectable
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Table 38. The effect of sub - MIC levels of tetracycline on the production
of a haemolysin
Strain 1/4MIC 1/2 MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence abser
Sensitive bacteria
Wood 46 470 22 UD
E3T 17 23 6 18
Oxford 36 64 40 36
12009 820 63 450 47
Cowan 1 UD UD
Resistant bacteria
cip 63 18 31 UD
cip 86 31 15 UD
cip 92 270 43 UD
cip 103 6 15 UD
cip 132 30 43 29 32
411-87 53 95 90 83
417-87 UD UD
591-89 36 82 UD
4953-88 UD UD
5538-88 UD UD






6989 22 88 13 16
3225 11 65 18 22
UD - undetectable
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Table 39. The effect of sub - MIC levels of methicillin on the production
of a haemolysin
Strain 1/4 MIC 1/2MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
Wood 46 4300 >200 4248 >200
E3T 2800 >200 252 >200
Oxford 290 >200 460 >200
12009 1600 123 2146 >200
Cowan 1 220 >200 145 >200
Resistant bacteria
rip 63 100 169 752 >200
rip 86 751 >200 1280 >200
cip 92 1500 >200 2062 >200
cip 103 1100 >200 313 >200
cip 132 65 94 3380 >200
411-87 1400 >200 2230 >200
417-87 4500 >200 4144 >200
591-89 5800 >200 336 >200
4953-88 4000 >200 444 >200
5538-88 310 >200 532 >200






6989 132 >200 330 >200
3225 53 >200 180 >200
UD - undetectable
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At 1/2 MIC levels of these two antibiotics, a majority of the strains
produced undetectable levels of a haemolysin, if they were producing
any a haemolysin at all. At 1/4 MIC levels chloramphenicol and
tetracycline still reduced a haemolysin production in most of the strains.
Again, when a haemolysin production in the presence of these two
antibiotics was related to total cell protein, there was still a reduction in
the levels of a haemolysin produced (appendix Table XII). Therefore the
reduction in a haemolysin did not result entirely from of a reduction in
general protein synthesis. Methicillin greatly increased a haemolysin
production by all the strains both at 1/2 and 1/4 MIC levels (Table 39).
This antibiotic affects the cell wall and so must be releasing the
haemolysin either by lysing the cells or by attacking the wall in some
way.
4.4 Production of 5 haemolysin in the presence of sub - MIC
levels of antibiotics
The production of 8 haemolysin was measured in the presence of
antibiotics like the other pathogenicity factors studied. Bacterial strains
were grown overnight and subcultured into fresh broth. The strains
were grown for four hours before the antibiotics were added and growth
continued for a further two hours. Strains were also grown in the
absence of antibiotics for comparison. The strains were harvested and the
production of 8 haemolysin, viable cells and total cell protein measured.
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The amount of 8 haemolysin produced in the presence of the antibiotics
was compared to the amount produced in the absence.
The effect of the six antibiotics on 8 haemolysin production was similar
to the effects seen with a haemolysin. Ciprofloxacin and enoxacin
reduced and in some cases completely inhibited 8 haemolysin
production, when 8 haemolysin production was related to viable cells
(Tables 40 and 41). Gentamicin had little effect on 8 haemolysin
production either at 1/2 or 1/4 MIC levels (Table 42). Chloramphenicol
and tetracycline again reduced 8 haemolysin production, similar to the
effects seen with a haemolysin (Tables 43 and 44). Most strains either
produced undetectable amounts or no 8 haemolysin in the presence of
1/2 MIC levels of these two antibiotics and at 1/4 MIC levels most
strains produced significantly reduced amounts of 8 haemolysin.
Methicillin again had a dramatic effect on the production of 8
haemolysin by increasing the amounts of 8 haemolysin produced in the
presence of 1/2 and 1/4 MIC levels of this antibiotic (Table 45).
4.5 Growth of strains and selection of resistant bacteria in the
presence of 1/2-MIC levels of ciprofloxacin
A ciprofloxacin sensitive and a ciprofloxacin resistant strain were grown
in the presence of 1/2 MIC levels of ciprofloxacin for 24 hours. Growth
was monitored for the first 8 hours by viable counts, taken every hour.
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Table 40. The effect of sub - MIC levels of ciprofloxacin on the production
of 8 haemolysin
Strain 1/4MIC 1/2MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
E5662 171.0 95 120.0 80
E3T 90.0 81 60.0 65
Oxford 5.2 82 4.8 76
12009 75.0 88 40.0 77
Cowan 1 1.3 74 0.5 50
Wood 46 18.0 90 8.6 61
Resistant bacteria
cip 63 40.0 35 UD
cip 86 57.0 90 35.0 50
cip 92 45.0 88 40.0 38
cip 103 0.8 80 1.0 66
cip 132 52.0 82 26.0 47
411-87 0.8 75 5.5 55
417-87 14.3 70 13.0 61
591-89 UD UD
4953-88 UD UD
5538-88 0.2 31 UD






6989 40.0 83 41.0 73
3225 20.0 69 UD
UD - undetectable
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Table 41. The effect of sub-MIC levels of enoxacin on the production of 8
haemolysin
Strain 1/4MIC 1/2MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
E5662 110.0 61 110.0 73
E3T 67.0 61 50.0 54
Oxford 2.4 38 UD
12009 37.0 43 20.0 38
Cowan 1 0.8 45 UD
Wood 46 20.0 100 12.0 85
Resistant bacteria
cip 63 49.0 43 UD
cip 86 58.0 90 40.0 57
cip 92 44.0 69 33.0 31
cip 103 106.0 102 0.8 51
cip 132 58.0 92 20.0 36
411-87 1.0 91 74.0 74










6989 23.0 49 UD
3225 26.6 92 25.0 54
UD - undetectable
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Table 42. The effect of sub - MIC levels of gentamicin on the production
of 8 haemolysin
Strain 1/4 MIC 1/2MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
E5662 170.0 95 145.0 97
E3T 105.0 95 87.0 95
Oxford 6.0 94 5.2 83
12009 84.0 99 50.0 96
Cowan 1 1.7 94 1.6 88
Wood 46 18.0 90 12.0 86
Resistant bacteria
cip 63 110.0 96 90.0 90
cip 86 65.0 101 60.0 86
cip 92 50.0 98 90.0 86
cip 103 1.0 100 1.5 97
cip 132 61.0 97 50.0 91
411-87 1.0 91 3.5 35
417-87 20.4 98 20.0 94
591-89 UD UD
4953-88 UD UD
5538-88 UD 0.5 100






6989 45.0 94 50.0 89
3225 27.0 93 42.0 91
UD - undetectable
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Table 43. The effect of sub - MIC levels of chloramphenicol on the
production of 8 haemolysin
Strain 1/4MIC 1/2 MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
E5662 53.0 30 UD
E3T 117.0 106 90.0 98
Oxford 2.8 45 1.1 18
12009 60.0 71 10.0 20
Cowan 1 0.5 28 UD
Wood 46 8.0 40 4.0 29
Resistant bacteria
cip 63 5.5 5 UD
tip 86 36.0 56 17.0 24
tip 92 17.0 33 UD
tip 103 1.0 97 1.0 63
tip 132 57.0 91 45.0 82
411-87 0.4 40 UD
417-87 16.0 78 15.0 70
591-89 UD UD
4953-88 UD UD
5538-88 0.4 65 0.2 30






6989 13.0 27 UD
3225 7.0 24 UD
UD - undetectable
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Table 44. The effect of sub-MIC levels of tetracycline on the production of
8 haemolysin
Strain 1/4MIC 1/2MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
E5662 62.0 35 UD
E3T 27.0 25 UD
Oxford 3.3 52 1.5 24
12009 58.0 69 UD
Cowan 1 1.0 55 UD
Wood 46 10.0 50 UD
Resistant bacteria
cip 63 15.1 13 UD
cip 86 40.0 63 19.0 27
cip 92 17.0 33 UD
cip 103 0.4 38 UD
cip 132 10.4 17 UD
411-87 0.4 38 UD










6989 9.5 20 UD
3225 5.0 17 UD
UD - undetectable
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Table 45. The effect of sub - MIC levels ofmethicillin on the production
of 5 haemolysin
Strain 1/4MIC 1/2MIC
HU/109 cells % amount HU/109 cells % amount
produced in produced in
absence absence
Sensitive bacteria
E5662 672 >200 800 >200
E3T 757 >200 205 >200
Oxford 7 113 50 >200
12009 240 >200 380 >200
Cowan 1 3 >200 3 >200
Wood 46 200 >200 280 >200
Resistant bacteria
cip 63 140 123 200 >200
cip 86 91 140 200 >200
cip 92 112 >200 316 >200
cip 103 7 >200 54 >200
cip 132 500 >200 197 >200
411-87 2 >200 23 >200
417-87 285 >200 95 >200
591-89 2 >200 3 >200
4953-88 UD UD
5538-88 2 >200 2 >200






6989 304 >200 202 >200
3225 213 >200 196 >200
UD - undetectable
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The presence of ciprofloxacin did not seem to affect bacterial growth and
the strains did not exhibit slower growth (Figures 25 and 26).
After 24 hours samples were taken from the cultures and plated out on
nutrient agar plates containing or lacking ciprofloxacin equivalent to lx
MIC, 2x MIC and 5x MIC. The strains which had been grown in the
presence of ciprofloxacin yielded ciprofloxacin resistant mutants on the
lx MIC, 2x MIC and the 5x MIC plates (Table 46). Strains which had not
been grown in the presence of ciprofloxacin did not have any resistant
mutants. This confirmed that the mutants had been selected by the
growth experiment and not by overnight growth on ciprofloxacin
containing plates. The resistant mutants were sub-cultured in
ciprofloxacin lacking broth for 10 passages to check that they were stable
and did not revert back to ciprofloxacin sensitivity.
Table 46. Isolation of resistant mutants after growth for 24 hours in
presence of 1 /2 MIC levels of ciprofloxacin
Strain cfu/ml
after 24 h
Number of mutants isolated on cipro plates
1 x MIC 2 x MIC 5 xMIC
E3T 3.6 x 1010 51 22 4
cip 103 2.5 x 10 10 21 9
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Figure 25. Growth of ciprofloxacin sensitive strain in absence and
presence of 1/2 MIC ciprofloxacin
Figure 26. Growth of ciprofloxacin resistant strain in absence and
presence of 1/2 MIC ciprofloxacin
cip 103
tip 103 + cipro
7
0 2 4 6
Time (hours)
150
4.6 The effect of sub - MIC levels of ciprofloxacin on in vivo
growth of S. aureus
The effect of sub - MIC levels of ciprofloxacin on the development of
S. aureus in mice was investigated. Before the experiment could proceed,
it was necessary to establish the levels of ciprofloxacin which when
injected into the mice produced sub-MIC levels of ciprofloxacin in the
blood and abscesses. Mice were injected with varying amounts of
ciprofloxacin, both intravenously into a vein in the tail and
subcutaneously on the left flank. The mice had previously been injected
with S. aureus on the right flank so that subcutaneous abscesses had
developed. Thirty minutes after the ciprofloxacin injections, blood
samples were taken ocularly. Three hours after the injections the mice
were sacrificed and the abscesses removed. The blood samples and
abscess material were analysed by HPLC for level of ciprofloxacin. The
levels of ciprofloxacin in the blood and abscesses could be related to the
initial injections (Table 47). Three mice were sacrificed for each
ciprofloxacin concentration.
By employing the figures of ciprofloxacin levels in the serum and
abscesses as guidelines, the amount of ciprofloxacin needed to achieve
1/2MIC levels of the drug in the abscesses was calculated.
Mice were injected with S. aureus as described in section 2.4.15 and, one
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Table 47. Levels of ciprofloxacin (mg/L) in the blood and abscesses after
injection by different routes
Initial injection Level of ciprofloxacin (mg/L)
of ciprofloxacin intravenous sub-cutaneous
(mg/kg body weight) injection injection
Blood Abscess Blood Abscess
20 2.4 2.5 4.5 4.7
12 1.2 1.5 1.9 2.3
8 0.7 0.7 1.0 1.5
4 0.4 0.6 0.6 0.9
2 0.2 0.3 0.3 0.5
hour after this subcutaneous injection, mice were injected with 1/2
MIC levels of ciprofloxacin. Since ciprofloxacin has a half life of 60
minutes in serum of mice (information obtained from Bayer UK) the
mice were injected with ciprofloxacin at two hourly intervals, so that
the level of ciprofloxacin remained near 1/2 MIC levels. These levels
were maintained for 8 hours and then resumed 16 hours later, since
injections were not given during the night. The mice were given two
injections the following day, to maintain the selective pressure, before
being sacrificed. The abscesses were excised and viable counts obtained
from them as described in section 2.4.16. Treatment with ciprofloxacin
at sub-MIC levels reduced the number of organisms recovered from
the abscesses (student t test p < 0.01), but 1/4 MIC levels did not reduced
the number of bacteria recovered greatly (Table 48).
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Table 48. Treatment of mice with sub MIC levels of ciprofloxacin for 24
hours
Number of viable bacteria after 24 hours (cfu/ml)
Control 1/2 MIC Control 1/4 MIC
(no drug) (no drug)
5.0 x 107 1.0 xlO6 5.0 x 107 3.5 x 107
6.5 x 107 1.0 xlO7 2.5 x 10s 7.0 x 106
1.8 x10s 4.0 x 106 3.5 x 107 2.8 x 107
1.4 x10s 5.0 x 105 2.0 x 107 3.1 x 107
7.5 x 107 6.0 x 106 7.0 x 107 1.6 xlO7
2.7 xlO7 2.0 x 106 3.9 x 107 7.0 x 106
7.5 x 107 2.0 x 106 4.0 x 107 3.0 x 107
2.2 xlO7 1.0 xlO6 6.0 x 107 8.0 x 106
5.0 x 107 7.0 x 106 8.0 x 107 2.8 x 107
7.0 xlO7 3.0 x 106 2.8 x 107 4.0 x 107
Mean
7.5 x 107 3.6 x 106 6.7 xlO7 4.0 x 107
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In a subsequent experiment, mice were injected with S. aureus as
described in section 2.4.15 and the abscesses were allowed to develop for
48 hours. After this time, treatment with 1/2 MIC levels of ciprofloxacin
for the strain injected (strain 6989 - ciprofloxacin sensitive) was started.
The treatment was continued for 24 hours as described in the previous
paragraph, with two hourly injections on the left flank. After the 24
hours of treatment was completed, the mice were sacrificed, the abscesses
removed and viable counts obtained from them as described in section
2.4.16. The abscess material was also plated out on agar plates containing
ciprofloxacin at 2 x MIC and 4 x MIC for strain 6989, to enable the
selection of ciprofloxacin resistant mutants which had developed during
the treatment. Abscess material from mice not treated with ciprofloxacin
was also plated out, to ensure that the resistant mutants had not been
selected out by overnight growth on the ciprofloxacin plates. Treatment
with ciprofloxacin led to the selection of isolates resistant to 2 x MIC and
4 x MIC (Table 49).
4.7 Summary
The effects of sub-MIC levels of six antibiotics on the pathogenicity of
S. aureus was investigated. The six antibiotics used were ciprofloxacin,
enoxacin, gentamicin, chloramphenicol, tetracycline and methicillin.
Coagulase production was affected by 1/4 and 1/2MIC levels of
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Table 49. Selection of ciprofloxacin resistant bacteria after 24 hours
treatment with ciprofloxacin
Untreated mice Treated mice
Viable bacteria cipro resistant Viable bacteria cipro resistant
6.4 x 107 9.1 x 107 19
7.0 x 107 5.1 x 107
1.0 x 108 9.5 x 107 11
2.0 x 108 5.4 x 107 4
3.5 x 107 1.7 xlO8 15
5.0 x 107 8.3 x 107 12
7.9 x 107 7.0 x 107
6.5 x 107 9.3 x 107 14
6.2 xlO7 1.5 x 108 15
8.1 x 107 3.5 x 108 17
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gentamicin, chloramphenicol and tetracycline. Ciprofloxacin, enoxacin
and methicillin had little or no effect on coagulase production. Protein A
production was not affected by 1/4 and 1/2 MIC levels of ciprofloxacin,
enoxacin and methicillin. However, chloramphenicol and tetracycline
reduced the production of both bound and extracellular protein A at 1/4
and 1/2 MIC levels. Gentamicin also reduced protein A production but
not to the same extent as the other two protein synthesis inhibitors.
The two haemolysins of all strains were affected by the six antibiotics in a
similar manner. Ciprofloxacin, enoxacin, chloramphenicol and
tetracycline at 1/2 MIC levels reduced and in some cases completely
inhibited the production of the two haemolysins. At 1/4 MIC levels of
these four antibiotics a and 8 haemolysin production was reduced to a
lesser extent. Gentamicin had little or no effect on a or 8 haemolysin
production. Methicillin at 1/2 and 1/4 MIC levels greatly increased a or 8
haemolysin production.
The effect of sub-MIC levels of ciprofloxacin on the growth of S. aureus
both in vitro and in vivo was investigated. In vitro, 1/2 MIC levels of
ciprofloxacin had little or no effect on the growth over 8 hours. After 24
hours, ciprofloxacin resistant mutants of the strains were isolated from
the culture medium. In vivo, treatment with 1/2 MIC levels of
ciprofloxacin reduced the number of bacteria recovered from the
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abscesses when treatment was started one hour after the sub-cutaneous
injection of the bacteria. Ciprofloxacin at 1/4 MIC levels had little or no
effect on the abscesses.
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5 Discussion
Microbial pathogenicity is complex and multifactorial (Smith 1958).
Pathogens often have several biochemical mechanisms which may act
individually or together to produce disease. Because of the multifactorial
nature of pathogenic mechanisms, they have been studied in many
ways. The organisms can be altered, so that they lack one particular
feature - toxin, adhesin etc, and then this organism can be examined in
vitro and in vivo (Jonsson et al 1985; Patel et al 1987; Bramley et al
1989). Virulent or avirulent strains can be compared for their production
of particular toxins etc. Another method is to investigate the effect of
antibiotics on virulence factor production (Lorian 1986). Antibiotics are
used at concentrations below those required to inhibit growth
(subminimum inhibitory concentrations - sub - MIC), since at
concentrations higher than this, i.e. equal to the MIC, the antibiotic
completely inhibits the growth of bacteria and therefore eliminates their
virulence. Since it has been realised that human infections increasingly
result from antibiotic resistant organisms, work has concentrated on the
pathogenicity of these resistant organisms, as a knowledge of their
products and role in pathogenesis may produce information of direct
medical importance.
The effect of antibacterials on the pathogenicity of S. aureus was
examined in this project. The effect of both sub-inhibitory concentrations
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of certain antibiotics on S. aureus was studied, as well as the effect of
antibiotic resistance on pathogenicity. It has been reported that strains
which have acquired antibiotic resistance, either plasmid-mediated or by
chromosomal mutations, exhibit reduced virulence (Rake et al 1944;
Blair et al 1946; Lacey and Chopra 1975; Musher et al 1977). In the light of
some preliminary reports concerning various bacterial species, it was
speculated that S. aureus, which had developed chromosomal resistance
to the 4-quinolone group of antibacterials, might also exhibit reduced
virulence (Ravizzola et al 1987; Crumplin 1987; Smith 1990). These
resistant bacteria were investigated, both in vitro and in vivo, to see if
they were more or less pathogenic than sensitive bacteria. They were also
compared to high factor producing strains. The pathogenicity of the
strains in the presence of sub-minimum inhibitory concentrations
(sub-MICs) of the 4-quinolones and other antibiotics was also examined,
since resistant strains sometimes are less virulent in the presence of
antibiotics (Nordstrom and Lindberg 1978).
5.1 Pathogenicity of ciprofloxacin resistant S. aureus
Ciprofloxacin-resistant clinical isolates of S. aureus were compared to
sensitive strains for their pathogenicity. The growth rates of the strains
were analysed along with the production of four virulence factors. The
four factors studied in detail were coagulase, protein A, ahaemolysin
and 5 haemolysin. These four factors were chosen since they are
generally produced by most S. aureus strains and also for their assorted
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effects on the host defence system. No one virulence factor can be solely
attributed to the pathogenicity of S. aureus, since the pathogenicity of S.
aureus is like pathogenicity in general - multifactorial and a result of
many components.
5.1.1 Growth of ciprofloxacin sensitive and resistant strains
The growth of the resistant and sensitive strains was studied, since
growth rate is important in pathogenicity (Smith 1990). A slow growing
pathogen will be overcome by the host defence mechanisms before it has
had a chance to cause disease. Avirulence can arise from inability of
bacteria to grow and divide (Smith 1968). Also, differences in the
production of toxins and enzymes might be a result of a slow growth
rate, rather than actual differences in toxin production.
The resistant and sensitive strains grew at similar rates during
logarithmic phase, which supports the views of Kayser and Novak
(1987). They also grew ciprofloxacin sensitive and resistant strains of
S. aureus and found no apparent differences.
Ban (1981) observed that in a mixed culture of penicillin resistant and
sensitive strains, the resistant strains grew at a higher specific growth
rate and that the ratio of resistant to sensitive bacteria changed from 1:1
to 1:1.5 over the 24 hour period. This was in contrast to Lacey and Chopra
(1975) who found that in a mixed culture of resistant and sensitive
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bacteria, the sensitive strains grew at a faster rate over 24 hours. In the
current study, when growth was continued in stationary phase, still no
differences were seen; indeed when replication rates of a mixture of
ciprofloxacin sensitive and resistant strains were studied, the
ciprofloxacin resistant strain persisted in the mixture, confirming that it
had a similar growth rate.
Nalidixic acid resistant mutants of E. coli and Salmonella typhimurium
lost the ability to grow anaerobically and so become obligate aerobes
(Yamamoto and Droffner 1985; Yoshizawa and Yamamoto 1989). Some
of the ciprofloxacin resistant strains were grown anaerobically, to
establish if they too had lost the ability to grow under anaerobic
conditions. However, they retained the ability to grow in the absence of
oxygen.
These quinolone resistant strains grew at similar rates to the sensitive
strains both in the logarithmic and stationary phases. They persisted in a
mixed culture of sensitive and resistant strains and they retained the
ability to grow under anaerobic conditions.
5.1.2 Production of virulence factors by sensitive and resistant strains
It has been observed previously that antibiotic resistant bacteria are less
pathogenic than their sensitive counterparts. Gentamicin resistant
S. aureus grew as small nonhaemolytic colonies, producing low levels
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of DNase, mannitol and coagulase (Musher et al 1977). These
gentamicin resistant strains were shown to be less virulent in rats and
mice (Musher et al 1977; Pelletier et al 1979). Penicillin resistant
S. aureus produced lower levels of coagulase and protein A (Rake et al
1944; Blair et al 1946). A similar situation was observed in methicillin
resistant S. aureus (Barber 1961; Knox and Smith 1961). Jordens et al
(1989) found that epidemic MRSA produced higher levels of coagulase,
but similar levels of the haemolysins. Roberts and Gaston (1987) also
found that higher levels of coagulase were produced by epidemic MRSA
and that these strains produced low levels of protein A. Mutants of
S. aureus resistant to ofloxacin were reported not to produce coagulase
(Smith 1990), but this was a study of a small number of laboratory
mutants and they were tested by the slide coagulase test. The slide
coagulase test detects bound coagulase production only and often leds to
false negative results. Lacey and Chopra (1975) suggested that acquisition
of resistance plasmids by S. aureus is associated with a decrease in
virulence. A similar study by Cutler (1979) could not corroborate this;
indeed, he showed the opposite, that the loss of bacterial virulence was
associated with the loss of antibiotic resistance determinants. Ishag and
Shibl (1985) also found no correlation between patterns of resistance and
the production of certain toxins and enzymes by clinical isolates of
S. aureus.
The production of the four virulence factors studied was measured
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during optimum production of the factor concerned. Bound and soluble
coagulase production was measured employing a much improved
chromogenic assay for coagulase. Bound and extracellular protein A
production was measured, since extracellular protein A production can
be as high as 30% of total protein A output in some strains and is much
enhanced in some MRSA strains (Winbald and Ericson 1973). Only the
extracellular production of the two haemolysins was studied since they
are considered as extracellular enzymes.
The 4-quinolone resistant strains tested in this study produced similar
levels of the four factors to the sensitive strains. Four strains were
acquired which produced high levels of each of the four factors studied.
Ciprofloxacin resistant mutants of these strains were made and tested for
the production of the factors. No differences were seen, suggesting that
in S. aureus, ciprofloxacin resistance does not affect pathogenicity. In
order to confirm these results, the behaviour of the strains in vivo was
investigated.
5.1.3 Pathogenicity of resistant and sensitive strains in vivo
The necessity to study pathogenicity in vivo as well as in vitro has been
well documented (Smith 1968; Shibl 1983). Bacteria often behave
differently in vivo and in vitro, producing different levels of toxins,
surface antigens etc. S. aureus grown in vivo have different surface
antigens (Karakawa and Kane 1975; Watson and Prideaux 1979), produce
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different levels of DNase, leucocidin and a haemolysin (Beining and
Kennedy 1963).
A selection of the resistant and sensitive strains were compared in vivo,
in a sub-cutaneous abscess model in mice. This model allowed easy
comparison of strains, as they grew in vivo, by monitoring the
development of the abscesses. The resistant strains produced similar
abscesses to the sensitive strains - both in size and degree of tissue
damage, suggesting that they were of similar virulence. Lacey and
Chopra (1975) found that methicillin resistant S. aureus were less
virulent for mice. Ciprofloxacin resistant Ps. aeruginosa were also found
to be less virulent for mice (Ravizzola et al 1987). The results from this
study suggest that for S. aureus, ciprofloxacin resistant strains have
similar virulence for mice. They would support findings of Ishag and
Shibl (1985) who found no correlation between patterns of resistance and
the production of virulence factors.
5.2 Pathogenicity of bacteria in the presence of sub-MIC s of
antibiotics
Dosage levels of antimicrobial agents are often determined by the use of
parameters which have little bearing on the drug levels found at the site
of infection. In fact antibiotics are often present in sub-MIC
concentrations at the site of infection (Zak and Kradolfer 1979).
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Therefore, it is of interest to investigate the effect of sub-MIC levels of
antibiotics on the virulence of microorganisms. If the various
components of virulence eg. growth rate, toxin production etc, are
altered by these levels of antibiotics in vitro, this might also influence
the virulence of the organism in vivo and alter the host's ability to
respond to the infection (Gemmell 1982).
The study was primarily concerned with the effects of sub-MIC levels of
the quinolones on virulence. However, to enable comparisons with
antibiotics with different modes of action, the effects of some protein
synthesis inhibitors and cell wall synthesis inhibitors were also
investigated. The antibiotics investigated were ciprofloxacin, enoxacin,
gentamicin, chloramphenicol, tetracycline and methicillin.
5.2.1 Coagulase Production
The three protein synthesis inhibitors, gentamicin, chloramphenicol and
tetracycline reduced coagulase production at 1/4 and 1/2 MIC levels. The
amount of coagulase produced in the presence of the antibiotics was
initially related to viable cells but then it was also related to total cell
protein. The reduction in coagulase production was still observed when
related to total cell protein which suggests that besides affecting protein
synthesis, and therefore coagulase production, these antibiotics affect
some other aspect of the secretion or synthesis of coagulase. Growth of
S. aureus in the presence of sub-MIC levels of chloramphenicol and
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tetracycline leads to a 3 - 4 fold thickening of the cell wall (Hash and
Davis 1962; Cardieuz et al 1970). This might reduce or prevent the
secretion of coagulase and other extracellular enzymes by the cell.
Gemmell and Shibl (1976) also showed that chloramphenicol, at sub-MIC
levels, reduced the production of coagulase. Lincomycin and
clindamycin were also shown to have a limiting effect on coagulase
production.
Several investigators have observed that exoenzyme synthesis is
considerably more sensitive to antibiotic inhibition than is general
protein synthesis (Stinson and Merrick 1974; Boethling 1975; Shibl 1977).
This phenomenon has led to the hypothesis that extracellular products
are synthesised or assembled on the surface of cell membranes (Shibl
1983). It has been shown that polyribosomes participating in the
synthesis of secretory proteins are tightly bound to the membrane
(Randall and Hardy 1977). Membrane-bound ribosomes are selected by
mRNA molecules, since they possess a unique sequence of codons,
which are not present in mRNAs coding for cytoplasmic proteins (Blobel
and Dobberstein 1975). Differential inhibition of the synthesis of E. coli
envelope proteins as compared with the synthesis of cytoplasmic
proteins, was observed in the presence of various ribosome specific
antibiotics e.g. chloramphenicol and tetracycline (Hirashima et al 1973).
Membrane-bound ribosomes are localised peripherally and are thus
more sensitive to inhibition by antibiotics than are cytoplasmic
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ribosomes. Antibiotics which do not inhibit extracellular products may
actually act on bacterial protein synthesis in general and not specifically
on proteins whose origins are at or near the cell membrane (Shibl 1983).
The effect of chloramphenicol and tetracycline on coagulase production
support this idea of membrane bound ribosomes, since coagulase
production was reduced more than the general protein synthesis.
5.2.2 Protein A production
Protein A is a cell wall protein which is maximally produced during
exponential growth phase (Forsgren 1969). Extracellular protein A has
also been detected in culture supernatants and its production follows the
pattern of cell bound protein A (Movitz 1976). He showed that
extracellular protein A produced during exponential growth is neither a
precursor nor a breakdown product of bound protein A - it is a true
extracellular protein. In stationary phase, the situation is completely
different and high levels of extracellular protein A are produced, as a
result of cell lysis and degradation of the cell wall (Movitz 1976). Protein
A production was measured during exponential growth and both types
of protein A were measured to see if the antibiotics tested had different
effects on protein A synthesis.
Streptomycin and novobiocin increased protein A production in
resistant mutants, and after two passages in medium containing
antibiotic, protein A production was increased even more (Nordstrom
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and Lindberg 1978). Gemmell and O'Dowd (1983) investigated protein A
production and tried to relate it to the phagocytosis of bacteria by
leucocytes. They showed that clindamycin and fusidic acid reduced the
production of protein A and increased the susceptibility of S. aureus to
phagocytosis. It has also been demonstrated that 1/8 MIC levels of the
quinolones increased ingestion of S. aureus by PMN and speculated that
this might be a result of lower levels of protein A produced in the
presence of quinolones.
This study shows that the quinolones did not have any effect on the
production of protein A and so the increased ingestion of S. aureus must
be a result of another factor. Again all three protein synthesis inhibitors
greatly affected both types of protein A synthesis. Chloramphenicol and
tetracycline had a greater effect than gentamicin. The production of
extracellular protein A was affected to a greater extent than the
production of cell bound protein A. Since extracellular protein A is a
secreted form of cell bound protein A, any reduction in the levels of cell
bound protein A will affect extracellular protein A production. That
extracellular protein A production is affected to a greater degree could be
a result of one of two reasons. If extracellular protein A is secreted as a
'surplus' form of bound protein A, when the levels of bound protein A
are reduced, extracellular protein A will not be secreted to the same
extent, so that normal levels of cell bound protein A will be produced.
Also in most strains, low levels of extracellular protein A are produced
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and any reduction in these levels will seem more noticeable.
Methicillin had little or no effect on protein A production which is
surprising since its mechanism of action is to inhibit cell wall synthesis.
It could have been expected that it might interfere with the
incorporation of protein A into the cell wall, thus reducing levels of cell
bound protein A but increasing levels of extracellular protein A. Movitz
(1974) showed that protein A production continued when peptidoglycan
synthesis ceased when strains were grown in the presence of
vancomycin. The bacteria could still incorporate protein A into the
membrane despite no peptidoglycan synthesis. The results from this
study suggest that in the presence of methicillin, protein A production
continues and is incorporated into the cell wall normally. It would be
interesting to observe the effects of longer exposure to methicillin on
protein A production, since a time interval of more than 2 hours might
have a more pronounced effect on protein A production.
5.2.3 Haemolysin Production
a haemolysin and 8 haemolysin will be discussed together since they
were affected similarly by the six antibiotics studied. Both these
haemolysins are produced mainly in stationary phase, and because of
this their production was measured in late exponential and early
stationary phase.
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Chloramphenicol and tetracycline inhibited haemolysin production
whereas gentamicin had little affect. Chloramphenicol and tetracycline
have been shown previously to inhibit haemolysin production (Hinton
and Orr 1960; Gemmell and Shibl 1976). This reduction was not just a
result of decreased protein synthesis because this project has shown that
a and 5 haemolysin in the presence of chloramphenicol and tetracycline
when related to total cell protein is still reduced. Some mechanisms
other than reduced protein synthesis must be affecting a and 8
haemolysin synthesis. Again considering that S. aureus grown in the
presence of chloramphenicol and tetracycline have thickened cell walls,
this might reduce haemolysin synthesis. The effect of these antibiotics on
membrane bound ribosomes, as discussed previously, might also have
some effect on haemolysin synthesis. Gentamicin had a reduced effect on
haemolysin synthesis - despite also affecting protein synthesis. This
could be because gentamicin does not affect the cell wall like the other
protein synthesis inhibitors studied and so the reduction in haemolysin
production is solely a result of reduced protein synthesis. The relation of
haemolysin production to viable cells and total cell protein help support
this idea because, when haemolysin production is related to total cell
protein, the levels are much nearer 100% of the normal levels than the
viable count figures. Again, it might result from gentamicin not
affecting membrane bound ribosomes but affecting general protein
synthesis instead.
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The production of the haemolysins in the presence of methicillin was
greatly increased. This observation has been noted previously (Kobayasi
et al 1966) and is probably a result of methicillin's mechanism of action -
affecting cell wall synthesis. Penicillin has a similar effect on haemolysin
production (Kobayasi et al 1966). By attacking the cell wall it releases the
toxins into the surrounding medium, so accelerating the secretion
process.
The two quinolones greatly reduced the production of the two
haemolysins - to undetectable levels in some strains. The quinolones
initiate cell death by binding to DNA gyrase (Wolfson et al 1990). The
actual mechanism of killing is multifactorial involving the prevention
of DNA synthesis, additionally at higher concentrations a reduction of
RNA and protein syntheses occurs (Wolfson et al 1990). At sub - MIC
levels, DNA synthesis might be affected and then in turn RNA
synthesis. Therefore the production of the haemolysins would be
affected. However, it has been reported that the quinolones have little
killing power on stationary phase bacteria, since DNA synthesis is
generally reduced during this period (Chalkley and Koornhof 1985).
In S. aureus, as in most other bacteria, pathogenicity is multifactorial and
the genes that encode the virulence factors are subject to coordinated
regulation. These regulatory systems are supposed to respond to changes
in the bacteria's surroundings during the infection process. The majority
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of extracellular proteins from S. aureus are produced preferentially at the
end of exponential phase (Abbas-Ali et al 1977). The synthesis of at least
14 extracellular toxins and enzymes is regulated by a set of trans-acting
elements from the agr locus (Recsei et al 1986). Coagulase and protein A
synthesis are negatively regulated by agr, whereas the haemolysins,
lipase, TSST-1 etc, positively regulated by it (Kornblum et al 1990). The
actual mechanism by which this regulatory system is controlled in
S. aureus is unknown. Various other virulence genes are controlled by
regulatory systems eg. toxin genes of Vibrio cholera (Peterson and
Mekallanos 1988) and the virulence genes of Bordetella pertussis (Stibitz
et al 1989) and they respond to environmental signals such as
osmolarity, anaerobiosis and temperature. It has been suggested that
DNA supercoiling is involved in this regulation of gene expression
(Dorman et al 1988; Higgins et al 1988). It has previously been
suggested that the S. aureus agr regulatory system is sensitive to
fluctuations in DNA topology (Dorman et al 1991). Nordstrom and
Lindberg (1978) found an inverse correlation between protein A
synthesis (negatively regulated by agr) and the production of a and p
haemolysin (positively regulated by agr) in the presence of novobiocin,
an antibiotic which affects DNA supercoiling. The production of protein
A was stimulated and the production of the haemolysins was reduced. It
is interesting to note that the production of the two virulence factors
investigated in this project (coagulase and protein A), which are
negatively controlled by agr , were not affected by the quinolones over
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the time period studied, but the two haemolysins which are positively
regulated by agr, are affected by the quinolones. Obviously, this could be
a result of the quinolones having an effect on factors produced in late
exponential phase or early stationary phase and nothing to do with agr.
To accumulate more evidence, the production of some other factors
affected or not affected by agr should be investigated in the presence of
the quinolones. Enterotoxin A which is neither positively or negatively
regulated by agr would be a good candidate for this, especially since it is
produced in the stationary phase. Also the production of coagulase and
protein A in the presence of quinolones over a longer time period than
one investigated in this study, should be considered.
5.2.4 Growth of bacteria in the presence of sub-MIC levels of
ciprofloxacin
Since the study was mainly concentrating on the effect of ciprofloxacin
on pathogenicity, the final section considers the growth of strains in the
presence of ciprofloxacin.
When strains were grown in the presence of 1/2 MIC levels of
ciprofloxacin, they grew at a similar rate to strains grown in the absence
of ciprofloxacin. Slower growth rates would be expected in higher
concentrations of ciprofloxacin as observed by Chalkley and Koornhof
(1985). At 1/2 MIC levels and for 8 hours only, no real effects on growth
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Table 50. The effects of sub-MICs of antibiotics on production of toxins
and enzymes by S. aureus
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rates would be expected. When 1/2 MIC levels of ciprofloxacin were
injected into mice, the resultant abscesses produced less tissue damage
and the number of viable bacteria recovered was considerably less. If the
growth of the strains in vivo was also not affected by 1/2 MIC levels then
the reduction in the number of bacteria recovered could have been a
result of reduced virulence, reduced production of virulence factors or
maybe in vivo 1/2 MIC levels of ciprofloxacin do reduce the growth rate.
After growth in 1/2 MIC levels of ciprofloxacin both in vitro and in
vivo, ciprofloxacin resistant strains were isolated. These strains had been
selected out by growth in sub-MIC levels of ciprofloxacin. The strains
were stable mutations because even after repeated subculture in medium
lacking ciprofloxacin, they were still resistant to ciprofloxacin. There
have been some reports of treatment failure in patients as a result of
ciprofloxacin resistant strains of S. aureus developing during therapy
(Humphreys and Mulvihill 1985; Milne and Faires 1988). Obviously this
is an area of concern and highlights the need for careful control of
ciprofloxacin administration, so that sub MIC levels of the drug are not
consistently achieved. The work presented here suggests that these
quinolone resistant bacteria are just as virulent as the sensitive strains
and will persist in the infection site.
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5.3 Conclusions
1. Ciprofloxacin resistant strains of S. aureus are no less
pathogenic than ciprofloxacin sensitive strains -
They grow at similar growth rates both in logarithmic phase
and stationary phase. They are still able to grow under anaerobic
conditions.
They produce similar amounts of the four virulence factors
studied - coagulase, protein A, a haemolysin and 8 haemolysin.
When grown in vivo, they produced subcutaneous abscesses in
mice of similar size and degree of tissue damage.
2. Sub-minimum inhibitory concentrations of the quinolones reduced
the production of the haemolysins, whereas the protein
synthesis inhibitors, chloramphenicol, tetracycline and
gentamicin reduced the production of all the factors studied.
Growth in vitro and in vivo, in the presence of 1/2 MIC levels
of ciprofloxacin, was not affected and resulted in the selection of
bacteria stably resistant to ciprofloxacin.
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3. Future work could involve investigating more accurately the effect of
ciprofloxacin resistance on pathogenicity of S. aureus, by
making genetically engineered isogenic strains differing solely
their sensitivity to ciprofloxacin. Therefore, any differences in
the pathogenicity of the strains would be a result of resistance to
ciprofloxacin.
The effect of sub-MIC levels of ciprofloxacin on the regulation
of agr could be investigated further to see if changes in DNA
supercoiling affected the regulation of agr. Production of
enterotoxin A in the presence of sub-MIC levels of ciprofloxacin
would give indications of this, since enterotoxin A production
is neither positively or negatively regulated by agr.
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Appendix
Table I. The effect of 1/4 MIC levels of ciprofloxacin on the production of
coagulase when related to viable cells
Strain Soluble coagulase Bound coagulase
ng coagulase/ % amount ng coagulase/ % amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 23.40 104 7.31 106
E3T 4.74 103 1.41 101
Oxford 6.53 99 3.01 97
Cowan 1 9.09 101 0.96 107
Wood 46 2.60 104 0.92 102
Resistant bacteria
cip 63 14.66 104 5.15 103
cip 86 5.14 107 1.20 109
cip 92 2.55 98 1.07 107
cip 103 5.56 101 1.55 103
cip 132 4.59 102 0.61 101
411-87 9.90 99 2.85 95
417-87 9.41 99 2.42 101
591-89 2.06 103 1.46 104
4953-88 5.25 105 1.17 106
5538-88 7.17 107 1.43 102
8984-88 3.61 103 0.92 102
Triplet
2219 11.51 101 3.09 103
2221 11.22 102 4.04 101
7777 10.03 109 4.60 107
Paired strains
6989 6.45 104 1.61 107
3225 6.90 103 3.57 102
Table II. The effect of 1/4 MIC levels of enoxacin on the production of
coagulase when related to viable cells
Strain Soluble coagulase Bound coagulase
ng coagulase/ % amount ng coagulase/ % amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 22.95 102 6.97 101
E3T 4.51 98 1.36 97
Oxford 6.73 102 3.19 103
Cowan 1 9.36 104 0.92 102
Wood 46 2.68 107 0.98 109
Resistant bacteria
cip 63 13.96 99 5.05 101
cip 86 4.66 97 1.06 96
cip 92 2.63 101 1.05 105
cip 103 5.89 107 1.59 106
cip 132 4.37 97 0.64 107
411-87 10.10 101 3.06 102
417-87 9.88 104 2.45 102
591-89 2.02 101 1.44 103
4953-88 5.20 104 1.18 107
5538-88 7.30 109 1.54 110
8984-88 3.57 102 0.94 104
Triplet
2219 11.97 105 3.21 107
2221 11.99 109 4.40 110
7777 9.38 102 4.47 104
Paired strains
6989 6.63 107 1.53 102
3225 7.10 106 3.82 109
Table III. The effect of 1/4 MIC levels of methicillin on the production of
coagulase when related to viable cells
Strain Soluble coagulase Bound coagulase
ng coagulase/ % amount ng coagulase/ % amount
109 cells produced in 109 cells produced in
absence absence
Sensitive bacteria
12009 22.28 99 6.76 98
E3T 4.65 101 1.44 103
Oxford 6.86 104 3.32 107
Cowan 1 9.81 109 0.99 110
Wood 46 2.55 102 0.94 104
Resistant bacteria
tip 63 14.81 105 5.30 106
tip 86 5.14 107 1.21 110
tip 92 2.63 101 1.02 102
tip 103 5.72 104 1.58 105
tip 132 4.77 106 0.66 110
411-87 10.40 104 3.15 105
417-87 9.69 102 2.50 104
591-89 1.82 91 1.39 99
4953-88 5.20 104 1.12 102
5538-88 6.90 103 1.50 107
8984-88 3.57 102 0.94 104
Triplet
2219 11.74 103 3.21 107
2221 11.88 108 4.28 107
2777 9.84 107 4.47 104
Paired strains
6989 6.32 102 1.55 103
3225 7.17 107 3.71 106
iii
Table IV. The effect of sub-MIC levels of ciprofloxacin on the production
of coagulase when related to total cell protein
Strain 1/2MIC 1/4MIC
Soluble Bound Soluble Bound
ng coagulase/ ng coagulase/ ng coagulase/ ng coagulase/
mg protein mg protein mg protein mg protein
Sensitive bacteria
12009 3.20 (99) 0.81 (101) 3.42 (106) 0.83 (104)
E3T 2.15 (101) 0.33 (103) 2.17 (102) 0.32 (99)
Oxford 1.69 (105) 0.32 (99) 1.58 (98) 0.32 (99)
Cowan 1 2.17 (98) 0.44 (101) 2.23 (101) 0.45 (103)
Wood 46 0.83 (99) 0.22 (102) 0.83 (97) 0.21 (97)
Resistant bacteria
rip 63 2.56 (89) 0.88 (102) 2.79 (97) 0.90 (105)
rip 86 1.61 (106) 0.36 (114) 1.54 (101) 0.35 (109)
rip 92 1.47 (105) 0.26 (116) 1.32 (102) 0.22 (98)
rip 103 2.67 (101) 0.63 (96) 2.72 (103) 0.69 (104)
rip 132 2.67 (103) 0.48 (108) 2.72 (105) 0.47 (107)
411-87 2.51 (98) 0.63 (92) 2.53 (99) 0.70 (101)
417-87 2.42 (99) 0.67 (103) 2.54 (103) 0.65 (105)
591-89 1.56 (98) 0.34 (106) 1.70 (107) 0.35 (109)
4953-88 1.99 (97) 0.34 (110) 2.03 (99) 0.30 (98)
5538-88 2.76 (101) 0.51 (104) 2.59 (95) 0.49 (99)
8984-88 1.88 (92) 0.34 (104) 2.06 (101) 0.34 (103)
Triplet
2219 1.40 (94) 0.36 (97) 1.46 (98) 0.37 (99)
2221 1.64 (97) 0.24 (101) 1.81 (107) 0.25 (106)
9779 1.92 (97) 0.25 (103) 2.10 (106) 0.26 (108)
Faired strains
6989 2.92 (101) 0.61 (110) 3.01 (104) 0.57 (103)
3225 3.03 (102) 0.58 (104) 3.06 (103) 0.57 (102)
Figures in parentheses are percentages of the amount of coagulase
produced in presence of antiobitics compared to that produced in
absence of antibiotics
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Table V. The effect of sub -MIC levels of enoxacin on the production of
coagulase when related to total cell protein
Strain 1/2MIC 1/4MIC
Soluble Bound Soluble Bound
ng coagulase/ ng coagulase/ ng coagulase/ ng coagulase/
mg protein mg protein mg protein mg protein
Sensitive bacteria
12009 3.42 (106) 0.79 (99) 3.33 (103) 0.82 (103)
E3T 2.24 (105) 0.33 (103) 2.15 (101) 0.32 (99)
Oxford 1.67 (104) 0.33 (102) 1.58 (98) 0.33 (103)
Cowan 1 2.28 (103) 0.44 (101) 2.14 (97) 0.46 (104)
Wood 46 0.88 (102) 0.22 (100) 0.87 (101) 0.22 (101)
Resistant bacteria
cip 63 2.85 (99) 0.83 (97) 2.88 (100) 0.88 (102)
cip 86 1.47 (97) 0.33 (104) 1.55 (102) 0.33(103)
cip 92 1.26 (98) 0.22 (100) 1.34 (104) 0.23 (105)
cip 103 2.59 (98) 0.59 (90) 2.67 (101) 0.67 (102)
cip 132 2.56 (99) 0.41 (94) 2.51 (97) 0.44 (100)
411-87 2.64 (103) 0.71 (106) 2.51 (98) 0.70 (101)
417-87 2.59 (105) 0.64 (104) 2.42 (98) 0.61 (99)
591-89 1.61 (101) 0.34 (115) 1.65 (104) 0.33 (102)
4953-88 2.19 (107) 0.36 (115) 2.11 (103) 0.31 (101)
5538-88 2.76 (101) 0.56 (115) 2.78 (102) 0.50 (103)
8984-88 2.10 (100) 0.30 (91) 2.08 (104) 0.34 (104)
Triplet
2219 1.52 (102) 0.35 (95) 1.49 (100) 0.39 (105)
2221 1.81 (107) 0.24 (99) 1.67 (99) 0.24 (101)
2.16 (109) 0.24 (101) 1.98 (98) 0.24 (101)
Paired strains
6989 3.21 (111) 0.55 (100) 2.83 (98) 0.57 (103)
3225 3.15 (106) 0.55 (99) 2.88 (97) 0.57 (102)
Figures in parentheses are percentages of the amount of coagulase
produced in presence of antiobitics compared to that produced in
absence of antibiotics
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Table VI. The effect of sub-MIC levels ofmethicillin on the production of
coagulase when related to total cell protein
Strain 1/2MIC 1/4 MIC
Soluble Bound Soluble Bound
ng coagulase/ ng coagulase/ ng coagulase/ ng coagulase/
mg protein mg protein mg protein mg protein
Sensitive strains
12009 3.59 (111) 0.84
E3T 2.36 (111) 0.32
Oxford 1.63 (101) 0.33
Cowan 1 2.14 (97) 0.44
Wood 46 0.84 (98) 0.22
Resistant strains
cip 63 2.97 (103) 0.90
cip 86 1.40 (92) 0.35
cip 92 1.28 (99) 0.23
cip 103 2.61 (100) 0.61
cip 132 2.59 (100) 0.44
411-87 2.61 (102) 0.71
417-87 2.47 (100) 0.62
591-89 1.61 (101) 0.37
4953-88 2.15 (105) 0.30
5538-88 2.92 (107) 0.56
8984-88 2.14 (105) 0.34
Triplet
2219 1.55 (104) 0.37
2221 1.74 (103) 0.24
7777 2.02 (102) 0.24
Paired strains
6989 2.92 (101) 0.57
3225 3.09 (104) 0.58
(105) 3.20 (99) 0.82 (102)
(100) 2.15 (101) 0.33 (104)
(103) 1.64 (102) 0.33 (103)
(99) 2.30 (104) 0.45 (102)
(101) 0.90 (105) 0.22 (101)
(105) 3.05 (106) 0.87 (101)
(108) 1.54 (101) 0.33 (104)
(103) 1.32 (102) 0.23 (103)
(92) 2.67 (101) 0.65 (99)
(100) 2.62 (101) 0.43 (98)
(106) 2.64 (103) 0.70 (102)
(100) 2.45 (99) 0.67 (102)
(115) 1.54 (97) 0.33 (104)
(98) 2.07 (101) 0.32 (103)
(115) 2.78 (102) 0.49 (101)
(103) 2.06 (101) 0.34 (103)
(99) 1.53 (103) 0.38 (104)
(102) 1.79 (106) 0.24 (102)
(102) 2.16 (109) 0.24 (101)
(104) 3.01 (104) 0.56 (102)
(103) 2.94 (99) 0.57 (101)
Figures in parentheses are percentages of the amount of coagulase
produced in presence of antiobitics compared to that produced in
absence of antibiotics
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Table VII. The effect of sub-MIC levels of gentamicin on the production
of coagulase when related to total cell protein
Strain 1/2MIC 1/4 MIC
Soluble Bound Soluble Bound
ng coagulase/ ng coagulase/ ng coagulase/ ng coagulase/
mg protein mg protein mg protein mg protein
Sensitive bacteria
12009 1.91 (51) 0.46 (57) 2.87 (89) 0.79 (99)
E3T 1.28 (60) 0.19 (60) 1.96 (92) 0.32 (100)
Oxford 0.68 (42) 0.15 (47) 1.38 (86) 0.32 (99)
Cowan 1 0.86 (39) 0.20 (45) 1.61 (72) 0.44 (99)
Wood 46 0.45 (52) 0.13 (61) 0.70 (90) 0.22 (100)
Resistant bacteria
cip 63 1.47 (51) 0.49 (57) 2.88 (100) 0.88 (102)
cip 86 0.65 (43) 0.16 (50) 0.73 (48) 0.36 (114)
cip 92 0.84 (65) 0.16 (71) 1.30 (101) 0.23 (103)
cip 103 1.45 (55) 0.41 (62) 2.30 (87) 0.61 (92)
cip 132 1.27 (49) 0.25 (56) 2.12 (82) 0.48 (103)
411-87 1.59 (62) 0.37 (53) 2.18 (85) 0.63 (92)
417-87 1.01 (41) 0.37 (59) 2.07 (84) 0.62 (100)
591-89 0.83 (52) 0.19 (59) 1.49 (94) 0.34 (106)
4953-88 1.13 (55) 0.19 (62) 2.13 (104) 0.34 (106)
5538-88 1.47 (54) 0.30 (61) 1.94 (71) 0.56 (115)
8984-88 1.08 (53) 0.20 (60) 1.96 (96) 0.34 (103)
Triplet
2219 0.92 (62) 0.24 (65) 1.36 (91) 0.37 (99)
2221 1.00 (59) 0.12 (50) 1.55 (92) 0.24 (101)
7777 1.17 (59) 0.13 (55) 1.72 (87) 0.24 (102)
Paired strains
6989 1.24 (43) 0.24 (44) 2.46 (85) 0.57 (104)
3225 1.16 (39) 0.22 (40) 2.49 (84) 0.58 (104)
Figures in parentheses are percentages of the amount of coagulase
produced in presence of antiobitics compared to that produced in
absence of antibiotics
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Table VIH. The effect of sub-MIC levels of chloramphenicol on the
production of coagulase when related to total cell protein
Strain 1/2MIC 1/4MIC
Soluble Bound Soluble Bound
ng coagulase/ ng coagulase/ ng coagulase/ ng coagulase/
mg protein mg protein mg protein mg protein
Sensitive bacteria
12009 1.78 (55) 0.41 (51) 3.13 (97) 0.84 (105)
E3T 1.04 (49) 0.13 (40) 2.00 (94) 0.83 (103)
Oxford 0.60 (37) 0.13 (40) 1.45 (90) 0.32 (99)
Cowan 1 0.77 (35) 0.09 (39) 2.01 (91) 0.44 (101)
Wood 46 0.35 (41) 0.09 (43) 0.77 (90) 0.22 (100)
Resistant bacteria
cip 63 2.88 (100) 0.79 (92) 2.88 (100) 0.90 (105)
dp 86 0.78 (51) 0.20 (63) 1.23 (81) 0.33 (94)
dp 92 0.71 (55) 0.12 (54) 1.05 (79) 0.22 (90)
dp 103 1.50 (57) 0.42 (63) 2.30 (87) 0.61 (92)
dp 132 1.17 (45) 0.25 (56) 2.38 (92) 0.44 (100)
411-87 1.18 (46) 0.30 (50) 2.64 (103) 0.63 (92)
417-87 1.36 (55) 0.33 (53) 1.78 (72) 0.67 (93)
591-89 0.83 (52) 0.17 (53) 1.19 (75) 0.34 (102)
4953-88 1.11 (54) 0.17 (55) 1.76 (86) 0.36 (105)
5538-88 1.06 (39) 0.20 (41) 2.51 (92) 0.56 (103)
8984-88 0.86 (42) 0.20 (60) 2.06 (101) 0.30 (91)
Triplet
2219 0.73 (49) 0.93 (55) 1.30 (87) 0.36 (97)
2221 0.93 (55) 0.12 (52) 1.27 (75) 0.24 (91)
7777 0.77 (39) 0.12 (51) 1.60 (81) 0.22 (91)
Paired strains
6989 1.30 (45) 0.28 (50) 2.51 (87) 0.55 (100)
3225 1.75 (59) 0.31 (55) 2.79 (94) 0.58 (104)
Figures in parentheses are percentages of the amount of coagulase
produced in presence of antiobitics compared to that produced in
absence of antibiotics
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Table IX. The effect of sub-MIC levels of tetracycline on the production of
coagulase when related to total cell protein
Strain 1/2MIC 1/4MIC
Soluble Bound Soluble Bound
ng coagulase/ ng coagulase/ ng coagulase/ ng coagulase/
mg protein mg protein mg protein mg protein
Sensitive bacteria
12009 1.32 (41) 0.42 (52) 2.42 (75) 0.84 (105)
E3T 1.02 (48) 0.20 (61) 1.90 (105) 0.32 (100)
Oxford 0.84 (52) 0.16 (49) 1.48 (92) 0.34 (99)
Cowan 1 0.91 (41) 0.22 (50) 1.86 (84) 0.42 (101)
Wood 46 0.48 (56) 0.12 (55) 0.79 (92) 0.22 (100)
Resistant bacteria
cip 63 3.05 (106) 0.84 (98) 2.88 (100) 0.83 (97)
tip 86 0.74 (49) 0.14 (45) 1.20 (79) 0.30 (99)
tip 92 0.54 (42) 0.12 (56) 1.12 (87) 0.22 (100)
cip 103 1.35 (51) 0.30 (45) 2.48 (94) 0.61 (92)
tip 132 1.37 (53) 0.22 (50) 2.05 (79) 0.44 (100)
411-87 1.82 (71) 0.38 (55) 2.10 (82) 0.71 (106)
417-87 1.61 (65) 0.33 (53) 2.49 (101) 0.62 (100)
591-89 0.67 (42) 0.15 (48) 1.46 (92) 0.30 (99)
4953-88 1.05 (51) 0.18 (57) 1.70 (85) 0.30 (101)
5538-88 2.92 (107) 0.52 (107) 2.70 (99) 0.46 (99)
8984-88 1.00 (49) 0.18 (55) 1.94 (95) 0.34 (103)
Triplet
2219 0.82 (55) 0.19 (50) 1.36 (91) 0.37 (102)
2221 0.91 (54) 0.12 (49) 1.47 (87) 0.20 (101)
9999 0.77 (39) 0.10 (40) 1.68 (85) 0.25 (103)
Paired strains
6989 1.04 (36) 0.24 (43) 2.28 (79) 0.55 (90)
3225 1.25 (42) 0.25 (44) 2.55 (86) 0.50 (95)
Figures in parentheses are percentages of the amount of coagulase
produced in presence of antiobitics compared to that produced in
absence of antibiotics
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Figure X. The effect of sub-MIC levels of ciprofloxacin and enoxacin on
the production of a haemolysin when related to total cell protein
Strain Ciprofloxacin Enoxacin
1/4MIC 1/2MIC 1/4 MIC 1/2 MIC
HU/mg HU/mg HU/mg HU/mg
Sensitive bacteria
Wood 46 258.4 (68) 125.0 (52) 247.0 (65) UD
E3T 6.4 (40) UD 11.2 (70) UD
Oxford 12.1 (55) 8.1(30) 19.8 (90) 11.1 (41)
12009 243.0 (90) UD 162.0 (60) 57.0 (30)
Cowan 9.7 (65) 10.4 (61) 15.2 (101) 11.7 (69)
Resistant bacteria
cip 63 16.2 (85) 9.1 (61) 9.5 (50) UD
cip 86 74.2 (70) 72.0 (61) 44.0 (41) UD
cip 92 213.0 (99) 202.0 (90) 217.2 (101) 199.0 (89)
cip 103 14.0 (70) 4.1 (34) 16.0 (80) 3.7 (31)
cip 132 27.0 (90) 27.6 (52) 27.0 (90) 17.0 (32)
411-87 6.5 (25) UD 10.4 (40) UD
417-87 12.1(101) 12.0 (80) 6.6 (55) UD
591-89 10.4 (40) UD 27.3 (105) UD
4953-88 12.8 (80) 4.1 (41) 13.0 (81) UD
5538-88 7.1 (71) UD UD UD
8984-88 6.2 (41) UD 15.5 (103) UD
Triplet
2219 UD UD UD UD
2221 UD UD UD UD
7777 UD UD UD UD
Paired strains
6989 218.0 (100) 130.0 (71) 113.4 (52) 73.2 (40)
3225 154.2 (94) 81.0 (52) 147.6 (90) 68.0 (43)
Figures in parentheses are percentages of the amount of a haemolysin
produced in presence of antiobitics compared to that produced in
absence of antibiotics
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Figure XI. The effect of sub-MIC levels of gentamicin and methicillin on
the production of a haemolysin when related to total cell protein
Strain Gentamicin Methicillin
1/4MIC 1/2MIC 1/4MIC 1/2MIC
HU/mg HU/mg HU/mg HU/mg
Sensitive bacteria
Wood 46 361.0 (95) 222.0 (92) 1050 (>200) 2080 (>200)
E3T 15.2 (95) 7.5 (94) 600 (>200) 35(>200)
Oxford 13.5 (90) 24.0 (88) 55 (>200) 182(>200)
12009 267.0 (99) 192.0 (101) 60 (>200) 531 (>200)
Cowan 1 20.0 (91) 13.1 (77) 100 (>200) 15 (>200)
Resistant bacteria
cip 63 18.2 (96) 14.4 (96) 191(>200) 473 (>200)
cip 86 105 (99) 117.0 (99) 405(>200) 292 (>200)
cip 92 204.0 (95) 207.0 (92) 390(>200) 896 (>200)
cip 103 18.4 (92) 10.4 (87) 150(>200) 149(>200)
cip 132 27.6 (92) 44.5 (84) 350 (>200) 597(>200)
411-87 20.8 (80) 29.0 (72) 410 (>200) 339 (>200)
417-87 11.0 (92) 14.1 (94) 110 (>200) 1137(>200)
591-89 25.7 (99) 25.5 (92) 130 (>200) 133 (>200)
4953-88 13.4 (84) 8.2 (82) 350 (>200) 62 (>200)
5538-88 9.4 (94) 10.9 (91) 410(>200) 113(>200)
8984-88 13.5 (96) 11.3 (87) 210(>200) 106(>200)
Triplet
2219 UD UD UD UD
2221 UD UD UD UD
???? UD UD UD UD
Paired strains
6989 198.4 (91) 172.0 (41) 740(>200) 196(>200)
3225 146.0 (89) 143.0 (92) 350 (>200) 57 (>200)
Figures in parentheses are percentages of the amount of a haemolysin
produced in presence of antiobitics compared to that produced in
absence of antibiotics
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Figure XII. The effect of sub-MIC levels of chloramphenicol and






HU/mg HU/mg HU/mg HU/mg
Sensitive bacteria
Wood 46 80.0 (21) UD 156.0 (41) UD
E3T 12.8 (80) UD 4.5 (30) 2.0 (25)
Oxford 21.8 (99) 13.0 (49) 16.0 (71) 13.0 (47)
12009 162.0 (60) 99.0 (52) 248.0 (92) 116.0 (61)
Cowan 1 UD UD UD UD
Resistant bacteria
cip 63 13.3 (70) 10.0 (67) 9.8 (52) UD
cip 86 97.5 (92) UD 33.0 (31) UD
cip 92 213.0 (99) 47.0 (21) 144.0 (67) UD
cip 103 15.0 (75) UD 10.2 (51) UD
cip 132 15.3 (51) 33.0 (62) 21.6 (72) 2.4 (49)
411-87 UD UD 26.3 (101) 39.0 (101)
417-87 12.1(101) 13.6 (91) UD UD
591-89 15.9 (61) UD 25.7 (99) UD
4953-88 10.3 (103) UD UD UD
5538-88 UD UD UD UD
8984-88 6.7 (45) UD 6.3 (42) UD
Triplet
2219 UD UD UD UD
2221 UD UD UD UD
7777 UD UD UD UD
Paired strains
6989 178.8 (82) 75.0 (41) 200.0 (92) 46.0 (25)
3225 162.4 (99) 139.0 (89) 129.6 (79) 66.0 (42)
Figures in parentheses are percentages of the amount of a haemolysin
produced in presence of antiobitics compared to that produced in
absence of antibiotics
xii
Figure Xm. The effect of sub-MIC levels of ciprofloxacin and enoxacin on
the production of 8 haemolysin when related to total cell protein
Strain Ciprofloxacin Enoxacin
1/4MIC 1/2 MIC 1/4 MIC 1/2MIC
HU/mg ITU /mg HU/mg HU/mg
Sensitive bacteria
E5662 100 (99) 92.0 (91) 85.9 (85) 79.8 (79)
E3T 72.9 (90) 57.5 (71) 68.0 (84) 48.6 (60)
Oxford 2.3 (90) 2.0 (80) 1.7 (69) UD
12009 18.0 (90) 16.4 (82) 19.8 (99) 9.8 (49)
Cowan 1 0.4 (80) 0.3 (60) 0.3 (60) UD
Wood 46 11.9 (79) 9.8 (65) 14.3 (95) 13.5 (90)
Resistant bacteria
cip 63 26.0 (40) UD 35.8 (55) UD
cip 86 36.5 (89) 25.4 (62) 39.0 (95) 26.7 (65)
cip 92 47.8 (81) 25.4 (43) 41.9 (71) 23.0 (39)
cip 103 0.8 (91) 0.7 (77) 0.9 (99) 0.5 (55)
cip 132 9.8 (89) 7.2 (65) 10.7 (97) 4.4 (40)
411-87 1.7 (80) 1.5 (72) 2.1 (101) 1.9 (90)
417-87 16.2 (90) UD 16.2 (90) 14.4 (80)
591-89 UD UD UD UD
4953-88 UD UD UD UD
5538-88 0.2 (50) UD UD UD
8984-88 4.0 (99) 2.1 (52) 3.6 (90) 2.9 (72)
Triplet
2219 UD UD UD UD
2221 UD UD UD UD
7777 UD UD UD UD
Paired strains
6989 31.9 (91) 28.0 (80) 19.3 (55) UD
3225 22.5 (75) UD 31.2 (104) 18.0 (60)
Figures in parentheses are percentages of the amount of 8 haemolysin
produced in the presence of antibiotics compared to that produced in the
absence
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Figure XIV. The effect of sub-MIC levels of gentamicin and methicillin
on the production of 8 haemolysin when related to total cell protein
Strain Gentamicin Methicillin
1/4MIC 1/2 MIC 1/4 MIC 1/2MIC
HU/mg HU/mg HU/mg HU/mg
Sensitive bacteria
E5662 105.0 (104) 100.0 (99) 239 (>200) 250 (>200)
E3T 78.6 (97) 77.8 (96) 289 (>200) 360(>200)
Oxford 2.5 (98) 2.3 (90) 15 (>200) 10(>200
12009 20.4 (102) 20.2 (101) 35 (>200) 40 (>200)
Cowan 1 0.5 (94) 0.5 (92) 4 (>200) 4 (>200)
Wood 46 15.3 (102) 13.5 (90) 70 (>200) 90 (>200)
Resistant bacteria
cip 63 61.1 (94) 61.1 (94) 200 (>200) 400 (>200)
cip 86 40.6 (99) 39.8 (97) 100(>200) 150(>200)
cip 92 58.4 (99) 59.6 (101) 79 (>200) 200(>200)
cip 103 0.9 (98) 0.9 (101) 2(>200) 2 (>200)
cip 132 11.1 (101) 10.9 (99) 30 (>200) 40(>200)
411-87 2.0 (94) 1.8 (84) 6 (>200) 6 (>200)
417-87 17.6 (98) 17.8 (99) 40 (>200) 60 (>200)
591-89 UD UD UD UD
4953-88 UD UD UD UD
5538-88 0.4 (104) 0.4 (101) 1 (>200) 2 (>200)
8984-88 4.0 (99) 3.9 (97) 9 (>200) 12 (>200)
Triplet
2219 UD UD UD UD
2221 UD UD UD UD
7777 UD UD UD UD
Paired strains
6989 33.6 (96) 31.9 (91) 70 (>200) 86 (>200)
3225 29.4 (98) 29.1 (97) 62 (>200) 60 (>200)
Figures in parentheses are percentages of the amount of 8 haemolysin
produced in the presence of antibiotics compared to that produced in the
absence
xiv
Figure XV. The effect of sub-MIC levels of chloramphenicol and
tetracycline on the production of 8 haemolysin when related to total cell
protein
Strain Chloramphenicol Tetracycline
1/4MIC 1/2MIC 1/4 MIC 1/2MIC
HU/mg HU/mg HU/mg HU/mg
Sensitive bacteria
E5662 49.5 (49) UD 51.5 (49) UD
E3T 82.6 (102) 81.8 (101) 40.5 (50) 0.8 (30)
Oxford 1.5 (61) 1.0 (40) 1.8 (70) UD
12009 16.0 (80) 6.2 (31) 14.2 (71) UD
Cowan 1 0.2 (42) UD 0.4 (70) UD
Wood 46 7.1 (47) 4.5 (30) 9.3 (62) UD
Resistant bacteria
cip 63 6.5 (10) UD 13.7 (21) UD
cip 86 24.6 (60) 16.8 (41) 30.8 (75) 17.2 (42)
cip 92 24.2 (41) UD 23.6 (40) UD
cip 103 0.9 (102) 0.6 (70) 0.5 (57) UD
cip 132 11.1 (101) 9.8 (89) 3.5 (32) UD
411-87 1.3 (60) UD 0.8 (40) UD
417-87 16.4 (91) 14.6 (81) 16.6 (92) UD
591-89 UD UD UD UD
4953-88 UD UD UD UD
5538-88 0.4 (104) 0.2 (41) UD UD
8984-88 4.0 (99) UD 3.6 (89) 2.8 (70)
Triplet
2219 UD UD UD UD
2221 UD UD UD UD
2797 UD UD UD UD
Paired strains
6989 14.0 (40) UD 15.1 (43) UD
3225 18.3 (61) UD 11.1 (37) UD
Figures in parentheses are percentages of the amount of 8 haemolysin
produced in the presence of antibiotics compared to that produced in the
absence
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